EP Latest

List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001484 Medroxyprogesterone acetate for peak identification
Y0001523 Ursolic acid New Y0001532 Norethisterone acetate for system suitability Y0001562 Doxylamine hydrogen succinate Y0001565 Recombinant Major Allergen rBet v 1 Y0001566 Recombinant Major Allergen rPhl p 5a New Y0001567 Docusate sodium New Y0001570 Nitrofural impurity B New Y0001571 Naloxone impurity D New Y0001574 Mesalazine for system suitability New Y0001575 Bupivacaine impurity F New Y0001577 Isoprenaline impurity A New Y0001580 Rocuronium bromide New Y0001585 Cellulose acetate butyrate New Y0001561 Abacavir sulfate New Y0001551 Abacavir for system suitability New Y0001552 Abacavir for peak identification Y0000055 Acamprosate calcium - reference spectrum Y0000116 Acamprosate impurity A Y0000500 Acarbose Y0000354 Acarbose for identification Y0000427 Acarbose for peak identification A0040000 Acebutolol hydrochloride Y0000359 Acebutolol impurity B Y0000127 Acebutolol impurity C Y0000128 Acebutolol impurity I Y0000056 Aceclofenac - reference spectrum Y0001094 Aceclofenac for peak identification Y0000085 Aceclofenac impurity F Y0000086 Aceclofenac impurity H Y0000810 Acemetacin Y0000811 Acemetacin impurity A Y0000842 Acemetacine impurity mixture A0070000 Acesulfame potassium Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 1 1 1 1 n/a 1 1 n/a 1 1 1 1 2 1 2 1 2 1 2 1 1 1 1 1 1 1 2 Quantity Sale per vial Unit 25 mg 1 25 mg 2.585 mg 60 mg 1 1 1 10.25 micrograms of rBet v 1 8.56 micrograms of rPhl p 5a 94.8 % CHON; (5-nitrofuran-2-yl)methylene diacetate 94.0 % CHO Information Monograph 0673 2439 0850 1589 1063 1063 1135 0729 1699 2,6-dimethylaniline 1-(3,4-dihydroxyphenyl)-2-[(1-methylethyl)amino]ethanone 0541 1332
Effective from 2013/1/2 Leaflet Yes Yes Yes Yes Yes Yes Yes Yes Storage +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C 2589 2589 2589 1585 3-aminopropane-1-sulphonic acid 94.7 mg CHNO Batch 1 is valid until 1 May 2013 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] acetamide (diacetolol) N-(3-acetyl-4-hydroxyphenyl)butanamide N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] butanamide propoxy]phenyl] 1585 2089 2089 2089 0871 0871 0871 0871 1281 1281 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] oxy]acetyl]oxy] acetic acid 4-chlorobenzoic acid 1281 1281 1686 1686 1686 1282 1 Yes Yes +5C +5C +5C +5C +5C +5C +5C Yes +5C +5C +5C +5C +5C +5C +5C +5C Yes Yes +5C +5C +5C Extra charges a a a a c c a a a a g a g a a a a l a a a a a a a a l g g g g a g a
0.01025 mg 1 0.00856 mg 1 10 mg 30 mg 25 mg 10 mg 70 mg 15 mg 10 mg 60 mg 20 mg 10 mg 10 mg n/a 50 mg 94.7 mg 10 mg 20 mg 50 mg 10 mg 20 mg 0.004 mg n/a 10 mg 20 mg 10 mg 100 mg 10 mg 0.06 mg 50 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code A0070020 Acesulfame potassium impurity B A0100000 Acetazolamide Y0001084 Acetazolamide for system suitability Y0000002 Acetylcholine chloride A0150000 Acetylcysteine A0152000 Acetylcysteine impurity C A0153000 Acetylcysteine impurity D Y0000565 -Acetyldigoxin Y0000642 -Acetyldigoxin for peak identification A0200000 Acetylsalicylic acid Y0001460 Acetylsalicylic acid for peak identification A0208000 N-Acetyltryptophan A0202000 N-Acetyltyrosine Y0001462 Acetylsulfadiazine Y0000693 Acholeplasma laidlawii BRP A0220000 Aciclovir Y0001271 Aciclovir for peak identification 1 Y0001269 Aciclovir for peak identification 2 Y0001264 Aciclovir for system suitability A0225000 Acitretin Y0001464 Actaea racemosa dry extract for system suitability HRS Y0001543 Actaea racemosa for assay CRS Y0001463 Actaea racemosa HRS Y0001121 Adapalene Y0001120 Adapalene impurity C Y0001119 Adapalene for peak identification A0230000 Adenine A0230200 Adenosine Y0000110 Adipic acid Y0000882 Adrenaline A0300000 Adrenaline tartrate Y0000740 Adrenaline impurity mixture Y0000707 Adrenaline tartrate with impurity A Y0000883 Adrenaline with impurity F Y0000728 Agnus castus fruit standardised dry extract Council of Europe, all rights reserved 2013 Batch n 3 1 1 1 3 8 5 2 1 4 1 2 1 1 1 3 2 2 1 2 1 1 1 1 2 1 2 1 1 1 5 2 1 1 1 Quantity Sale Information per vial Unit 50 mg 1 5-chloro-6-methyl-1,2,3-oxathiazin-4(3)-one 2,2-dioxide 100 mg 0.0068 mg 50 mg 50 mg 10 mg 10 mg 50 mg 10 mg 15 mg 10.26 mg 125 mg 200 mg 0.002 mg 1 ml 75 mg 0.3 mg 0.004 mg 10 mg 100 mg 1200 mg 300 mg 1200 mg 100 mg 6 mg 2.022 mg 50 mg 50 mg 50 mg 5 mg 100 mg 0.005 mg 15 mg 10 mg 200 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0.13% CHO 2 Batch 1 is valid until 30 April 2012 99.9% CHO 1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane 74.7% CHNO; Monoammonium glycyrrhizate 99.7% CHO Batch 2 is valid until 31 January 2012 Batch 1 is valid until 31 August 2012 Batch 1 is valid until 30 September 2012 Batch 3 is valid until 29 February 2012 Batch 2 is valid until 29 February 2012 88.5% CHNOS; N,N'-diacetyl-L-cystine N,-diacetyl-L-cysteine 98.6% CHO Monograph 1282 0454 0454 1485,1971 0967 0967 0967 2168 2168 0309 0309 1383 1384 0294 20607 0968 0968 0968 0968 1385 2069 2069 2069 2445 2245 2445 0800,1486 1486 1586 2303 0254, 0285, 0732 0254,2303 0254 2303 2147 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -80C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C Extra charges a a a c a a a f f a a a a a d a a a a g(b) c a a a a a g a a g f f f g c
List of European Pharmacopoeia Reference Standards Order Code A0325000 Alanine A0325100 Albendazole A0325200 Alcuronium chloride A0325450 Alfacalcidol A0325451 Alfacalcidol - reference spectrum A1225000 Alfadex A0325500 Alfentanil hydrochloride - reference spectrum A0325800 Alfuzosin hydrochloride Y0000832 Alfuzosin for system suitability A0349000 Allantoin A0350000 Allopurinol A0350010 Allopurinol impurity A A0350020 Allopurinol impurity B New A0350030 Allopurinol impurity C A0350040 Allopurinol impurity D G0400000 Glycerol (85 per cent) - reference spectrum A0350050 Allopurinol impurity E A0351000 Allylstrychnine bromide H0215000 Hepatitis C Virus RNA for NAT testing BRP Y0000235 Almagate Y0000255 Almagate - reference spectrum A0357000 Alprazolam - * psy A0360000 Alprenolol hydrochloride Y0000054 Alprostadil Y0000606 Altizide Y0000843 Altizide impurity B Y0000687 Alverine citrate Y0000595 Alverine for peak identification Y0000607 Alverine impurity D A0363000 Amantadine hydrochloride A0363700 Ambroxol hydrochloride A0900000 Amfetamine sulfate - reference spectrum A0365000 Amidotrizoic acid dihydrate Council of Europe, all rights reserved 2013 Reference Standard Batch n 3 1 2 8 1 3 1 2 1 1 2 2 3 3 3 1 1 1 1 1 1 2 1 2 2 1 1 1 1 1 3 1 1 Quantity Sale per vial Unit 60 mg 1 50 mg 50 mg 5 mg n/a 150 mg n/a 10 mg 10 mg 60 mg 100 mg 10 mg 10 mg 10 mg 15 mg n/a 20 mg 10 mg 40 mg 25 mg n/a 100 mg 100 mg 50 mg 150 mg 15 mg 5 mg 0.125 mg 10 mg 100 mg 125 mg n/a 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine 99.4% CHO ; Batch 1 is valid until 31 January 2013 99.9% CHClNOS 3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene HCV-RNA content 500 IU per vial; For plasma pool testing by NAT 13.4% carbonic acid ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate 99.9% CHNO 5-amino-1H-pyrazole-4-carboxamide 5-formylamino-1H-pyrazole-4-carboxamide ; Batch 2 is valid until 31 December 2012 5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide ; Batch 2 is valid until 1 May 2013 ethyl 5-amino-1H-pyrazole-4-carboxylate 89.7% [CH0] 99.8% CHO ; Batch 6 is valid until 31 March 2012 Batch 7 is valid until 31 December 2012 Information Monograph 0614,0752 1386 1285 1286 1286 1070,1487 1062 1287 1287 1288 0576 0576 0576 0576 0576 0496,0497 0576 1285 See leaflet, 20621 2010 2010 1065 0628,0876 1488 0370,2185 2185 2156 2156 2156 0463 1489 0368 0873 Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C -20C -20C Extra charges a g g(c) e(d) l +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C a l a a a g g g g g l g g(c) e(d) a l j a g(c) a a a a a a a l a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001461 Amidotrizoic acid for system suitability A0368000 Amikacin Y0001467 Amikacin impurity I A0365900 Amikacin sulfate Y0001117 Amikacin for system suitability Batch n 1 3 1 3 2 Quantity Sale per vial Unit 0.08 mg 1 200 mg 20 mg 200 mg 10 mg 1 1 1 1 Information Monograph 0873 91.7 % CHNO ; Batch 2 is valid until 28 February 2013 (2S)-4-amino-2-hydroxybutanoic acid The batch 3 is not suitable for use in the assay in monograph 1290:07/2012. Amikacin CRS A0368000 is also needed. See leaflet. amikacin for system suitability CRS 1 is suitable for 01/2010:1289 and 01/2010:1290 only. Batch 2 is suitable for 07/2012:1289 and 07/2012:1290. ; Batch 1 is valid until 30 June 2012 methyl-3,5-diamino-6-chloropyrazine-2-carboxylate Batch 1 is valid until 31 March 2012 Cefadroxyl impurity B (3)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione; (3-aminoglutethimide) 3,3'-[diazenediyldi(4,1-phenylene)]bis(3-ethylpiperidine-2,6-dione); (azoglutethimide) (2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone (2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone ; Batch 2 is valid until 31 August 2012 Batch 1 is valid until 31 May 2012 4-amino-N-[[(2RS)-1-ethylpyrrolidin-2-yl]methyl]-5-(ethyl sulphonyl)-2hydroxybenzamide 99.7% CHClNOS 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-2-[[2-(1,3-dioxo-1,3-dihydro-2Hisoindol-2-yl)ethoxy]methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate ; Batch 1 is valid until 1 June 2013 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-6-methyl-2-[[2-[[2(methylcarbamoyl)benzoyl]amino]ethoxy]methyl]-1,4-dihydropyridine-3,5dicarboxylate dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylate ; Batch 1 is valid until 1 June 2013 1289,1290 1290 1290 1289,1290 Yes Yes Leaflet Yes Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C Extra charges a a a a a
A0370000 Amiloride hydrochloride Y0000020 Amiloride impurity A Y0000173 4-Aminobenzoic acid A0420000 Aminocaproic acid A0460000 7-Aminodesacetoxycephalosporanic acid A0496000 Aminoglutethimide A0496005 Aminoglutethimide impurity A A0496020 Aminoglutethimide impurity D A0575000 Amiodarone hydrochloride Y0000129 Amiodarone impurity D Y0000130 Amiodarone impurity E A0590000 Amisulpride Y0001534 Amisulpride for system suitability A0590004 Amisulpride impurity B Y0000563 Amitriptyline hydrochloride Y0000049 Amlodipine besilate Y0001067 Amlodipine for peak identification New Y0001068 Amlodipine impurity A
1 2 2 1 2 1 1 1 3 3 3 2 n/a 1 1 4 1 2
100 mg 10 mg 60 mg 50 mg 20 mg 125 mg 20 mg 10 mg 100 mg 20 mg 20 mg 10 mg 1.0015 mg 10 mg 10 mg 150 mg 10 mg 15 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0651 0651 1687 0874 0708,0813 1291 1291 1291 0803 0803 0803 1490 1490 1490 0464 1491 1491 1491 Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g g a a a a a a g(b) g g a a a g g g g
Y0001069 Amlodipine impurity B
10 mg
1491
+5C
New Y0001070 Amlodipine impurity G Y0000302 Ammonio methacrylate copolymer(type A) - reference spectrum Y0000303 Ammonio methacrylate copolymer(type B) - reference spectrum Council of Europe, all rights reserved 2013
2 1 1
15 mg n/a n/a
1 1 1
1491 2081 2082
+5C
g l l
List of European Pharmacopoeia Reference Standards Order Reference Standard Code A0650000 Amobarbital - * psy A0700000 Amobarbital sodium - * psy A0800000 Amoxicillin trihydrate Batch n 1 1 5 Quantity Sale per vial Unit 500 mg 1 500 mg 200 mg 1 1 86.2% CHNOS Information Monograph 0594 0166 0167,0168,02 60, 0577,0578,08 13, 1140,1653 1292 1292 20702 0167,0168,05 78, 1168,1169 0168,0260,05 77, 0578,0808,22 11, 2212 2406 2,2'-[5-(hydroxymethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile) 93.3% CHNO 99.5% CHO 2406 2556 0210,0211,16 54 2405 2405 2593 0972 0198 0136 88.2% CHNOS,5HO; morphine sulfate 88,0% CHNO ; Batch 4 is valid until 31 July 2012 22.3 Ph. Eur. Units per ml 0136 0198 0579,0580 0580 1381 93.5% CHO 99.8% CHNO; Arginine CRS 2 is suitable for monographs 01/2008:0806, 04/2008:1654, 01/2008:2114 and 01/2008:0930 only ; Batch 2 is valid until 31 January 2012 1054 0806,0930,16 54, 2114 2096 0805,0885,09 98 20821 5 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C Extra charges j j a
Y0000005 Amphotericin B New Y0001014 Amphotericin B for peak identification Y0001361 Amphotericin B for microbiological assay A1000000 Ampicillin (anhydrous) A1100000 Ampicillin trihydrate
4 2 1 4 2
100 mg 10 mg 100 mg 250 mg 150 mg
1 1 1 1 1
Batch 4 is not suitable for microbiological assay (see leaflet). Batch 1 is valid until 1 June 2013 944 IU per mg 97.6% CHNOS
-20C -20C -20C +5C +5C
c c c a a
Y0001522 Anastrozole Y0001531 Anastrozole impurity E Y0001386 Angelica dahuria root A1200000 Anhydrotetracycline hydrochloride Y0001244 Amylmetacresol Y0001245 Amylmetacresol for peak identification Y0001466 Anhydrous Docetaxel A1210000 Antazoline hydrochloride A1220000 Alpha-apo-oxytetracycline Y0001465 Apomorphine hydrochloride hemihydrate Y0001471 Apomorphine impurity B (morphine sulfate) * - narc A1230000 Beta-apo-oxytetracycline A1250000 Aprotinin solution BRP Y0001154 Aprotinin for system suitability A1269000 L-Arabinitol Y0000806 Arbutin A1270000 Arginine
1 n/a 1 4 1 1 1 1 4 1 1 5 3 1 1 1 3
100 mg 10 mg 160 mg 15 mg 285 mg 10 mg 15 mg 50 mg 20 mg 15 mg 40 mg 20 mg 0.5 ml 2.7 mg 10 mg 100 mg 50 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a a g g a a g a k g a a a a a
Y0000304 Arginine aspartate A1271000 Arginine hydrochloride Y0001323 Aristolochia Council of Europe, all rights reserved 2013
1 2 1
20 mg 50 mg 140 mg
1 1 1
+5C +5C +5C
a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001185 Aristolochic acid I Y0001175 Aristolocholic acid for system suitability Y0000079 Articaine hydrochloride Y0000080 Articaine impurity A Y0000081 Articaine impurity E A1300000 Ascorbic acid Y0001024 Ascorbic acid impurity C Y0001170 Ascorbic acid impurity D Y0000800 Ascorbyl palmitate Y0000305 Asparagine monohydrate A1320000 Aspartame A1321000 Aspartame impurity A A1330000 Aspartic acid Y0001171 Astragaloside IV A1340000 Atenolol Y0001089 Atenolol for system suitability Y0001327 Atorvastatin calcium trihydrate Y0001328 Atorvastatin impurity A Y0001329 Atorvastatin impurity B Y0001330 Atorvastatin impurity C Y0001331 Atorvastatin impurity D Y0001332 Atorvastatin impurity E Y0000424 Atracurium besilate Y0000105 Rutoside trihydrate Y0000503 Atracurium for impurity F identification Y0000504 Atracurium for peak identification Y0000878 Atropine Y0000845 Atropine for peak identification Y0000816 Atropine impurity B A1400000 Atropine sulfate Y0000029 Azaperone A1500000 Azathioprine Y0001240 Azathioprine impurity A Council of Europe, all rights reserved 2013 Batch n 1 1 2 2 1 4 2 2 1 1 2 4 2 1 3 1 1 1 1 1 1 2 2 3 1 1 1 2 1 3 1 1 1 Quantity Sale per vial Unit 1 mg 1 1.00 mg CHNO 1 mg 100 mg 15 mg 10 mg 100 mg 20 mg 10 mg 10 mg 60 mg 40 mg 10 mg 50 mg 40 mg 100 mg 5 mg 150 mg 10 mg 10 mg 10 mg 10 mg 10 mg 120 mg 100 mg 5 mg 5 mg 30 mg 0.25 mg 10 mg 50 mg 50 mg 100 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1-methyl-4-nitro-1H-imidazol-5-amine 6 Batch 1 is valid until 31 January 2013 (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate (noratropine) 95.2% CHCaFNO desfluoroatorvastatin 3-epi-atorvastatin fluoroatorvastatin 3-[(4-fluorophenyl)carbonyl]-2-(2-methylpropanoyl)-N,3-diphenyloxirane-2carboxamide ent-atorvastatin ; Batch 1 is valid until 28 February 2013 98.5% CHNOS ; Batch 1 is valid until 30 April 2012 87.6% CHO ; Batch 2 is valid until 31 January 2012 2-(5-benzyl-3,6-dioxopiperazin-2-yl) acetic acid (diketopiperazine) methyl3-[[2-(propylamino)acetyl]amino]-4-methylthiophene-2- carboxylate methyl 4-methyl-3-[[(2RS)-2-[(1-methylethyl)amino]propanoyl]amino] thiophene-2-carboxylate Vitamin C ; Batch 3 is valid until 31 December 2012 D-xylo-hex-2-ulosonic acid (D-sorbosonic acid) methyl D-xylo-hex-2-ulosonate (methyl D-sorbosonate) ; Batch 1 is valid until 31 December 2012 Information Monograph 20821 20821 1688 1688 1688 0253,1791 0253,1791 0253,1791 0807 2086 0973 0973 0750,0797 2435 0703 0703 2191 2191 2191 2191 2191 2191 1970 1795,2184,24 27,1874 1970 1970 2056 0068,2056 0068,2056 0068 1708 0369 Yes Yes Yes Yes Yes Yes Yes Leaflet Yes Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g a a a a a a a a a a a c a a a a a a a a g(b) a g(b) g(b) g g g g a a
0369 +5C a For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001246 Azathioprine impurity G Y0000326 Azelastine hydrochloride Y0000327 Azelastine impurity B Y0000328 Azelastine impurity D Y0000329 Azelastine impurity E Y0000306 Azithromycin Y0000637 Azithromycin for peak identification Y0000641 Azithromycin for system suitability Y0000307 Azithromycin impurity A Y0000285 B19 virus DNA for NAT testing BRP Batch n 2 1 1 1 1 3 2 5 2 1 Quantity Sale Information per vial Unit 5 mg 1 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purin-2-amine (thiamiprine) ; Batch 1 is valid until 30 April 2012 25 mg 5 mg 5 mg 5 mg 200 mg 15 mg 0.05 mg 10 mg 150 mg 1 1 1 1 1 1 1 1 5 Batch 4 is valid until 30 June 2012 6-demethylazithromycin B19 virus DNA content log 5.8 IU per ml for plasma pool testing by NAT 1-benzoyl-2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]diazane 4-(4-chlorobenzyl)phthalazin-1(2H)-one 3-(4-chlorobenzilidene)isobenzofuran-1(3H)-one 94.6% CHNO Monograph 0369 1633 1633 1633 1633 1649 1649 1649 1649 See leaflet, 0557, 1527,1646 0808,0852 0465,0466,20 702 0653 91.4% CHClNO; ()-4-amino-3-(4-chlorophenyl)butyric acid lactam ; Batch 2 is valid until 31 January 2013 88.5% CHO 0653 2438 1293 0170 1975 1975 99.2% CHClO ; Batch 3 is valid until 1 June 2013 0654,1449, 1709 1709 Batch 2 is valid until 28 February 2013 0654,1709 0654,1709 0654,1709 99.5 % CHClNO [(3R)-3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2-oxo-2,3,4,5tetrahydro-1H-1-benzazepin-1-yl]acetic acid 4-amino-6-(trifluoromethyl)benzene-1,3-disulphonamide 2388 2388 2388 0370 0370 1601 7 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C Extra charges a g g g g a a a a e(d)
B0070000 Bacampicillin hydrochloride B0100000 Bacitracin zinc B0200000 Baclofen B0200050 Baclofen impurity A Y0001273 Baicalin B0250000 Bambuterol hydrochloride B0300000 Barbital - * psy Y0001525 Basic butylated methacrylate copolymer Y0000295 Basic butylated methacrylate copolymer -reference spectrum New B0305000 Beclometasone dipropionate anhydrous Y0000351 Beclometasone dipropionate monohydrate Y0000352 Beclometasone dipropionate for system suitability Y0000469 Beclometasone dipropionate for peak identification Y0001073 Beclometasone dipropionate impurities F and N Y0001025 Benazepril hydrochloride Y0001038 Benazepril for system suitability Y0001026 Benazepril impurity A B0400000 Bendroflumethiazide Y0000564 Bendroflumethiazide impurity A Y0000044 Benfluorex hydrochloride Council of Europe, all rights reserved 2013
3 2 1 3 1 1 1 1 1 4 1 3 1 1 1 1 1 1 1 1
120 mg 150 mg 50 mg 50 mg 10 mg 100 mg 500 mg 20 mg n/a 150 mg 10 mg 15 mg 10 mg 0.052 mg 160 mg 0.016 mg 10 mg 100 mg 5 mg 50 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
92.9% CHClNOS 62.9 IU per mg
+5C -20C +5C +5C +5C +5C +5C +5C
a b g g a a j a l
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a a a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000043 Benfluorex hydrochloride for system suitability B0470000 Benperidol B0477000 Benserazide hydrochloride B0477010 Benserazide impurity A Y0001071 Benserazide impurity C Y0001079 Benserazide for peak identification Y0001064 Benzaldehyde Y0001060 Benzalkonium chloride for system suitability B0490000 Benzarone B0500000 Benzathine benzylpenicillin Y0000775 Benzbromarone B0550000 Benzethonium chloride B0600000 Benzocaine Y0001470 Benzoic acid Y0000647 Benzophenone Y0000167 Benzyl alcohol B0670000 Benzyl benzoate - reference spectrum B0680000 S-Benzylmercaptoacetyltriglycin B0700000 Benzylpenicillin potassium B0900000 Benzylpenicillin sodium Y0001149 Berberine chloride B0950000 Betadex Y0000391 Betahistine dihydrochloride B0990000 Betahistine mesilate B1000000 Betamethasone B1030000 Betamethasone acetate B1040000 Betamethasone dipropionate Y0001416 Betamethasone dipropionate for peak identification Y0001418 Betamethasone dipropionate for system suitability Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 3 1 2 1 1 1 1 1 2 1 1 2 7 1 4 2 1 4 2 3 1 1 Quantity Sale per vial Unit 360 mg 1 100 mg 50 mg 20 mg 10 mg 10 mg 150 mg 20 mg 10 mg 200 mg 10 mg 100 mg 50 mg 30 mg 40 mg 50 mg n/a 10 mg 50 mg 200 mg 20 mg 200 mg 50 mg 100 mg 75 mg 100 mg 150 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 8 99.5% CHFO; Betamethasone dipropionate CRS 2 is suitable for monograph 01/008:0809 only. ; Batch 2 is valid until 31 March 2012 99.4% CHNNaOS; Penicillin G sodium 84.3% CHClNO 88.4% [CHO] Batch 1 is valid until 31 May 2012 See leaflet (2-ethylbenzofuran-3-yl)(4-hydroxyphenyl)methanone 90.7% CHNOS 24.1% CHN (N,N'-dibenzylethylenediamine) ()-2-amino-3-hydroxypropanohydrazide (2RS)-2-amino-3-hydroxy-2'-[(1EZ)-(2,3,4-trihydroxybenzylidene)] propanohydrazide Information Monograph 1601 1010,1172,12 54, 1708 1173 1173 1173 1173 0372,0371 0371,0372 1393 0373 1393 0974 0011,1088 2424,2425,24 74 1784 0256,0371,03 72,1827 0705 1372 0113,0148,01 49 0113,0114,01 48, 0149 1831,2500 1070,1487,18 04 1665 1071 0312,0354,03 88, 0561,0811 0548,0975 0809 0809 0809 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a a g g a a g g a a g a l +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C a a a a a a a g g g g g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code B1045000 Betamethasone sodium phosphate B1054000 Betamethasone 17-valerate B1055000 Betamethasone 21-valerate Y0001027 Betamethasone valerate for system suitability Y0001065 Betamethasone valerate impurity mixture New B1103000 Betaxolol hydrochloride B1103100 Betaxolol impurity A Y0001354 Betaxolol impurity C Y0001360 Betaxolol for peak identification B1115000 Bezafibrate Y0001444 Bicalutamide Y0001448 Bicalutamide for system suitability Y0001078 Bicisate labelling kit B1110000 Bifonazole B1110004 Bifonazole impurity B Y0001421 Bifonazole for system suitability Y0001059 Bilberry dry extract B1116000 Biotin B1120000 Biperiden hydrochloride B1121000 Biperiden impurity A B1140000 Bisacodyl Y0000608 Bisacodyl for peak identification Y0000694 Bisacodyl for system suitability Y0000812 Bisoprolol fumarate Y0000877 Bisoprolol for peak identification Y0000813 Bisoprolol for system suitability B1141000 Bleomycin sulfate Y0000434 Boldine B1142000 Bordetella pertussis mouse antiserum BRP B1143000 Bromazepam - * psy Y0000645 Bromazepam for system suitability - * psy B1145000 Bromhexine hydrochloride Council of Europe, all rights reserved 2013 Batch n 3 3 3 1 2 2 2 1 1 1 1 1 1 1 3 1 1 2 1 2 3 1 1 1 2 2 1 2 1 3 1 3 Quantity Sale per vial Unit 100 mg 1 100 mg 15 mg 25 mg 0.018 mg 60 mg 10 mg 5 mg 15 mg 100 mg 100 mg 15 mg 24 mg 100 mg 10 mg 10 mg 250 mg 20 mg 60 mg 20 mg 50 mg 10 mg 5 mg 50 mg 1 mg 1 mg 7 mg 30 mg 0.5 mg 60 mg 10 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 Bisoprolol for system suitability method A CRS has been renamed as Bisoprolol for peak identification CRS. ; Batch 1 is valid until 31 August 2012 Bisoprolol for system suitability method B CRS has been renamed as Bisoprolol for system suitability CRS ; Batch 1 is valid until 30 April 2012 8910 IU per vial; bleomycin A : 67.0%; Bleomycin B : 29.2%; demethylbleomycin A : 2.6% 98.8% CHNO ; Batch 1 is valid until 31 January 2012 Anti-PT: 19.5 ELU/vial Anti-FHA: 69 ELU/vial Anti-69k: 17 ELU/vial Anti-Fim 2/3: 28 ELU/vial (1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl- 3(piperidin-1-yl)propan-1-ol (endo form) 3.44% of cyanidin 3-O-glucoside chloride (CHClO) Vitamin H 4-[(RS)-(biphenyl-4-yl)phenylmethyl]-1H-imidazole trifluoroacetate 99.8% CHFNOS Batch 1 is valid until 31 December 2012 Batch 1 is valid until 1 June 2013 (2RS)-1-(4-ethylphenoxy)-3-[(1-methylethyl)amino]propan-2-ol 2-[[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane Information Monograph 0549,0810 0322,0811 0811 0811 0811 1072 1072 1072 1072 1394 2196 2196 2123 1395 1395 1395 2394 1073 1074 1074 0595 0595 0595 1710 1710 1710 0976,20702 1396, 1816 See leaflet, 20716 0778,0879 0879 0706 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C -20C +5C +5C +5C Extra charges g g g g g a a c a a g g g a a a c a g g a a a a a a a a c j j g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code New Y0000200 Bromhexine impurity C B1150000 Bromocriptine mesilate Y0000677 Bromocriptine mesilate for system suitability B1152000 Bromperidol B1152050 Bromperidol decanoate B1153000 Brompheniramine maleate Y0000468 Brotizolam - * psy Y0000470 Brotizolam impurity B B1155000 Brucella melitensis Rev. 1 strain BRP - * MOT (Biotox) B1157300 Budesonide Y0001148 Budesonide for system suitability B1156000 Bufexamac B1157400 Buflomedil hydrochloride New Y0001529 Buflomedil for peak identification B1157410 Buflomedil impurity B B1158000 Bumetanide Y0000309 Bumetanide impurity A Y0000310 Bumetanide impurity B B1160000 Bupivacaine hydrochloride Y0000088 Bupivacaine impurity B Y0000089 Bupivacaine impurity E Y0001108 Buprenorphine - * psy Y0001109 Buprenorphine hydrochloride - * psy Y0001122 Buprenorphine for system suitability - * psy B1168000 Buserelin B1168020 D-His-Buserelin Y0000131 Buspirone hydrochloride Y0000471 Buspirone for system suitability B1170000 Busulfan Y0001487 Butyl methacrylate Y0001304 Butyl methanesulfonate B1217000 Butyl parahydroxybenzoate Y0001357 Butyl parahydroxybenzoate impurity E B1212000 Butylhydroxyanisole Council of Europe, all rights reserved 2013 Batch n 3 2 1 1 1 1 1 1 1 4 1 1 2 1 2 1 1 1 2 2 2 1 1 1 2 1 1 1 1 n/a 1 2 1 3 Quantity Sale Information per vial Unit 10 mg 1 N-(2-aminobenzyl)-N-methylcyclohexanamine ; Batch 2 is valid until 1 June 2013 30 mg 5 mg 100 mg 60 mg 100 mg 10 mg 10 mg 1 mg 110 mg 10 mg 100 mg 100 mg 0.45 mg 20 mg 150 mg 5 mg 5 mg 100 mg 20 mg 20 mg 10 mg 10 mg 10 mg 2 mg 0.5 mg 5 mg 2 mg 50 mg 100 mg 30 L 100 mg 15 mg 50 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 10 See leaflet 2-methylpropyl 4-hydroxybenzoate (iso-butyl parahydroxybenzoate) 2.00 mg per vial of CHNO (2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide 6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide 3-nitro-4-phenoxy-5-sulphamoylbenzoic acid 3-amino-4-phenoxy-5-sulphamoylbenzoic acid 4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1-one 99.7% CHO 2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (demethylbrotizolam) Monograph 0706 0596 0596 0616,1178 1397,1431 0977,1196 2197 2197 0793 1075 1075 1179 1398 1398 1398 1076 1076 1076 0541 0541 0541 1180 1181 1180,1181 1077 1077 1711 1711 0542 1975 20537,20538, 20539 0881,1216 0881 0880 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a g(c) g(c) a a a j a e(b) a a a a a a a a a g a g j j j c c g g g g a a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code B1215000 Butylhydroxytoluene Batch n 1 Quantity Sale per vial Unit 50 mg 1 Plastic additive 07 Information Monograph 0581,30103, 30105,30106, 30107 1773 0267,0268,15 04 0267, 0268 95.3% CHO ; Batch 3 is valid until 28 February 2013 1295 1295 2011 93.9% CHO 0.95 mg per vial CHNOS ; Batch 8 is valid until 1 June 2013 About 0.9 mg per ml about 0.1mg N-acetyl-cys-1-calcitonin per vial 99.8% CHO ; Batch 7 is valid until 31 July 2012 2011,2284 2284 0471 0471 0471 0883 0883 1182 85.5 % CHCaNO Calcium digluconate 0978,1606 1399 0172,0658,09 79,1399,2161 ,2162,2164,2 364 1296 20234 0470 0655,1600 2375 2375 2573 0688 1401,1471 98,7% CHNO ; (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8methylnon-6-enamide ; Batch 1 is valid until 1 April 2013 1859,2336,23 37 1079 1079 87.4% CHBrNO; (2S)1-[(2S)-3-bromo-2-methylpropanoyl]pyrrolidine-2carboxylic acid 11 1079 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C Extra charges g
Y0000472 Cabergoline C0100000 Caffeine Y0000787 Caffeine for system suitability C0166000 Calcifediol C0166001 Calcifediol - reference spectrum Y0000499 Calcipotriol (anhydrous) - reference spectrum Y0000473 Calcipotriol monohydrate Y0000474 Calcipotriol monohydrate - reference spectrum New C0200000 Calcitonin (salmon) Y0000632 Calcitonin-Gly C0200010 N-acetyl-cys1-calcitonin C0225000 Calcitriol C0226000 Calcitriol - reference spectrum C0249000 Calcium ascorbate - reference spectrum C0250000 Calcium folinate C0299000 Calcium glucoheptonate C0300000 Calcium gluconate
1 4 2 4 1 1 1 1 9 2 4 8 1 1 5 1 1
100 mg 70 mg 20 mg 5 mg n/a n/a 5 mg n/a 1 mg 0.4 ml 20 mg 10 mg n/a n/a 100 mg 60 mg 100 mg
1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1
99.8% CHNO See leaflet
-20C +5C +5C -20C
c g g e(d) l l
+5C -20C -20C -20C -20C
g l c c c e(d) l l
+5C +5C +5C
a a a
C0340000 Calcium levulinate dihydrate C0350000 Calcium oxalate monohydrate C0400000 Calcium pantothenate C0405000 Camphor (racemic) Y0001388 Candesartan cilexetil Y0001387 Candesartan cilexetil for peak identification Y0001389 Candesartan cilexetil for system suitability C0410000 Canrenone C0426000 Caprylic acid Y0000671 Capsaicin C0430000 Captopril Y0001182 Captopril for system suitability Y0001219 Captopril impurity B Council of Europe, all rights reserved 2013
1 1 3 1 1 1 1 3 1 2 2 1 1
250 mg 500 mg 60 mg 50 mg 60 mg 10 mg 10 mg 50 mg 200 mg 50 mg 10 mg 20 mg 10 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 Loss of 12.1% m/m (U= 0.2%, n=10, k=2.23)
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a g a a a g g g a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001220 Captopril impurity C Y0001221 Captopril impurity D Y0000435 Captopril impurity E Y0001450 Captopril impurity J Y0000113 Carbachol C0450000 Carbamazepine Y0000033 Carbamazepine impurity A C0451000 Carbasalate calcium - reference spectrum Y0001161 Carbasalate impurity B C0455000 Carbenicillin sodium C0460000 Carbidopa C0465000 Carbimazole C0470000 Carbocisteine C0499900 Carbon dioxide - reference spectrum C0550000 Carboplatin - reference spectrum Y0000475 Carboprost trometamol Y0000536 Carboprost trometamol - reference spectrum Y0000035 Carisoprodol Y0000036 Carisoprodol impurity A Y0001214 Carmellose C0580004 Carmustine - reference spectrum C0580010 Carmustine impurity A Y0000846 Carprofen for veterinary use Y0000884 Carprofen for system suitability Y0000192 Carteolol hydrochloride - reference spectrum Y0000193 Carteolol for system suitability Y0001427 Carvedilol Y0000075 Carvedilol - reference spectrum Y0000103 Carvedilol impurity C Y0001426 Carvedilol for system suitability C0600000 Casein BRP C0630000 Cefaclor C0640000 Delta-3-Cefaclor Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 4 5 1 1 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 3 2 3 Quantity Sale Information per vial Unit 10 mg 1 84.8% CHOS; (2RS)-2-methyl-3-sulphanylpropanoic acid 10 mg 1 85.4% CHBrO; (2RS)-3-bromo-2-methylpropanoic acid 10 mg 10 mg 50 mg 200 mg 10 mg n/a 5 mg 50 mg 50 mg 120 mg 60 mg n/a n/a 40 mg n/a 50 mg 10 mg 10 mg n/a 20 mg 30 mg 5 mg n/a 30 mg 50 mg n/a 10 mg 10 mg 100000 mg 450 mg 20 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 12 Batch 2 is valid until 31 December 2012 95.0% CHClNOS (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H- carbazol-4-yloxy) propan-2-ol 1,3-bis(2-chloroethyl)urea (2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)carbamate 99.1% CHNO 99.7% CHNOS ; Batch 1 is valid until 30 June 2012 100.0% CHNO 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (10,11dihydrocarbamazepine) (2S)-1-isobutyryl-pyrrolidine-2-carboxylic acid 92.5% CHNOS; (2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl] pyrrolidine-2-carboxylic acid (acetylcaptopril) Monograph 1079 1079 1079 1079 1971 0543 0543 1185 1185 0956 0755 0884 0885 0375 1081 1712 1712 1689 1689 2360 1187 1187 2201 2201 1972 1972 1745 1745 1745 1745 0350 0986 0986 Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a g a a l +5C +5C +5C +5C +5C a a a a a l l -20C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C -20C c l a a a l g(c) g g l a g l g g a a c
List of European Pharmacopoeia Reference Standards Order Code C0650000 Cefadroxil Reference Standard Batch n 2 3 2 1 3 1 1 1 3 1 1 1 3 2 1 1 4 1 3 n/a 1 1 1 1 1 1 1 4 2 1 2 1 Quantity Sale per vial Unit 250 mg 1 93.7% CHNOS 150 mg 100 mg 10 mg 125 mg 100 mg 150 mg 60 mg 150 mg 150 mg 15 mg 10 mg 200 mg 100 mg n/a 80 mg 30 mg 10 mg 100 mg 15 mg 70 mg 10 mg 10 mg 120 mg 10 mg 20 mg 10 mg 300 mg 15 mg 0.04 mg 200 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 13 93.9% Must be used with Cefradine impurity mixture CRS Y0001174 Must be used with Cefradine for peak identification Y0000568 85.3% CHNOS (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid (p-hydroxyphenylglycine) 97.1% CHNOS 97.4% CHNNaOS 94.3% CHNOS (6R,7R)-7-amino-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 88.8% CHNOS 94.2% CHNOS 99.0% CHNNaOS 98.5% CHNNaOS 81.8% CHNOS 7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4-yl)sulfanyl]-methyl-8- oxo-5-thia-1azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (7-ACA triazole) 99.6% CHNOS 95.2% CHClNOS 94.2% CHNOS 98.8% CHNNaOS Information Monograph 0260,0577,08 13,2342 0708,0814 0987 0987 1402 1650 1403 1403 0988 2126 2126 2126 1188 1404 1404 0989 0708,0989 0989 0990 0990 2341 2341 2341 2342 2342 2342 2342 0167,0168,05 78, 0708,0814 0814 0814 1405 1405, 2344 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a a a a a g g g(c) c a l a a a g g b b b a a a a a a a g g
C0675000 Cefalexin monohydrate C0682000 Cefalotin sodium Y0000505 Cefalotin for impurity B identification C0682300 Cefamandole nafate Y0000240 Cefapirin sodium C0682400 Cefatrizine propylene glycol C0682410 Cefatrizine impurity A C0682800 Cefazolin Y0000633 Cefepime dihydrochloride monohydrate Y0000634 Cefepime dihydrochloride monohydrate for system suitability Y0001336 Cefepime impurity E C0684000 Cefixime C0684750 Cefoperazone dihydrate C0684800 Cefoperazone sodium - reference spectrum Y0000420 Cefotaxime acid C0685000 Cefotaxime sodium Y0000506 Cefotaxime for peak identification C0688000 Cefoxitin sodium Y0001496 Cefoxitin sodium for peak identification Y0001305 Cefpodoxime proxetil Y0001318 Cefpodoxime proxetil for impurity H identification Y0001306 Cefpodoxime proxetil for peak identification Y0001371 Cefprozil Y0001368 Cefprozil impurity mixture Y0001372 Cefprozil impurity A Y0001367 Cefprozil for peak identification C0690000 Cefradine Y0000568 Cefradine for peak identification Y0001174 Cefradine impurity mixture C0690500 Ceftazidime Y0001111 Ceftazidime for peak identification Council of Europe, all rights reserved 2013
List of European Pharmacopoeia Reference Standards Order Reference Standard Code C0690510 Ceftazidime impurity A Batch n 3 Quantity Sale Information per vial Unit 15 mg 1 89.9% CHNOS ; (6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2-[(1carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5- thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylate (delta-2ceftazidime) Ceftazidime impurity A CRS is currently not available, it has been temporarily replaced by Ceftazidime for peak identification CRS (Y0001111) 90.4% CHNNaOS E-isomer 97.4% CHNOS 96.7% CHNNaOS 99.9% CHFNOS 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide 4-[3-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide 1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea Batch 1 is valid until 30 June 2012 Monograph 1405 Leaflet
C0691000 Ceftriaxone sodium C0692000 Ceftriaxone impurity A C0694990 Cefuroxime axetil C0695000 Cefuroxime sodium Y0001445 Celecoxib Y0001446 Celecoxib impurity A Y0001447 Celecoxib impurity B Y0000311 Celiprolol hydrochloride Y0000312 Celiprolol impurity I Y0000239 Celiprolol for peak identification Y0000784 Cellulose acetate C0698005 Cellulose acetate butyrate - reference spectrum Y0001054 Cellulose acetate phthalate C0700000 Cephaline hydrochloride
3 4 3 3 1 1 1 1 1 2 1 1 1 3
100 mg 10 mg 60 mg 150 mg 200 mg 10 mg 10 mg 10 mg 0.02 mg 20 mg 40 mg n/a 10 mg 15 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1
0991 0991 1300 0988,0992 2591 2591 2591 1632 1632 1632 0887 1406 0314 0080,0081,00 93, 0094,1530,18 75 1084
Yes
+5C +5C +5C
a a a a a a a a a a a l a g
Yes Yes
+5C +5C +5C +5C +5C +5C
Yes
+5C +5C +5C +5C
C0980650 Cetirizine dihydrochloride C0980651 Cetirizine impurity A Y0001197 Cetirizine for peak identification C0984100 Cetostearyl isononanoate - reference spectrum C0990000 Cetyl alcohol
4 4 1 1 1
100 mg 10 mg 1.01 mg n/a 250 mg
1 1 1 1 1 100% CHO (RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine Replaces Cetirizine impurity mixture CRS
+5C +5C Yes Yes +5C +5C
g g g l a
1084 1084 1085 0540,0702,08 01, 0802,0847,09 69, 1411 1906 1906
Y0000073 Cetyl palmitate 15 Y0000074 Cetyl palmitate 95 C1000000 Cetylpyridinium chloride C1050000 Chenodeoxycholic acid Y0000104 Chitosan hydrochloride C1100000 Chlorambucil Y0001298 Chlorambucil for system suitability Council of Europe, all rights reserved 2013
1 1 2 2 1 1 1
60 mg 50 mg 20 mg 125 mg 30 mg 100 mg 10 mg
1 1 1 1 1 1 1 14 Batch 1 is valid until 30 April 2012
+5C +5C +5C +5C +5C +5C Yes +5C
a a g a a g g
0379 1189,1275 1774 0137 0137
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001299 Chlorambucil with impurity G C1200000 Chloramphenicol C1300000 Chloramphenicol dipalmitate C1350000 Chloramphenicol disodium disuccinate C1400000 Chloramphenicol palmitate isomer C1425000 Chloramphenicol sodium succinate C1435000 Chlorcyclizine hydrochloride C1450000 Chlordiazepoxide - * psy C1500000 Chlordiazepoxide hydrochloride - * psy Y0000476 Chlordiazepoxide impurity A C1510000 Chlorhexidine C1520000 Chlorhexidine diacetate C1540000 Chlorhexidine dihydrochloride C1530000 Chlorhexidine for performance test Y0000569 Chlorogenic acid Batch n 1 3 1 3 1 1 1 1 1 1 4 2 2 5 1 Quantity Sale per vial Unit 10 mg 1 500 mg 100 mg 25 mg 100 mg 1500 mg 100 mg 50 mg 100 mg 10 mg 50 mg 10 mg 50 mg 50 mg 20 mg 1 1 1 1 1 1 2 1 1 1 1 1 1 1 96.9% CHO ; (1S,3R,4R,5R)-3-[(3,4-Dihydroxycinnamoyl)oxy]-1,4,5trihydroxycyclohexanecarboxylic acid 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide 91.1% CHClNNaO Information Monograph 0137 0071,0473,07 09 0473 0709 0473 0709 1086 0656,1974 0474 0474,0656 0658 0657 0659 0657,0658,06 59 1821,1822,18 23, 1824,1866,18 97, 2389 1190 0544,0545 0385,0394 0386,0977,10 84, 1196 2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino) ethyl]butanenitrile (3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1amine 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1amine S-oxide (chlorpromazine sulphoxide) 3-(2-chloro-10H-phenothiazin-10-yl)-N-methypropan-1-amine (demethylchlorpromazine) 2-chloro-10H-phenothiazine 3-(4-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine 1,3-Dipropylurea 2.0% E-isomer 15 0386 0386 0475,20303 0475 0475 0475 0475 1087 1087 0815,1365 Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g g g a j j a g g g g a
C2223030 1-(4-Chlorophenyl)-1-phenylethanol C1650000 Chloroquine sulfate C1700000 Chlorothiazide C1800000 Chlorphenamine maleate Y0000436 Chlorphenamine impurity A Y0000437 Chlorphenamine impurity C C1900000 Chlorpromazine hydrochloride Y0000507 Chlorpromazine impurity A Y0000479 Chlorpromazine impurity D Y0000508 Chlorpromazine impurity E Y0001449 Chlorpromazine impurity F C1905000 Chlorpropamide C1905020 Chlorpropamide impurity B C1915000 Chlorprothixene hydrochloride Council of Europe, all rights reserved 2013
3 3 2 1 3 1 1 1 1 1 1 1 1 4
15 mg 200 mg 100 mg 100 mg 0.01 mg 10 mg 200 mg 15 mg 10 mg 10 mg 2 mg 100 mg 50 mg 50 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1
Clemastine fumarate impurity C
-20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g(c) g a g g g f f f g f a a g
List of European Pharmacopoeia Reference Standards Order Code C1950000 Chlortalidone Reference Standard Batch n 2 2 5 1 8 Quantity Sale per vial Unit 150 mg 1 99.5% CHClNOS 1.017 mg 100 mg 20 mg 480 mg 1 1 1 1 100% CHO ; Vitamin D3 ; Batch 7 is valid until 30 June 2012 92.4% of of C22H24Cl2N2O8 ; Batch 4 is valid until 31 December 2012 Information Monograph 0546 0546 0173 0173 0072,0574,05 75, 0598,1192,11 93 0072,0082,05 74, 0575,0598 0993,0593 1189 99.6 % HO(CHNNaOS) ; Batch 1 is valid until 1 May 2013 6.01 microkatals per mg 99.8 % CHO (2S)-2-cyclohexyl-11b-hydroxy-3,20-dioxo-16bH-[1,3]dioxolo[4,5:16,17] pregna-1,4-diene-21-yl 2-methylpropanoate (S-epimer of ciclesonide) (2R)-2-cyclohexyl-11b,21-dihydroxy-16bH-[1,3]dioxolo[4,5:16,17] pregna-1,4-diene-3,20-dione (2R)-2-[(1RS)-cyclohex-3-enyl]-11b-hydroxy-3,20-dioxo-16bH-[1,3]dioxolo [4,5:16,17]pregna-1,4-diene-21-yl 2-methylpropanoate ()-2-(3-cyclohexyl-5-methyl-4,5-dihydroisoxazol-5-yl)acetic acid 6-cyclohexyl-4-methyl-2H-pyran-2-one Batch 1 is valid until 31 May 2012 98.5% CHNO 2064,2090 2064 0476,0694 2703 2703 2703 2703 1407 1302,1407 1302,1407 1302 0994 0994 1408 1499 1,1-dimethylethyl(1S,9S)-9-[[(S)-1-ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-caboxylate (1S,9S)-9-[[(R)-1-ethoxycarbonyl-3-phenylpropyl]amino]-10- oxooctahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid 1499 1499 0756 1500 0756 756 16 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C -20C Extra charges a a a a g(c)
Y0000779 Chlortalidone for peak identification C2000000 Chlortetracycline hydrochloride Y0001451 Chlortetracycline for system suitability C2100000 Cholecalciferol
C2150000 Cholecalciferol for system suitability C2155000 Cholesterol C2158000 Cholic acid New Y0000280 Chondroitin sulfate sodium Y0000593 Chondroitin sulfate sodium (marine) C2160000 Chymotrypsin BRP Y0001553 Ciclesonide New Y0001554 Ciclesonide containing impurity A Y0001555 Ciclesonide impurity B New Y0001556 Ciclesonide impurity C Y0000040 Ciclopirox C2162701 Ciclopirox impurity A C2162702 Ciclopirox impurity B C2162700 Ciclopirox olamine C2163000 Ciclosporin Y0000361 Ciclosporin for system suitability C2170000 Cilastatin sodium C2174000 Cilazapril C2174002 Cilazapril impurity A C2174005 Cilazapril impurity D C2175000 Cimetidine C2175500 Cimetidine hydrochloride Y0001130 Cimetidine for peak identification Y0001146 Cimetidine for system suitability Council of Europe, all rights reserved 2013
6 3 2 2 1 2 1 1 1 1 1 3 3 2 3 1 2 1 1 1 1 1 1 1
1 mL 100 mg 60 mg 250 mg 100 mg 100 mg 150 mg 15 mg 10 mg 10 mg 100 mg 20 mg 20 mg 150 mg 120 mg 5 mg 10 mg 50 mg 25 mg 10 mg 50 mg 100 mg 10 mg 0.5085 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 99.5% CHO
-20C Yes +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g(c) a a a a a a a a a g g c g a a a a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code C2177000 Cinchocaine hydrochloride Y0000176 Cineole C2180000 Cinnarizine Y0000362 Ciprofibrate Y0000363 Ciprofibrate for system suitability Y0000198 Ciprofloxacin C2190000 Ciprofloxacin hydrochloride Y0000199 Ciprofloxacin hydrochloride for peak identification C2190050 Ciprofloxacin impurity A C2210000 Cisplatin Y0001018 Cisplatin impurity A Y0001019 Cisplatin impurity B Y0001008 Citalopram hydrobromide Y0001007 Citalopram hydrochloride Y0000855 Citalopram for system suitability A1202000 Citric acid (anhydrous) C2219000 Citric acid monohydrate Y0000639 Cladribine Y0000609 Cladribine for peak identification Y0000610 Cladribine impurity C Y0000320 Clarithromycin Y0000321 Clarithromycin for peak identification Y0000269 Clazuril for system suitability Y0001193 Clazuril C2221000 Clebopride malate C2223000 Clemastine fumarate C2248000 Clenbuterol hydrochloride C2248010 Clenbuterol impurity B C2250000 Clindamycin hydrochloride C2269000 Clindamycin phosphate Y0000364 Clioquinol Y0000205 Clobazam - reference spectrum Y0000241 Clobazam impurity A Y0000559 Clobetasol propionate Y0000570 Clobetasol for peak identification Council of Europe, all rights reserved 2013 Batch n 1 2 2 1 1 1 4 1 4 5 1 1 1 1 3 2 1 1 1 1 3 2 1 1 1 1 2 2 4 2 1 1 1 1 1 Quantity Sale per vial Unit 60 mg 1 180 mg 100 mg 5 mg 5 mg 20 mg 100 mg 10 mg 10 mg 100 mg 15 mg 15 mg 5 mg 5 mg 0.065 mg 50 mg 50 mg 50 mg 10 mg 5 mg 160 mg 40 mg 10 mg 10 mg 100 mg 100 mg 30 mg 10 mg 200 mg 250 mg 5 mg n/a 10 mg 40 mg 2 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 17 7-chloro-5-phenyl-1,5-dihydro-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione 99.6% CHClFO 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino] ethanone 94.4% CHClNOS 95.7% CHClNOPS 2-chloro-7H-purin-6-amine 97.7% CHNO ; Batch 2 is valid until 31 March 2012 Batch 1 is valid until 31 October 2012 99.1% CHClNO Batch 2 is valid until 30 September 2012 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (fluoroquinolonic acid) 99.7% [PtCl(NH)] trans-diamminedichloroplatinum (II) 94.1% [PtCl(NH)]-; amminetrichloroplatinate(-) 93.6% CHClFNO Information Monograph 1088 1973 0816 2013 2013 1089 0888,1353 0888,1089 0888,1089,22 29 0599 0599 0599 2288 2203 2203,2288 0455 0456 2174 2174 2174 1651 1651 1714 1714 1303 1190 1409 1409 0582,0583,09 96 0996 2111 1974 1974 2127 2127 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g a a a g g g a g a g g g g g g g(b) g(b) g(b) a a a a a g g g a a g l a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000571 Clobetasol impurity J C2285000 Clobetasone butyrate Y0001137 Clobetasone butyrate for system suitability Y0000888 Clodronate disodium tetrahydrate Y0000885 Clodronate impurity D Y0000313 Clofazimine Y0000358 Clofazimine for system suitability C2300000 Clofibrate C2320000 Clomifene citrate C2332000 Clomifene citrate for performance test C2360000 Clomipramine hydrochloride Y0000132 Clomipramine impurity C Y0000133 Clomipramine impurity D Y0000134 Clomipramine impurity F C2385000 Clonazepam - * psy Y0000286 Clonazepam - reference spectrum C2385015 Clonazepam impurity B C2400000 Clonidine hydrochloride Y0000801 Clonidine impurity B Y0000833 Clopamide Y0000848 Clopamide for system suitability Y0001333 Clopidogrel hydrogen sulfate Y0001335 Clopidogrel impurity A Y0001334 Clopidogrel for system suitability Y0000392 Closantel sodium dihydrate Y0000393 Closantel for system suitability C2424400 Clostridia (multi-component) rabbit antiserum(for vaccines-vet.use)BRP C2424550 Clostridium tetani guinea pig antiserum (for vaccines human use) BRP C2424500 Clostridium tetani guinea pig antiserum (for vaccines vet. use) BRP C2425600 Clostridium tetani rabbit antiserum (for vaccines - vet. use) BRP C2430000 Clotrimazole Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 3 Quantity Sale Information per vial Unit 0.4 mg 1 (17R)-4'-chloro-5'-ethyl-9-fluoro-11-hydroxy-16-methylspiro [androsta-1,4-diene-17,2'(3'H)-furan]-3,3'-dione (17 alpha-spiro compound) 50 mg 30 mg 5 mg 5 mg 150 mg 10 mg 0.5 ml 50 mg 50 mg 100 mg 10 mg 10 mg 5 mg 50 mg n/a 5 mg 100 mg 20 mg 40 mg 10 mg 60 mg 10 mg 100 mg 20 mg 20 mg 1 mg 1 mg 1 mg 1 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 18 see information on the accompanying leaflet 0.20 IU per vial (determined using toxin neutralisation test) 34 IU per vial 15 IU per vial (2S)-(2-chlorophenyl)[6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]acetic acid 1-acetyl-2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazole 3-Amino-4-(2-chlorophenyl)-6-nitro-1-quinolin-2-one 94.5% CHClN; 3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,Ndimethylpropan-1-amine 3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,Ndimethylpropan-1-amine ; Batch 1 is valid until 31 December 2012 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine 44% of Z-isomer CHClNO (chloromethylene)bis(phosphonic acid) Monograph 2127 1090 1090 1777 1777 2054 2054 0318 0997,1046 0997 0889 0889 0889 0889 1974,0415 0890 0890 0477 0477 1747 1747 2531 2531 2531 1716 1716 0362,0363,03 64, 0697 20708 See leaflet, 0697 See leaflet, 0697 0757 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C -20C -20C +5C Extra charges a a a g g a a g a a a a a a j l a f a a a g g g g g c c c c g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000818 Clotrimazole impurity E Y0000849 Clotrimazole for peak identification C2450000 Cloxacillin sodium C2460000 Clozapine Y0000758 Clozapine for peak identification Y0001472 Coagulation Factors V, VIII, XI and XIII plasma Y0000162 Cocaine hydrochloride - reference spectrum C2480000 Cocoyl caprylocaprate Y0000722 Codeine - * narc C2500000 Codeine - reference spectrum Y0000334 Codeine impurity A C2500100 Codeine hydrochloride dihydrate - reference spectrum C2510000 Codergocrine mesilate New Y0001500 Coix seed HRS C2580000 Colchicine Y0000209 Colchicine for system suitability Y0000374 Colestyramine C2600000 Colistimethate sodium Y0000277 Colistin sulfate Batch n 2 2 4 2 1 1 1 1 1 1 3 1 1 1 2 2 1 2 3 Quantity Sale per vial Unit 15 mg 1 1 mg 200 mg 60 mg 0.41 mg 1 mg n/a 40 mg 20 mg n/a 15 mg n/a 60 mg 1300 mg 15 mg 10 mg 10 mg 20 mg 25 mg 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 285000 IU per vial CHNNaOS 33.7% colistin E2, 2.6% colistin E3, 3.3% colistin E1-I, 3.1% colistin E1-7MOA, 44.2 % colistin E1. 25.0 mg of colistin sulphate per vial 576 000 IU per vial; For microbiological assay only 7,8-didehydro-4,5 alpha-epoxy-3,6 alpha-dimethoxy-17-methylmorphinan See leaflet 93.9% CHClNNaOS Batch 1 is valid until 29 February 2012 Information Monograph 0757 Batch 1 is valid until 31 October 2012 0757 0661,0663,06 68, 2260 1191 Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C -20C Extra charges g g a g g d l +5C Yes +5C a k l +5C a l +5C +5C +5C Yes +5C +5C +5C Yes -20C a a g g a a g
1191 Factor V : 0.73 IU per vial, Factor VIII : 0.74 IU per vial, Factor XI : 0.59 IU per 0903,1646,20 vial, Factor XIII : 0.79 IU per vial 740,20722 0073 1411 0076,1839,18 41 0074,0075,00 76 0074,0075,00 76, 1412 1412 1416,2060 2454 0758 0758 1775 0319,20702 0320
C2700000 Colistin sulfate for microbiological assay C2725000 Copovidone - reference spectrum C2800000 Cortisone acetate Y0000438 Coumarin C2900000 Cotton wool standard for neps Y0001053 Crospovidone C2970000 Crotamiton C2970005 Crotamiton impurity A Y0001061 Cyanidin chloride C3000000 Cyanocobalamin Council of Europe, all rights reserved 2013
2 1 6 1 1 1 2 3 1 4
25 mg n/a 250 mg 80 mg 1000 mg 5 mg 100 mg 70 mg 20 mg 20 mg
1 1 1 1 1 1 1 1 1 1
20702 0891 0321,0736,07 67
Yes
-20 C +5C +5C +5C +5C -20C -20C +5C
g l a g a a c c a
99.9% CHO
2120 0036 0892
99.2% CHNO (sum of E and Z-isomers); 3.5% Z-isomers N-ethyl-N-(2-methylphenyl)but-3-enamide ; Batch 2 is valid until 31 March 2012 99.1% CHClO Vitamin B12 19
1194 1194 2394
0269,0270,05 +5C a 47, 0710,1505 For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code C3090000 Cyclizine hydrochloride Y0000886 Cyclizine impurity A Y0000887 Cyclizine impurity B C3200000 Cyclobenzaprine hydrochloride C3230000 Cyclohexa-1,4-dienylglycine C3245000 Cyclopentolate hydrochloride Y0001088 Cyclopentolate for system suitability C3250000 Cyclophosphamide C3280000 Cyproheptadine hydrochloride Y0001095 Cyproheptadine impurity C C3283000 Cyproterone acetate Y0001390 Cyproterone acetate for peak identification Y0001223 Cyproterone impurity mixture C3290000 Cysteine hydrochloride monohydrate C3300000 Cystine C3350000 Cytarabine Y0000733 Dacarbazine Y0000734 Dacarbazine impurity A Y0000735 Dacarbazine impurity B D0070000 Dalteparin sodium Y0000600 Danaparoid sodium D0100000 Dapsone D0125000 Daunorubicin hydrochloride D0120000 Daunorubicinone D0160000 Deferoxamine mesilate D0201000 Dehydrohexetidine Y0000611 Dembrexine hydrochloride monohydrate D0300000 Demeclocycline hydrochloride D0350000 N-Demethylerythromycin A Y0000228 Demethylflumazenil - reference spectrum D0406200 Deptropine citrate D0430000 Dequalinium chloride D0431000 Dequalinium chloride for performance test Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 3 2 1 2 1 1 2 1 1 1 2 1 1 2 1 2 1 2 4 3 2 2 1 4 2 1 1 1 1 Quantity Sale per vial Unit 50 mg 1 15 mg 10 mg 100 mg 15 mg 50 mg 60 mg 50 mg 30 mg 5 mg 30 mg 5 mg 0.01 mg 50 mg 100 mg 150 mg 20 mg 20 mg 10 mg 250 mg 10 mg 100 mg 120 mg 10 mg 30 mg 50 mg 10 mg 100 mg 10 mg n/a 60 mg 50 mg 50 mg 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 20 92.4% CHClNO 2-ethyl-N-[[1-(2-ethylhexyl)-4-methyl-4,5-dihydro-1H-imidazol-4-yl]methyl] hexan-1-amine ; Batch 1 is valid until 31 March 2012 98.5% CHClNO Daunorubicin aglycone 147 anti-factor Xa units per ampoule, 4.3 anti-factor IIa units per ampoule 89.4% CHNO; 3,7-dihydro-4H-imidazo[4,5-d]-1,2,3-triazin-4-one (2azahypoxanthine) 87.9% CHO; 5-amino-1H-imidazole-carboxamide 86.7% CHNO; (2R)-amino(cyclohexa-1,4-dienyl)acetic acid (ddihydrophenylglycine) ; Batch 2 is valid until 27 April 2012 1-methylpiperazine diphenylmethanol (benzhydrol) Information Monograph 1092 1092 1092 0408,0464 0814 1093 1093 0711 0817,0846 0817 1094 1094 1094 0895 0998 0760 1691 1691 1691 0828 2090 0077 0662 0662 0896 1221 2169 0176 0179,0274,04 90, 0552,1098 1917 1308 1413 1413 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C Extra charges g g(b) a a c a a g g g g g g g a a b b b a b a g g c a a a a l +5C +5C +5C a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001321 Dermatan sulfate and oversulfated chondroitin sulfate D0480000 Desacetylvinblastine Y0000879 Desflurane - reference spectrum Y0000807 Desflurane impurity A D0500000 Desipramine hydrochloride D0600000 Deslanoside D0630000 Desmethylmetrifonate D0650000 Desmopressin Y0000509 Desogestrel Y0000510 Desogestrel for system suitability D0400000 Desoxycortone acetate Y0000001 Detomidine hydrochloride D0660020 Detomidine impurity B D0700000 Dexamethasone Batch n 1 1 1 1 1 2 1 8 1 1 2 2 1 5 Quantity Sale Information per vial Unit 1 mL 1 Dermatan sulfate 10 mg/mL Oversulfated chondroitin sulfate 2.5 mg/mL 1 mg n/a 1 ml 100 mg 150 mg 30 mg 0.94 mg 50 mg 10 mg 100 mg 100 mg 20 mg 50 mg 2 1 1 1 1 1 1 1 1 1 1 1 1 (RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol Batch 4 is valid until 31 August 2012 0.94 mg per vial of CHNOS ; Batch 7 is valid until 1 March 2013 99.9% CHO 98.8% CHO 1,1'-oxybis(1,2,2,2-tetrafluoroethane) Monograph 0332,0333 1276 1666 1666 0481 0482 1133 0712 1717 1717 0322,0809,08 50, 1327 1414 1414 0312,0388,05 48, 0768,1376,22 37,0549 0548,0933,09 75, 2237 9-fluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregn-4-en-21-yl acetate 0548 0388 2237 2237 1327 88.3 % CHFNaOP; Dexamethasone sodium phosphate CRS 4 is suitable for 01/2008:0810, 01/2008:0549 and 01/2008:0735 only. ; Batch 4 is valid until 31 October 2012 0549,0735,08 10 0549 1196 0761 0999,1000,10 01 Average molecule mass : 930-1000 Fraction with less than 3 glucose units : 8.0 to 10.5% Fraction with more than 9 glucose units : 10.0 to 12.5% M 3050-M 3850 21 1506 Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -20C -80C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C Extra charges c g(d) l b g g g c a a a g g a
D0710000 Dexamethasone acetate Y0001169 Dexamethasone acetate impurity E Y0001177 Dexamethasone for system suitability Y0000538 Dexamethasone isonicotinate Y0000511 Dexamethasone isonicotinate for impurity C identification D0718000 Dexamethasone pivalate D0720000 Dexamethasone sodium phosphate
3 1 1 1 1 1 5
100 mg 0.013 mg 10 mg 10 mg 10 mg 50 mg 100 mg
1 1 1 1 1 1 1
+5C +5C +5C +5C +5C +5C +5C
a a a a a a a
Y0001477 Dexamethasone sodium phosphate for peak identification D0720800 Dexchlorpheniramine maleate D0730000 Dexpanthenol D0731000 Dextran D0731005 Dextran 1
1 1 4 1 1
10 mg 60 mg 5 mg 25 mg 50 mg
1 1 1 1 1
Yes
+5C +5C +5C +5C +5C
a g a a a
D0732000 Dextran Vo D0733000 Dextran 4 for calibration Council of Europe, all rights reserved 2013
1 1
10 mg 50 mg
1 1
20239
+5C
List of European Pharmacopoeia Reference Standards Order Reference Standard Code D0734000 Dextran 10 for calibration D0735000 Dextran 40 for calibration D0736000 Dextran 70 for calibration D0737000 Dextran 250 for calibration D0738000 Dextran 40 for performance test D0739000 Dextran 60/70 for performance test Y0000744 Dextranomer D0740000 Dextromethorphan hydrobromide Y0000261 Dextromethorphan impurity A Y0001058 Dextropropoxyphene hydrochloride - * narc Y0001150 Dextropropoxyphene for system suitability - * narc D0940000 Diazepam - * psy Y0000596 Diazepam for system suitability - * psy D0950000 Diazoxide D0970000 Dibenzocycloheptene D1000000 Dibenzosuberone Y0000480 Dibrompropamidine diisetionate Y0000481 Dibrompropamidine for system suitability D1010000 Dibutyl phthalate New Y0000275 Dichlorodiaminocyclohexaneplatinum Y0000264 Diclazuril for veterinary use - reference spectrum Y0000259 Diclazuril for system suitability D1039990 Diclofenac potassium D1040000 Diclofenac impurity A D1050000 Dicloxacillin sodium D1060000 Dicycloverine hydrochloride Y0000439 Didanosine Y0000440 Didanosine for system suitability Y0000441 Didanosine impurity A Y0000442 Didanosine impurity G D1200000 Dienestrol D1250000 Diethanolamine fusidate D1300000 Diethylcarbamazine citrate Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 4 1 1 1 1 2 1 2 1 1 1 1 4 1 1 2 7 5 2 1 1 1 1 3 2 2 Quantity Sale per vial Unit 50 mg 1 M 8800 - M 10450 50 mg 1 M 30500- M 40900 50 mg 50 mg 50 mg 50 mg 50 mg 100 mg 5 mg 10 mg 5 mg 30 mg 0.5 mg 50 mg 20 mg 100 mg 10 mg 20 mg 1 ml 15 mg n/a 20 mg 100 mg 0.005 mg 250 mg 100 mg 10 mg 10 mg 10 mg 10 mg 150 mg 50 mg 250 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 99.9% CHNO 22 1,7-dihydro-6H-purin-6-one (hypoxanthine) 9-(2,3-dideoxy--D-glycero-pentofuranosyl)-9H-purin-6-amine (2',3'dideoxyadenosine) 100% CHO 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one ; Batch 6 is valid until 31 March 2012 94.7% CHClNNaOS ; Batch 4 is valid until 31 July 2012 Batch 1 is valid until 31 March 2012 Batch 3 is valid until 1 April 2013 Batch 1 is valid until 31 August 2012 Batch 3 is valid until 31 January 2013 ent-3-methoxymorphinan M 58900- M 70300 M 121800- M 238200 Information Monograph 20239 20239 20239 20239 20239 20239 2338 0020 0020 0713 0713 0022 0022 0550 0817 0464,0817,09 41 2300 2300 0762 2017 1718 1718 1508 1002,1281,15 08 0661,0663,06 68 1197 2200 2200 2200 2200 0483,0484 0798,0848 0271 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a a a g g k k j j a g a a a g g l g g g a a a a a a a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Batch n Code Y0000217 Diethylene glycol (monoethyl ether) - reference spectrum 1 D1410000 Diethyl phthalate D1500000 Diethylstilbestrol D1600000 Diethylstilbestrol dimethyl ether D1700000 Diethylstilbestrol monomethyl ether Y0001423 Difloxacin hydrochloride Y0001429 Difloxacin impurity G D1750000 Diflunisal D1800000 Digitoxin Y0000640 Digoxigenin D1900000 Digoxin Y0000554 Digoxin for peak identification D1940001 Dihydralazine sulfate (hydrated) - reference spectrum Y0000232 Dihydralazine for system suitability Y0000216 Dihydrocodeine hydrogen tartrate - reference spectrum Y0000053 17 alpha-dihydroequilin D1945000 Dihydroergocristine mesilate D1950000 Dihydroergotamine mesilate Y0000831 Dihydroergotamine for peak identification D1952000 Dihydroergotamine tartrate D1954000 Dihydrostreptomycin sulfate Y0000544 Dihydrotachysterol Y0000482 Dihydrotachysterol for system suitability D1980000 Diltiazem hydrochloride Y0001141 Diltiazem for system suitability Y0001439 Diltiazem impurity F D2000000 Dimenhydrinate Y0000234 N,N-Dimethylacetamide - reference spectrum Y0001103 Dimenhydrinate for peak identification D2050000 Dimethyl sulfoxide Y0001489 2-(Dimethylamino)ethyl methacrylate D2200000 Dimeticone D2205000 Dimetindene maleate D2255000 Dinoprost trometamol D2250000 Dinoprostone Council of Europe, all rights reserved 2013 1 1 1 1 1 1 1 3 1 7 1 1 1 1 1 2 3 1 2 4 2 1 5 1 1 1 1 1 2 n/a 4 1 1 2 Quantity Sale per vial Unit n/a 1 1 ml 100 mg 10 mg 10 mg 60 mg 15 mg 30 mg 200 mg 5 mg 30 mg 10 mg n/a 10 mg n/a 10 mg 250 mg 100 mg 10 mg 150 mg 25 mg 30 mg 5 mg 300 mg 10 mg 10 mg 100 mg n/a 1 mg 1 ml 50 mg 200 mg 50 mg 60 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 98.2% CHNO 99.8% CHO 23 99.9% dimeticone Replaces Diltiazem impurity A CRS (2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3dihydro-1,5-benzothiazepin-4(5H)-one 100.0% CHNO. Dried at 100-105C at constant weight 23.9 mg per vial of CHNOS 99.6% CHO 98.2% CHO 98.5% CHO 99.4% CHO ; Batch 2 is valid until 30 October 2012 7-chloro-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Dried at 100-105C for 2 h. 100% CHO Information Monograph 1198 0897 0483,0484 0484 0484 2239 2239 0818,0864 0078,0117 0079 0079 0079 1310 1310 1776 1512 1416,2060 0551 0551 0600 0485 2014 2014 1004 1004 1004 0601 1667 0601 0763 1975 0138,1470 1417 1312 1311 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage Extra charges l a a a a a a a g f g g l +5C -20C +5C +5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C a l c a a a a a g(d) g(d) g g g a l a a g a a c c
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
List of European Pharmacopoeia Reference Standards Order Reference Standard Code D2250015 Dinoprostone impurity C Y0000094 Diosmin Y0000095 Diosmin for system suitability D2600000 Diphenhydramine hydrochloride Y0000135 Diphenhydramine impurity A D2630000 Diphenoxylate hydrochloride - reference spectrum Y0001415 Diphenoxylate hydrochloride - * narc Y0001430 Diphenoxylate for system suitability - * narc Y0000258 Diphtheria toxin BRP Batch n 2 3 2 1 3 1 1 1 1 Quantity Sale Information per vial Unit 10 mg 1 (E)-7-[(1S,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]- 5oxocyclopentyl]-hept-5-enoic acid (5-trans-PGE2 ; (5E)-PGE2) 70 mg 5 mg 100 mg 10 mg n/a 15 mg 10 mg 1 ml 1 1 1 1 1 1 1 1 Nominal concentration of Diphtheria toxin: 1 Lf/ml (0.4l/ml) Systemic toxicity: 77.6 LD/ml (determined in the subcutaneous challenge test in guinea pigs) Maximum intradermal toxicity: 75,000Lr/Lf (determined in the guinea pig intradermal skin test) Toxicity in the Vero cell assay: concentrations of 5x10- Lf/ml and below cause cytotoxic effects. 97 IU per vial 2-(diphenylmethoxy)-N-methylethanamine 90.9% CHO ; Batch 2 is valid until 31 August 2012 Monograph 1311,1488 1611 1611 0023,0601,11 90 0023,0601 0819 0819 0819 See leaflet, 0443 Yes Yes Leaflet
Effective from 2013 Storage -20C +5C +5C +5C +5C +5C +5C +5C Extra charges c a a a a l k j g(b)
D2700000 Diphtheria vaccine (adsorbed) BRP Y0000376 Dipivefrine hydrochloride Y0000394 Dipivefrine for system suitability D2750100 Dipotassium clorazepate - reference spectrum D2800000 Diprophylline D2850000 Dipyridamole Y0000802 Dipyridamole for peak identification D2880000 Dirithromycin D2900000 Disodium edetate D2920000 Disopyramide D2922000 Disopyramide phosphate D2950000 Disulfiram D2953000 Dithranol New D2953025 Dithranol impurity C
4 1 1 1 1 1 2 1 1 1 1 1 2 3
32 mg 100 mg 10 mg n/a 100 mg 50 mg 2 mg 100 mg 100 mg 100 mg 100 mg 100 mg 55 mg 20 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1
See leaflet, 20706 1719 1719 0898 0486 1199
Yes
-20C +5C +5C +5C +5C
c g g l a a a a a a a g g g
Batch 1 is valid until 30 September 2012 97.4% CHNO
1199 1313 0232 1006 1005 0603
Yes
+5C +5C +5C +5C +5C +5C +5C
Batch 1 is valid until 31 December 2012 Dithranol-dimer 4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione ; Batch 2 is valid until 1 June 2013 94.9% CHO; 1-hydroxyanthracen-9(10H)-one
1007 1007 Yes
+5C
D2953050 Dithranol impurity D D2954000 Dobutamine hydrochloride Y0001239 Dobutamine impurity mixture Y0001133 Docetaxel trihydrate Y0001155 Docetaxel for system suitability Council of Europe, all rights reserved 2013
3 1 1 1 2
20 mg 100 mg 0.1 mg 160 mg 10 mg
1 1 1 1 1
1007 1200 1200 Yes Yes
+5C +5C +5C +5C +5C
g a a a a
93.6% CHNO Batch 1 is valid until 1 March 2013 24
2449,2593 2449,2593
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001452 Docetaxel impurity E D2954600 Docosahexaenoic acid ethyl ester D2954500 Docusate sodium - reference spectrum Y0000365 Dodecyl gallate D2955000 Domperidone D2957000 Domperidone maleate D2960000 Dopamine hydrochloride Y0000612 Dopexamine dihydrochloride Y0000613 Dopexamine impurity B Y0000614 Dopexamine impurity F Y0000726 Dorzolamide hydrochloride Y0000727 Dorzolamide impurity A Y0000750 Dorzolamide for system suitability D2962000 Dosulepin hydrochloride D2962005 Dosulepin impurity A Y0001385 Angelica pubescent root D2963000 Doxapram hydrochloride Y0000208 Doxapram impurity B Y0000553 Doxazosin mesilate Y0000551 Doxazosin impurity D Y0000552 Doxazosin impurity F Y0000838 Doxepin hydrochloride Y0000851 Doxepin for system suitability D2975000 Doxorubicin hydrochloride D3000000 Doxycycline hyclate Y0001492 Doxylamine for system suitability Y0000163 Doxylamine hydrogen succinate - reference spectrum Y0000160 Doxylamine impurity A D3100000 Droperidol Y0001105 Drospirenone Y0001115 Drospirenone impurity E Council of Europe, all rights reserved 2013 Batch n 1 4 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 4 1 1 2 2 1 1 Quantity Sale Information per vial Unit 15 mg 1 5,20-epoxy-4-(acetyloxy)-1,7,10,13-tetrahydroxy-9-oxotax-11-en-2-yl benzoate (10-desacetyl-baccatin III) 150 mg n/a 30 mg 150 mg 150 mg 50 mg 10 mg 10 mg 10 mg 50 mg 5 mg 5 mg 100 mg 50 mg 500 mg 50 mg 10 mg 60 mg 10 mg 10 mg 5 mg 1 mg 150 mg 50 mg 100 mg n/a 10 mg 150 mg 60 mg 0.06 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 99.9% CHO 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-3'H,3''H-dicyclopropa [6,7:15,16]pregn-4-ene-21,17- carbolactone (17-epidrospirenone) 25 N,N-dimethyl-2-[1(RS)-1-phenyl-1-(pyridin-4-yl)ethoxy]ethanamine ; Batch 1 is valid until 30 April 2012 99.4% CHClNO ; Batch 5 is valid until 31 May 2012 92.9% CHClNO corresponding to 85.9% CHNO (4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one 99.2% CHNOS 6,7-dimethoxyquinazoline-2,4(1H,3H)-dione 2-chloro-6,7-dimethoxyquinazolin-4-amine (E)-3-(6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-N,N'dimethylpropan-1-amine -oxide (4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2sulphonamide 7,7-dioxide 2-methoxy-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]phenol 4-chloro-5-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]benz -ene-1,2-diol 93.1% DHA ethyl ester ; Batch 3 is valid until 7 May 2012 Monograph 2593 2063,20429 1418 2078 1009 1008 0664,1200 1748 1748 1748 2359 2359 2359 1314 1314 2557 1201 1201 2125 2125 2125 1096 1096 0714,0662,15 90 0272,0820 1589 1589 1589 1008,1009,10 10, 1172 2404 2404 Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C -20C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C Extra charges a c l a a a g a c c a a a g g a g g a a a g g g(c) a a l a a g g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001453 Duloxetine hydrochloride Y0001454 Duloxetine for system suitability Y0001455 Duloxetine impurity A Y0001004 Dydrogesterone Y0001005 Dydrogesterone impurity A Y0001006 Dydrogesterone impurity B Y0000249 Ebastine - reference spectrum Y0000247 Ebastine impurity C Y0000248 Ebastine impurity D Y0001236 Econazole E0050000 Econazole nitrate Batch n 1 1 1 1 1 1 1 1 1 1 3 Quantity Sale per vial Unit 120 mg 1 99.8 % CHClNOS 40 mg 10 mg 50 mg 6 mg 5 mg n/a 10 mg 10 mg 10 mg 100 mg 1 1 1 1 1 1 1 1 1 1 4-(diphenylmethoxy)piperidine 1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine 99.5% CHO 9,10-pregna-4,6,8(14)-triene-3,20-dione pregna-4,6-diene-3,20-dione Information Monograph 2594 2594 2594 2357 2357 2357 2015 2015 2015 2049 0513,0665,09 21, 0935, 1017,1018 0665,2049 93.6% EPA ethyl ester CHO 1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1yl)benzimidazole. 2063,20429 2242 2242 0080,0081,00 93, 0094,1530,18 75 1420 1420 1420 1749 1749 (2SR)-2-[(3SR,8aRS)-3-methyl-1,4-dioxohexahydropyrrolo[1,2-a] pyrazin-2 (1H)-yl]-4-phenylbutanoic acid (1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol 10 000 IU per vial ; Batch 4 is valid until 31 December 2012 1749 1720 1720 20614 0828,1097 1511 2229 2229 99.9% CHNO Z isomer of entacapone 26 2574 2574 0350 Yes Yes Yes Yes Yes Yes Yes Leaflet Yes Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g a a a l a a a a
Y0000254 Econazole for system suitability E0085000 Eicosapentaenoic acid ethyl ester Y0000537 Emedastine difumarate Y0000512 Emedastine impurity E E0100000 Emetine hydrochloride
1 3 1 1 2
20 mg 200 mg 10 mg 10 mg 100 mg
1 1 1 1 1
+5C -20C +5C +5C +5C
a c a a f
E0110000 Enalapril for system suitability Y0001211 Enalapril impurity mixture E0109000 Enalapril maleate Y0000615 Enalaprilat dihydrate Y0000629 Enalaprilat for system suitability Y0000678 Enalaprilat impurity G Y0000136 Enilconazole Y0000137 Enilconazole impurity E E0150000 Endotoxin standard BRP E0180000 Enoxaparin sodium E0180500 Enoxolone Y0001259 Enrofloxacin Y0001160 Enrofloxacin for system suitability Y0001249 Entacapone Y0001250 Entacapone impurity A E0200000 Enterokinase BRP Council of Europe, all rights reserved 2013
1 1 2 1 1 1 1 1 5 4 1 1 1 1 1 1
20 mg 0.06 mg 50 mg 100 mg 10 mg 0.005 mg 60 mg 20 mg 10 mg 200 mg 100 mg 5 mg 10 mg 160 mg 10 mg 200 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
+5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C
a a a a a a g g a a a g g a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code E0305000 Ephedrine hydrochloride (racemic) - * Drug Precursor E0300000 Ephedrine hydrochloride - * Drug Precursor E0400000 4-Epianhydrotetracycline hydrochloride E0440000 4-Epidemeclocycline hydrochloride E0500000 6-Epidoxycycline hydrochloride Y0001139 Epinastine hydrochloride Y0001128 Epinastine hydrochloride for system suitability E0530000 4-Epioxytetracycline E0550000 Epirubicin hydrochloride E0600000 4-Epitetracycline hydrochloride Y0000052 Equilin Y0001325 Equisetum palustre E0850010 Eq Influenza Subtype 1 Strain A/eq/Newmarket/77 Horse Antiserum BRP E0850021 Eq Influenza Subtype 2 American-like/Newmarket Horse Antiserum BRP E0850022 Eq Influenza Subtype 2 European-like/Newmarket Horse Antiserum BRP Y0000712 Eq Influenza Subtype 2 American-like/South Africa Horse Antiserum BRP E0900000 Ergocalciferol Batch n 1 2 6 1 5 1 1 7 6 8 1 1 2 2 2 1 7 Quantity Sale per vial Unit 50 mg 1 150 mg 20 mg 20 mg 50 mg 20 mg 10 mg 40 mg 100 mg 30 mg 15 mg 200 mg 1 mg 1 mg 1 mg 1 mg 500 mg 1 1 1 1 1 1 1 1 1 1 1 3 3 3 3 1 100.0% CHO ; Vitamin D2 Assigned SRH antibody titre: 125 mm +/-20%; Common standard OIE Strain A/eq/Newmarket/77 Assigned SRH antibody titre: 180 mm +/- 20%; Common standard OIE Strain A/eq/Newmarket/1/93 Assigned SRH antibody titre: 155 mm +/- 20%; Common standard OIE Strain A/eq/Newmarket/2/93 99.7% CHO 81.1% CHNO 96.4% CHClNO 99.8% CHClNO 87.1% CHNO.HCl ; Batch 5 is valid until 29 February 2012 Information Monograph 0715 0487,0488,04 89, 1367,2451 0210,0211,16 54 0176 0272,0820 2411 2411 0198,0199 0662,0714,15 90 0210,0211,16 54 1512 1825 See leaflet, 0249 See leaflet, 0249 See leaflet, 0249 See leaflet, 0249 0082,0574,05 75, 0598,1192,11 93 0223 Batch 4 is valid until 31 March 2012 0.5ml Freeze dried (0.367g protein) 99.8% CHO 960 IU per mg 97.0% CHNO 0082 0224, 0551 See leaflet, 0064 1803 20702 0179,0274,02 93, 0490,0552,10 98 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C -20C +5C -20C -20C -20C -20C -20C Extra charges i i a a a g g g c a c a c c c c g(c)
E1000000 Ergometrine maleate - * Drug Precursor E1100000 Ergosterol E1200000 Ergotamine tartrate - * Drug Precursor Y0000051 Erysipelas ELISA coating antigen BRP Y0000177 Erythritol E1300000 Erythromycin for microbiological assay E1305000 Erythromycin A
2 5 2 1 1 4 3
50 mg 20 mg 100 mg 0.4 mg 1000 mg 250 mg 250 mg
1 1 1 1 1 1 1
+5C -20C +5C -20C +5C -20C -20C
i g(c) i c a a g
E1310000 Erythromycin B Council of Europe, all rights reserved 2013
50 mg
98.4% CHNO 27
0179,0274,04 -20C g 90, 0552,1098 For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code E1320000 Erythromycin C E1400000 Erythromycin estolate E1500000 Erythromycin ethylsuccinate E1500800 Erythromycin stearate E1515000 Erythropoietin BRP Y0000324 Esketamine hydrochloride - reference spectrum Y0000338 Esketamine impurity D Y0001028 Esomeprazole magnesium trihydrate Y0000749 Essential oil E1600000 Estradiol benzoate Y0000852 Estradiol benzoate for system suitability Y0000045 Estradiol butyrate E1620000 Estradiol hemihydrate Y0000314 Estradiol for peak identification Y0000046 Estradiol valerate E1680000 Estriol E1680005 Estriol impurity A E1700000 Estrone E1800000 Etacrynic acid Y0001263 Etacrynic acid for system suitability E1830000 Etamsylate E1840000 Ethacridine lactate monohydrate E1850000 Ethambutol hydrochloride Y0000803 Ethambutol for system suitability A1202800 Ethanol (anhydrous) - reference spectrum E1860100 Ethanol 96% - reference spectrum E1900000 Ethinylestradiol New Y0001124 Ethinylestradiol for system suitability E2000000 Ethionamide E2150000 Ethosuximide E2250000 Ethosuximide impurity A E2195000 Ethyl acetate - reference spectrum E2195900 Ethylcellulose - reference spectrum E2202000 1-N-Ethylgaramine sulfate New E2205500 1,1'-Ethylidenebistryptophan Council of Europe, all rights reserved 2013 Batch n 4 1 2 1 3 1 1 1 1 1 1 1 3 1 1 2 1 4 1 1 1 1 3 1 1 1 4 2 1 1 4 1 1 3 5 Quantity Sale per vial Unit 50 mg 1 97.6% CHNO 100 mg 10 mg 50 mg 37.5 mg n/a 10 mg 10 mg 1000 mg 250 mg 10 mg 10 mg 100 mg 10 mg 50 mg 50 mg 20 mg 15 mg 100 mg 10 mg 30 mg 50 mg 250 mg 10 mg n/a n/a 200 mg 1.0124 mg 100 mg 30 mg 30 mg n/a n/a 50 mg 0.002 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 77.6% of 1-N-Ethylgaramin sulphate ; Batch 2 is valid until 18 September 2012 0.00182mg per vial of CHNO ; Batch 4 is valid until 1 May 2013 28 (2RS)-2-ethyl-2-methylbutanedioic acid ; Batch 3 is valid until 1 February 2012 Batch 3 is valid until 31 March 2012 Batch 1 is valid until 1 May 2013 9,11-didehydroestriol 100.0% CHO ; Batch 3 is valid until 31 March 2012 (2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone ((R)-ketamine) 35280 IU per vial Information Monograph 0179,0274,04 90, 0552,1098 0552 0274 0490 1316 1742 1742 2372 2098 0139 0139 1614 0821,1203 0821 1614 1203 1203 1512,0140 0457 0457 1204 1591 0553 0553 1318 1317 0140,0821,09 40 0140 0141 0764 0764 0899 0822 1351 1272,1383 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -20C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g a l a a g a a a a a a a a a a a a a a a l l +5C +5C +5C +5C +5C g g a a a l l +5C +5C a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000617 Ethyl indole-3-carboxylate E2300000 Ethylmorphine hydrochloride - reference spectrum E2400000 Ethylnicotinamide E2425000 Ethyl parahydroxybenzoate Batch n 1 1 1 3 Quantity Sale per vial Unit 10 mg 1 n/a 150 mg 150 mg 1 1 1 100.0% CHO; batch 2 valid until 31/12/10 excepted for use with monograph 0900. Information Monograph 2102 0491 0233 0409,0431,09 00, 1262,1263,21 34 0585 1205 2-ethylamino-1-(3-hydroxyphenyl)ethanone 1205 1778 1422 2-(7-ethylindol-3-yl)ethanol 1422 1422 1513 1513 2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate 1513 0492 1514 methyl 1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate 98.4% CHO 1514 0823 0823 1100 1012 1012 3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphanyl]propanamide 99.9% CHNOS 1012 2176 2176 2304 4-acetyl biphenyl 0.994 mg CHNOS methyl(1-benzimidazol-2-yl)carbamate methyl[5(6)-chlorobenzimidazol-2-yl]carbamate 100.0% CHClO 29 2304 1013 1634 1208,1458 1208 1208 1209 1322 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C Extra charges a l g a
E2450000 Etifenin E2451000 Etilefrine hydrochloride E2451010 Etilefrine impurity A Y0000572 Etidronate disodium E2470000 Etodolac E2470050 Etodolac impurity H Y0000768 Etodolac for peak identification E2499900 Etofenamate E2499901 Etofenamate for peak identification E2499914 Etofenamate impurity G E2500000 Etofylline E2503000 Etomidate E2503004 Etomidate impurity B E2600000 Etoposide Y0001365 Etoposide for for system suitability E5000000 Eugenol F0005000 Famotidine Y0000382 Famotidine for system suitability Y0000409 Famotidine impurity D Y0000556 Febantel Y0000660 Febantel for system suitability Y0000731 Felbinac Y0000732 Felbinac impurity A F0030000 Felodipine Y0000415 Felypressin F0040000 Fenbendazole F0040010 Fenbendazole impurity A F0040020 Fenbendazole impurity B F0041000 Fenbufen F0048000 Fenofibrate Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 1 2 1 1 2 1 5 1 2 2 1 2 1 1 1 1 2 1 2 1 1 1 3
25 mg 75 mg 20 mg 10 mg 60 mg 10 mg 10 mg 40 mg 20 mg 20 mg 100 mg 50 mg 25 mg 150 mg 10 mg 500 l 100 mg 10 mg 10 mg 110 mg 10 mg 10 mg 20 mg 120 mg 0.994 mg 150 mg 20 mg 20 mg 100 mg 100 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C
a g g a g g g g g g a a a a a a a a a a a g a g c g g g g a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code F0048005 Fenofibrate impurity A F0048010 Fenofibrate impurity B F0048035 Fenofibrate impurity G Y0000756 Fenoterol for peak identification F0050000 Fenoterol hydrobromide F0054990 Fentanyl - reference spectrum Y0001509 Fentanyl for system suitability - * narc F0055000 Fentanyl citrate - reference spectrum F0060000 Fenticonazole nitrate F0060040 Fenticonazole impurity D F0100000 Ferrous gluconate Y0001013 Ferulic acid Y0000789 Fexofenadine hydrochloride Y0000751 Fexofenadine impurity A Y0000752 Fexofenadine impurity B Y0000753 Fexofenadine impurity C Y0001173 Filgrastim Y0000090 Finasteride Y0000091 Finasteride for system suitability Y0000736 Flavoxate hydrochloride Y0000737 Flavoxate impurity A Y0000738 Flavoxate impurity B F0120000 Flecainide acetate New F0120005 Flecainide impurity A F0120010 Flecainide impurity B Y0001274 Flecainide for system suitability Y0000138 Flubendazole Y0000139 Flubendazole for system suitability Y0000892 Flucloxacillin magnesium octahydrate Y0000889 Flucloxacillin impurity C Y0000890 Flucloxacillin impurity D Y0000891 Flucloxacillin impurity E Council of Europe, all rights reserved 2013 Batch n 3 4 4 1 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 1 3 1 1 1 1 1 1 1 1 Quantity Sale Information per vial Unit 20 mg 1 (4-chlorophenyl)(4-hydroxyphenyl)methanone 10 mg 1 2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid (fenofibric acid) 25 mg 1.2 mg 100 mg n/a 25 mg n/a 50 mg 20 mg 100 mg 20 mg 60 mg 5 mg 0.01 mg 5 mg 0.2 ml 60 mg 100 mg 10 mg 10 mg 10 mg 200 mg 50 mg 25 mg 10 mg 25 mg 20 mg 5 mg 5 mg 5 mg 5 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6-aminopenicillanic acid 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid 6-aminopenicillanic acid flucloxacillin amide 30 3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a-hexahydroimidazo[1,5a]pyridine ; Batch 2 is valid until 1 May 2013 (RS)-(piperidin-2-yl)methanamine 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid ethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate 99.8% CHO 99.8% CHClNO 2-[4-[4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butanoyl]phenyl]-2methylpropanoic acid 2-[3-[(1RS)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl] phenyl]-2-methylpropanoic acid (1RS)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]-1-[4-(1-methylethyl) phenyl]butan-1-ol 1.95 mg per ml of CHNOS 99.7% CHNO Contains 0.7% of impurity A ()-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-[4-(phenyl suphanyl) benzyl]imidazolium nitrate contains 1.3% of impurity A 1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl] oxy]-2-methylpropanoate Monograph 1322 1322 1322 0901 0901 1210 1210 1103 1211 1211 0493 1834,2558 2280 2280 2280 2280 2206 1615 1615 1692 1692 1692 1324 1324 1324 1324 1721 1721 2346 2346 2346 2346 Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a l k l a a a a a a a a d a a a a a a a a a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code F0150000 Flucloxacillin sodium Y0000557 Fluconazole Y0000558 Fluconazole for peak identification Y0000573 Fluconazole impurity B Y0000574 Fluconazole impurity C F0175000 Flucytosine Y0001262 Flucytosine for system suitability Y0000419 Fludarabine phosphate F0180000 Fludrocortisone acetate F0188000 Flumazenil - reference spectrum Y0000335 Flumazenil impurity B F0189000 Flumequine F0189020 Flumequine impurity B F0188500 Flumetasone pivalate F0189900 Flunarizine dihydrochloride Y0000265 Flunarizine dihydrochloride - reference spectrum Y0000266 Flunarizine dihydrochloride for system suitability F0190000 Flunitrazepam - * psy Y0000169 Flunitrazepam - reference spectrum Y0000443 Flunixin meglumine Y0000444 Flunixin impurity B Y0000445 Flunixin impurity C F0200000 Fluocinolone acetonide F0230000 Fluocortolone pivalate Y0000796 Fluorescein Y0000804 Fluorescein impurity C Y0000454 Diacetylfluorescein F0245000 Fluoresceine sodium - reference spectrum F0250000 Fluorouracil Y0000762 Fluorouracil impurity A Y0000763 Fluorouracil impurity B Y0000764 Fluorouracil impurity C Y0000765 Fluorouracil impurity F Council of Europe, all rights reserved 2013 Batch n 7 1 1 2 2 1 1 2 2 1 1 1 2 1 3 1 1 1 1 1 1 1 3 1 1 1 1 1 2 1 1 1 1 Quantity Sale Information per vial Unit 250 mg 1 95.1% CHClFNNaOS ; Batch 6 is valid until 31 May 2012 50 mg 10 mg 10 mg 5 mg 100 mg 10 mg 120 mg 100 mg n/a 5 mg 60 mg 0.1 mg 100 mg 100 mg n/a 20 mg 100 mg n/a 10 mg 10 mg 50 mg 100 mg 100 mg 120 mg 0.01 mg 100 mg n/a 40 mg 10 mg 10 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) dihydropyrimidine-2,4,5(3H)-trione (isobarbituric acid or 5-hydroxyuracil) pyrimidine-2,4(1H,3H)-dione (uracil) 2-ethoxy-5-fluoropyrimidin-4(1H)-one (2-ethoxy-5-fluorouracil) 31 99.2% CHO 2-(2,4-dihydroxybenzoyl)benzoic acid 99.6% CHO 2-methyl-3-(trifluoromethyl)aniline ethyl 2-chloropyridine-3-carboxylate ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j] quinolizine-2-carboxylate ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4] benzodiazepine-3-carboxylate 98.3% CHFNOP ; Batch 1 is valid until 30 September 2012 93.2% CHNOF ; 2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis (1H-1,2,4 -triazol-1-yl)propan-2-ol 1,1'-(1,3-phenylene)di-1H-1,2,4-triazole Monograph 0661,0663,06 68,2346 2287 2287 2287 2287 0766 0766 1781 0767 1326 1326 1517 1517 1327 0816 1722 1722 1280 0717 1696 1696 1696 0494 1212 2348 2348 1213 1213 0611,0766 0611 0611 0611 0611 Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges c a a a a a a a a l a a a a a l a j l f f f f a a a a l g a g a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000791 Fluorouracil impurity mixture F0253000 Fluoxetine hydrochloride F0253020 Fluoxetine impurity B F0253030 Fluoxetine impurity C Y0000064 Flupentixol dihydrochloride Y0000067 Flupentixol impurity D Y0000078 Flupentixol impurity F F0260000 Fluphenazine decanoate Y0000009 Fluphenazine enantate F0280000 Fluphenazine dihydrochloride Y0000708 Fluphenazine impurity mixture Y0000298 Fluphenazine octanoate Y0000299 Fluphenazine sulfoxide Y0000211 Flurazepam monohydrochloride - reference spectrum F0285200 Flurbiprofen F0285202 Flurbiprofen impurity A Y0000236 Fluspirilene Y0000375 Fluspirilene impurity C F0285600 Flutamide F0285603 Flutamide impurity C Y0000284 Fluticasone propionate Y0000221 Fluticasone impurity D Batch n 1 4 5 4 1 1 2 2 2 1 1 3 1 1 1 1 1 1 1 1 3 2 Quantity Sale per vial Unit 0.0002 mg 1 250 mg 10 mg 5 mg 100 mg 15 mg 25 mg 60 mg 100 mg 50 mg 0.07 mg 20 mg 10 mg n/a 50 mg 20 mg 20 mg 10 mg 50 mg 20 mg 100 mg 20 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide 99.6% CHFOS S-methyl 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17apropionyloxy-androsta-1,4-diene-17-carbothioate (S-methyl derivative) (RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol 8-[4,4-bis(4-fluorophenyl)butyl]-3-(hydroxymethyl)-1-phenyl-1,3,8triazaspiro[4.5]decan-4-one (2RS)-2-(biphenyl-4-yl)propanoic acid 99.9% CHClFNO methyl(3-phenylpropyl)amine ()-methyl-[3-phenyl-3-(3-trifluoromethylphenoxy)-propyl] amine ; Batch 3 is valid until 30 April 2012 43.6% of Z-isomer CHClFNOS 2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl] piperazin-1-yl]ethoxy]ethanol 80.9% CHFNOS; 2-[4-[(EZ)-3-[(9RS)-2-(trifluoromethyl)-9Hthioxanthen-9-yl] prop-2-enyl]piperazin-1-yl]ethanol Information Monograph 0611 1104 1104 1104 1693 1693 1693 1014,1015 1014,1015 0904,1014 0904 1014,1015 0904,1014,10 15 0905 1519 1519 1723 1723 1423 1423 1750 1750 Yes Leaflet Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g a a a g(b) g g g g g l +5C +5C +5C +5C +5C +5C +5C +5C g g a a g g a a
F0290000 Flutrimazole F0290010 Flutrimazole impurity B Y0001090 Fluvastatin sodium Y0001082 Fluvastatin for system suitability Y0000854 Fluvoxamine maleate Y0000853 Fluvoxamine for system suitability Y0000916 Fluvoxamine impurity D Y0000386 Foeniculin for peak identification F0300000 Folic acid Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 1 8
100 mg 60 mg 110 mg 0.5 mg 5 mg 1.004 mg 10 mg 100 mg 300 mg
1 1 1 1 1 1 1 1 2 5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one Anise oil 91.3 % CHNO 32
1424 1424 2333 2333 1977 1977 1977 0804 0067 Yes Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C
g g a a g g g a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001242 Folic acid impurity A Y0001243 Folic acid impurity D F0372000 Formoterol fumarate dihydrate Y0000339 Formoterol for impurity I identification Y0000340 Formoterol fumarate for system suitability F0380000 Formylfolic acid F0389000 Foscarnet sodium hexahydrate F0389004 Foscarnet impurity B Y0001222 Foscarnet impurity D Y0001213 Foscarnet impurity mixture Y0000782 Fosfomycin calcium F0399950 Fosfomycin sodium - reference spectrum F0400000 Fosfomycin trometamol Y0001227 Fosinopril sodium Y0001228 Fosinopril impurity A Y0001229 Fosinopril impurity B Y0001230 Fosinopril impurity C Batch n 1 2 2 1 1 3 1 1 1 1 1 1 2 1 1 1 1 Quantity Sale Information per vial Unit 15 mg 1 (2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid (N-(4-aminobenzoyl)-lglutamic acid) 70 mg 10 mg 10 mg 10 mg 30 mg 50 mg 10 mg 50 mg 0.012 mg 10 mg n/a 1500 mg 60 mg 5 mg 5 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (2S,4S)-4-cyclohexyl-1-[[(R)-hydroxy(4-phenylbutyl)phosphoryl]acetyl] pyrrolidine-2-carboxylic acid (2RS,4RS)-4-cyclohexyl-1-[[(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy) propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid mixture of (2S,4S)-4-cyclohexyl-1-[[(S)-[(1S)-2-methyl-1-(1-oxopropoxy) propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid and (2S,4S)-4-cyclohexyl-1-[[(R)-[(1R)-2-methyl-1-(1-oxopropoxy)propoxy](4phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid (2S,4R)-4-cyclohexyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid [(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl] acetic acid (2S,4S)-4-cyclohexyl-1-(2,2-dimethyl-1-oxopropyl)pyrrolidine-2-carboxylic acid 17640 IU per vial CHNO,xHSO ; Batch 4 is valid until 30 April 2012 99.7% CHNOP disodium (ethoxyoxydophosphanyl)formate 91.4% CHNO; 10-Formylfolic acid 4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid (pteroic acid) Monograph 0067 0067 1293,1724 1724 1724 0978,1606 1520 1520 1520 1520 1328 1329 1425 1751 1751 1751 1751 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a g g g c a a a a a l a a a a a
Y0001231 Fosinopril impurity D Y0001232 Fosinopril impurity I Y0001233 Fosinopril impurity K Y0001212 Fosinopril impurity mixture F0450000 Framycetin sulfate F0550000 Fructose
1 1 1 1 5 1
10 mg 5 mg 5 mg 0.02 mg 25 mg 100 mg
1 1 1 1 2 1
1751 1751 1751 1751 0180,0197,20 702 0177,0178,01 87, 0188,0204,02 09, 1061,1570 2443 2443 Yes Yes
+5C +5C +5C +5C -20C +5C
a a a a a a
Y0001399 Fulvestrant Y0001413 Fulvestrant for system suitability
1 1
120 mg 40 mg
1 1
98.8% CHFOS
Yes Yes
+5C +5C
a a
Council of Europe, all rights reserved 2013
33
List of European Pharmacopoeia Reference Standards Order Code F0600000 Fumaric acid F0700000 Furosemide Y0001493 Furosemide for peak identification F0702000 Furosemide impurity A Y0001411 Fusidic acid F1000000 Fusidic acid - reference spectrum Y0001394 Fusidic acid for peak identification Y0001384 Fusidic acid impurity mixture Y0001280 Gabapentin Y0001281 Gabapentin impurity A Y0001348 Gabapentin impurity B Y0001349 Gabapentin impurity D G0049000 Galactitol G0050000 Galactose Y0001279 Galantamine hydrobromide Y0001190 Galantamine natural for system suitability Y0001201 Galantamine racemic mixture Y0001191 Galantamine synthetic for system suitability G0100000 Gallamine triethiodide New G0150000 Gammacyclodextrin Y0001129 Ganciclovir Y0001144 Ganciclovir impurity mixture Y0000675 Gemcitabine hydrochloride Y0000676 Gemcitabine impurity A Y0000513 Gemfibrozil Y0000514 Gemfibrozil for system suitability G0200000 Gentamicin sulfate Y0001112 Gestodene Y0001363 Gentamicin for peak identification Y0001110 Gestodene for system suitability Y0001116 Gestodene impurity I Y0001012 Ginkgo dry extract for peak identification Y0001010 Ginkgolic Acids Y0001029 Ginseng dry extract Y0001347 Ginsenoside Rb1 Council of Europe, all rights reserved 2013 Reference Standard Batch n 3 2 1 4 1 1 1 1 1 1 1 1 2 2 1 1 1 1 1 2 1 1 1 1 1 1 8 1 1 1 1 1 2 1 1 Quantity Sale Information per vial Unit 120 mg 1 Batch 2 is valid until 31 July 2012 100 mg 10 mg 5 mg 10 mg n/a 5 mg 0.0475 mg 300 mg 20 mg 20 mg 10 mg 50 mg 60 mg 10 mg 10 mg 10 mg 5 mg 100 mg 60 mg 220 mg 0.005 mg 50 mg 20 mg 5 mg 0.196 mg 25 mg 100 mg 10 mg 10 mg 0.01 mg 150 mg 20 mg 500 mg 30 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 88.1 % CHO 34 0.37% of ginkgolic acid C17 ; Batch 1 is valid until 31 May 2012 13-ethyl-17-hydroxy-5-methoxy-18,19-dinor-5alpha,17alpha-pregn-15-en-20yn-3-one 16500 IU per vial ; Batch 7 is valid until 31 January 2013 99.4% CHO 99.9% CHClFNO 4-aminopyrimidin-2(1H)-one (cytosine) 91,2% CHO ; Batch 1 is valid until 1 June 2013 99.9% CHNO 2-azaspiro[4.5]decan-3-one (1-cyanocyclohexyl)acetic acid [1-[(3-oxo-2-azaspiro[4.5]dec-2-yl)methyl]cyclohexyl]acetic acid 2-chloro-4-(furfurylamino)-5-sulphamoylbenzoic acid Batch 1 is valid until 31 January 2013 Monograph 0365,0902,11 90, 1592 0391,2185 0391 0391 0798 0798,0848 0798,0848 0798,0848 2173 2173 2173 2173 1381 1215 2366 2366 2366 2366 0181 1070,1487 1752 1752 2306 2306 1694 1694 0331,20702 1726 0331 1726 1726 1827 1827 2356 2356 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C -20C -20C -20C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C -20C +5C +5C -20C -20C -20C +5C Extra charges a a a a c l c c a a c a a a g g g g a a a a g a g g c a c a a c c c a
List of European Pharmacopoeia Reference Standards Order Code G0300000 Gitoxin G0325000 Glibenclamide Y0001511 Glibenclamide for peak identification G0325010 Glibenclamide impurity A Y0000242 Glibenclamide impurity B G0326000 Gliclazide G0326004 Gliclazide impurity B G0326012 Gliclazide impurity F Y0000515 Glimepiride Y0000516 Glimepiride for system suitability G0340000 Glipizide G0342000 Glipizide impurity A Y0000523 Glipizide impurity C Y0000643 Glipizide impurity D Y0001140 Glipizide impurity mixture Y0001406 Glucosamine hydrochloride Y0000191 Human glucagon Y0001381 Glucosamine for system suitability Y0001407 Glucosamine sulfate sodium chloride G0350500 Glucose Reference Standard Batch n 2 3 1 3 2 2 3 4 1 3 1 1 1 1 1 1 2 1 1 2 Quantity Sale per vial Unit 30 mg 1 100 mg 30 mg 10 mg 20 mg 20 mg 25 mg 50 mg 60 mg 0.012 mg 50 mg 10 mg 10 mg 10 mg 0.002 mg 10 mg 2.94 mg 40 mg 15 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 Batch 1 is valid until 30 April 2012 2.94 mg pure human glucagon per vial CHNOS ; Batch 1 is valid until 30 April 2012 4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzene sulphonamide ethyl [2-[4-[(cyclohexylcarbamoyl)sulphamoyl]phenyl]ethyl] carbamate 6-methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide 2-nitroso-octahydrocyclopenta[c]pyrrole 1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(2-methylphenyl) sulphonyl] urea ; Batch 3 is valid until 31 March 2012 99.4% CHNOS Batch 2 is valid until 31 January 2013 4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzene- sulphonamide ; Batch 2 is valid until 31 December 2012 methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl] sulphonyl]carbamate Information Monograph 0078,0079,21 68 0718 0718 0718 0718 0718,1524 1524 1524 2223 2223 0906 0906 0906 0906 0906 2446 1635 2446,2447 2447 0177,0178,01 87, 0188,0204,02 09, 1061,1215,15 70 0750,0797,14 45, 2076 1670 1291 1428 1671 2213 Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C Extra charges g a a a a a a a a a a a a a a a c a a a
G0355000 Glutamic acid Y0000517 Glutathione G0360000 Glutethimide - * psy G0400004 Glycerol distearate Y0001391 Glycerol formal Y0000794 Glycerol monocaprylate
2 1 1 2 1 1
50 mg 10 mg 50 mg 2000 mg 20 mg 400 mg
1 1 1 1 2 1
+5C +5C +5C +5C +5C +5C
a a j a a g
35
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000795 Glycerol monocaprylocaprate Batch n 1 Quantity Sale Information per vial Unit 500 mg 1 In the chromatogram supplied within the leaflet (Rev 02) of the current CRS batch 1, some peaks have been mislabelled, the correct version of the leaflet (Rev 03) is now available on the website. The quality of the product itself is not questioned and can still to be used. 2000 mg 2500 mg 2000 mg n/a 0.5 ml 50 mg 10 mg 10 mg 10 mg 70 mg 300 mg 5 mg 2 mg n/a 0.1 mg 1 mg 14 mg 250 mg 120 mg 1 mg 1 mg 15 mg 50 mg 2200 mg 100 mg 125 mg 10 mg 50 mg 60 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 36 99.6% CHClFNO [1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol 99.5% CHO Supplied with the Ph. Eur. reference chromatogram replace Y0000126 1081 IU per mg 99.8% CHClNO 2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2Hindazole-3-carboxamide N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3carboxamide (1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine 78.6% CHNO 4.96 mg per vial of CHNO ; Batch 4 is valid until 31 March 2012 1.87 mg per vial of CHNO 94.0% CHNO+; (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl) oxy]-1,1-dimethylpyrrolidinium 1% m/m in ethanol CHNO Batch 1 is valid until 1 April 2013 Monograph 2392 Leaflet Yes
G0400006 Glycerol monolinoleate G0400007 Glycerol mono-oleate G0400008 Glycerol monostearate 40-55 G0400101 Glyceryl trinitrate - reference spectrum G0400100 Glyceryl trinitrate solution G0450000 Glycine Y0001308 Glycopyrronium bromide Y0001309 Glycopyrronium for peak identification Y0001358 Glycopyrronium impurity N Y0000433 Ammonium glycyrrhizate G0460000 Glycyrrhizate (monoammonium) G0525000 Gonadorelin Y0000125 Goserelin Y0000126 Gosereline - reference spectrum Y0000019 4-D-Ser-goserelin Y0000194 Goserelin validation mixture Y0001473 Goserelin for NMR identification G0550000 Gramicidin Y0000396 Granisetron hydrochloride Y0000477 Granisetron impurity A Y0000478 Granisetron impurity B Y0000395 Granisetron impurity E G0600000 Griseofulvin Y0000619 Guaiacol G0700000 Guaifenesin Y0000117 Halofantrine hydrochloride Y0000118 Halofantrine impurity C H0100000 Haloperidol H0100100 Haloperidol decanoate Council of Europe, all rights reserved 2013
1 2 3 1 2 3 1 1 1 1 3 5 2 1 1 1 1 1 1 2 2 3 2 1 1 1 1 1 1
1429 1430 0495 1331 1331,1355 0614,0752 1783 1783 1783 1772 0277,1536, 2378 0827 1636 1636 1636 1636 1636 0907,1662,20 702 1695 1695 1695 1695 0182 1978 0615 1979 1979 0616,0995,11 78, 1503 1397,1431 Yes Yes Yes Yes Yes Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a l f a a a a a a c c l c c c a a a a a a a a g g g a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001518 Haloperidol for peak identification Y0001517 Haloperidol for system suitability H0150000 Halothane - reference spectrum Y0000673 Harpagoside H0185000 Heparin Low-Molecular-Mass for assay BRP H0190000 Heparin Low-Molecular-Mass for calibration CRS H0200000 Heparin sodium BRP Y0001287 Heparin calcium for NMR identification Y0001283 Heparin sodium for NMR identification Y0001282 Heparin for physico-chemical analysis H0205010 Hepatitis A vaccine (inactivated, adsorbed) Type B BRP Y0001192 Hepatitis A Vaccine (Inactivated, Non-Adsorbed) Y0000389 Hepatitis B vaccine (rDNA) BRP method A (thiomersal free) H0210010 Hepatitis B vaccine (rDNA) BRP method B H0220000 Heptadecanol Y0000063 Heptaminol hydrochloride Y0000057 Heptaminol impurity A H0250000 alpha-Hexachlorocyclohexane H0330000 Hexamidine diisetionate H0325000 Hexetidine H0400000 Hexobarbital H0420000 Hexylresorcinol H0500000 Hide powder H0600000 Histamine dihydrochloride H0700000 Histamine phosphate H0750000 Histidine H0755000 Histidine hydrochloride monohydrate H0800000 Homatropine hydrobromide H0830000 Homatropine methylbromide Y0001383 Homatropine methylbromide for system suitability Batch n 1 1 1 1 7 2 3 1 1 1 2 1 2 2 3 1 2 3 2 2 1 1 4 2 2 2 1 1 1 1 Quantity Sale per vial Unit 25 mg 1 25 mg n/a 1.03 mg 1 mg 25 mg 2 ml 30 mg 30 mg 300 mg 0.5 ml 0.8 ml 0.5 ml 1 ml 600 mg 150 mg 20 mg 10 mg 20 mg 100 mg 500 mg 100 mg 500 mg 250 mg 250 mg 100 mg 100 mg 100 mg 25 mg 5 mg 1 1 1 5 1 1 1 1 1 3 3 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 Batch 1 is valid until 31 December 2012 Batch 1 is valid until 31 January 2013 93.4% CHN; (2RS)-6-methylhept-5-en-2-amine 262 IU per ml; Please contact us for information on the type needed for your use To be stored below -50C 16.6 micrograms per ml 20 micrograms per ml 97.9% CHO 1.01mg per vial CHO Anti-IIa activity : 31 IU per vial; Anti-Xa activity : 104 IU per vial ; Batch 6 is valid until 30 April 2012 Mna = 3800 1010 IU per ml Information Monograph 0616 0616 0393 1095, 1871 0828 0828 0569, 0686,20705 0332 0333 0333 See leaflet, 20714 20714,1526,1 935, 1107 See leaflet, 20715 See leaflet, 1056 0801,0802,08 47 1980 1980 0772 1436 1221 0183 1437 20814 0143 0144 0911 0910 0500,0720 0720 0720 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g l a b a a a a a b d b b a a a g g a a a a a a a a a a a
37
List of European Pharmacopoeia Reference Standards Order Reference Standard Code H0837000 L-Homocysteine thiolactone hydrochloride - reference spectrum Y0001290 Honokiol H0900000 Human albumin for electrophoresis BRP Y0000219 Human anti-D immunoglobulin BRP Y0000667 Human coagulation factor VII concentrate BRP H0920000 Human coagulation factor VIII concentrate BRP H0920500 Human coagulation factor IX concentrate BRP H0950000 Human hepatitis A immunoglobulin BRP Y0001504 Human immunoglobulin BRP (ACA and Molecular size) Y0001512 Human Immunoglobulin BRP (Fc Function and Molecular size) H1000000 Human immunoglobulin for electrophoresis BRP Y0000488 Human immunoglobulin (molecular size) BRP Batch n 1 1 2 1 2 4 2 1 1 1 2 1 Quantity Sale per vial Unit n/a 1 20 mg 1 ml 40 mg 26 mg 37 mg 30 mg 10 mg 6000 mg 9000 mg 96 mg 700 mg 1 1 1 2 5 5 3 1 1 1 3 75.7% to 80.9% of the total protein is the main band (Ig), protein content: 5% Each vial contains 0.7 gram of immunoglobulin G 99.6% CHO 96,7% to 99,2% of the total protein is the main band (albumin), protein content : 5% 285 IU anti-D immunoglobulin per ampoule 1uc=40 mg 9.9 IU per vial 10.4 IU per vial ; Batch 3 is valid until 31 March 2012 7.9 IU/vial; Common standard with FDA and WHO (4th IS) 10.2 IU per vial Information Monograph 1617 2567 0255 See leaflet, 20713 See leaflet, 20710 See leaflet, 20704 See leaflet, 20711 See leaflet, 0338, 0769 See leaflet, 0338, 0918 See leaflet, 0338, 0918 0338,0918 See leaflet, 0338, 0918,1928 See leaflet, 20621 See leaflet, 0723 0398 See leaflet 0912 0829 91,7% CHClNO 99.7% CHClNOS ; Batch 5 is valid until 31 March 2012 1831,2500 0394 0394 1784 1784 0335,0353,05 61 Batch 1 is valid until 31 December 2012 38 0335 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage Extra charges l g(c) c c c c a c a a a a
-20C -20C -20C -20C -20C -20C -20C +5C +5C +5C +5C
H1005000 Human Plasma Pools for NAT validation H1100000 Human rabies immunoglobulin BRP H1110000 Human tetanus immunoglobulin BRP Y0000502 Human vaccinia immunoglobulin H1115000 Hyaluronidase BRP H1120000 Hydralazine hydrochloride Y0001151 Hydrastine hydrochloride H1200000 Hydrochlorothiazide Y0001494 Hydrochlorothiazide for peak identification Y0000646 Hydrocodone hydrogen tartrate 2.5-hydrate - * narc Y0000710 Hydrocodone for peak identification - * narc H1300000 Hydrocortisone Y0001092 Hydrocortisone for peak identification Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 6 1 1 1 8 2
3502 mg 170 mg 87 mg 1 ml 50 mg 20 mg 20 mg 160 mg 10 mg 10 mg 10 mg 100 mg 5 mg
1 3 1 3 1 1 1 1 1 1 1 1 1
Set of 103 plasma pool samples 91 IU per vial 120 IU per vial 23 IU per vial 328 IU per mg
Yes Yes Yes Yes Yes
-20C -20C -20C -20C +5C +5C -20C +5C +5C +5C +5C +5C +5C
c c c b a g c a a k k a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code H1400000 Hydrocortisone acetate Batch n 9 Quantity Sale Information Monograph per vial Unit 125 mg 1 99% CHO; Hydrocortisone acetate CRS 8 is suitable for monographs 0321,0334,07 01/2011:0335, 01/2008:334, 01/2008:0321, 01/2008:0767 and 01/2008:0734 34, 0767 only. ; Batch 8 is valid until 30 September 2012 15 mg 100 mg 250 mg 10 mg n/a 10 mg 175 mg 125 mg 20 mg 50 mg 1200 mg 800 mg 10 mg 600 mg 100 mg 25 mg 25 mg 10 mg 10 mg 20 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (1R,2R,4S,5S,7S)-9-butyl -7-[[(2S)-3-hydroxy2-phenylpropanoyl]oxy]-3-oxa -9-azoni atricyclo [3.3.1.02,4]nonane (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenyl -propanoate Batch 4 is valid until 31 May 2012 solution of 0.06% m/V in acetonitrile - to be diluted as appropriate.; (2RS)-2(4-Butylphenyl)propanoic acid 39 (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate (norhyoscine) Resorcinol 7-hydroxy-2-methyl-4H-1-benzopyran-4-one. 98.4% CHKNOS (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid - Cefadroxyl impurity A Average Mw 130100 Da 507900 Da 99.9% CHNO 0334 0768,1131 0969 2099 0704 0913,0914,09 15 1616 1225 0148,0149 0813 1785 1785 1804 0916,1086,10 92 1786 1786 1786 2167 2167 0737 0737 Yes Yes Yes Leaflet Yes
Effective from 2013 Storage +5C Extra charges a
Y0001482 Hydrocortisone acetate for peak identification H1425000 Hydrocortisone hydrogen succinate H1426000 Hydrogenated wool fat Y0000446 Hydromorphone hydrochloride - * narc B0650000 Hydrous benzoyl peroxide - reference spectrum H1428000 Hydroxocobalamin Y0000119 Hydroxycarbamide H1429400 Hydroxyethyl salicylate H1429700 4-Hydroxyphenoxymethylpenicillin potassium H1430000 D-alpha-(4-Hydroxy-phenyl)glycine Y0001277 Hydroxyethyl starch (medium MW) Y0001322 Hydroxyethyl starch (high Mw) Y0000186 Hydroxypropylbetadex H1435000 Hydroxyzine hydrochloride Y0000011 Hymecromone Y0000012 Hymecromone impurity A Y0000013 Hymecromone impurity B Y0000483 Hyoscine Y0000484 Hyoscine impurity A H1450000 Hyoscine butylbromide Y0000447 Hyoscine butylbromide impurity E
1 2 1 1 1 1 1 1 3 1 1 1 1 3 1 1 2 1 1 2 1
Yes
+5C -20C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a k l a a a a a a a a g a g a g g a a
H1500000 Hyoscine hydrobromide Y0000448 Hyoscine hydrobromide impurity B H1600000 Hyoscyamine sulfate Y0000449 Hyoscyamine impurity E Y0000915 Hypromellose phthalate I0020000 Ibuprofen B1220000 Ibuprofen impurity B Council of Europe, all rights reserved 2013
1 1 1 1 1 5 6
50 mg 10 mg 100 mg 10 mg 10 mg 250 mg 1.15 mL
1 1 1 1 1 1 1
0106,0500 0106 0501 0501 347 0721 0721
+5C +5C +5C +5C +5C +5C +5C
a a g g a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000140 Ibuprofen impurity F Y0000881 Ibuprofen for peak identification I0050000 Idoxuridine I0060000 Ifosfamide I0060100 Ifosfamide - reference spectrum I0060002 Ifosfamide impurity A I0060004 Ifosfamide impurity B I0060010 Ifosfamide impurity E I0060012 Ifosfamide impurity F I0086000 Imidazole I0090000 Imipenem I0100000 Imipramine hydrochloride Y0000893 Imipramine for system suitability Y0001153 Immunoglobulin for anti-A, anti-B antibodies limit test BRP Y0001152 Immunoglobulin panel for anti-A, anti-B antibodies test Y0000540 Immunoglobulin panel for anti-D antibodies test BRP Y0001205 Imperatorin I0150000 Indapamide I0150020 Indapamide impurity B Y0000788 Indinavir Y0000880 Indinavir sulfate - reference spectrum Y0000746 Indinavir for system suitability I0200000 Indometacin Y0000349 Insulin aspart Batch n 2 4 1 1 1 3 1 1 2 1 2 2 1 1 1 1 1 5 3 1 1 1 2 2 Quantity Sale Information per vial Unit 5 mg 1 3-[4-(2-methylpropyl)phenyl]propanoic acid 0.09 mg 1 Batch 3 is valid until 31 August 2012 50 mg 50 mg n/a 100 mg 20 mg 10 mg 10 mg 100 mg 100 mg 50 mg 10 mg 45 mg 96 mg 2 uc 20 mg 150 mg 5 mg 100 mg n/a 20 mg 50 mg 8 mg 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 7.45 mg of insulin aspart + B28iso insulin aspart + A21Asp insulin aspart + B3Asp insulin 8 aspart + B3iso Asp insulin aspart per vial ; Batch 1 is valid until 30 April 2012mg insulin + A21 desamido per vial CHNOS 7.99 6.94 mg insulin + A21 desamido per vial CHNOS 5.93 mg insulin lispro per vial ; Batch 1 is valid until 1 June 2013 8.61 mg insulin + A21-desamido per vial see recommandations for use on accompagnying leaflet CHNOS About 1.52 mg per mL About 9.74 mg per mL 40 98.8 % CHO 97.6% CHClNOS ; Batch 4 is valid until 31 October 2012 4-chloro-N-(2-methyl-1H-indol-1-yl]-3-sulphamoylbenzamide 97.2% CHNO 92.9% CHNOS 3-[(2-chloroethyl)amino]propyl dihydrogen phosphate ; Batch 2 is valid until 30 April 2012 bis[3-[(2-chloroethyl)amino]propyl] dihydrogen diphosphate 3-chloro-N-(2-chloroethyl)propan-1-amine (RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide 100.0% CHClNOP Monograph 0721 0721 0669 1529 1529 1529 1529 1529 1529 0757,1424 1226 0029,0408,08 17, 0889,1787 0029 20620 20620 See leaflet, 20626 2556 1108 1108 2214 2214 2214 0092,0922,16 86 2084 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C -20C +5C +5C +5C +5C -20C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C -20C Extra charges a a a g l g(c) g g b g c g g c c a a a a a l a g c
I0305000 Insulin (bovine) I0310000 Insulin (human) New Y0000348 Insulin lispro I0320000 Insulin (porcine) I0320300 Interferon alfa-2a I0320301 Interferon alfa-2b Council of Europe, all rights reserved 2013
3 4 2 3 3 5
7.99 mg 8 mg 5.75 mg 8.61 mg 1 ml 200 L
1 1 1 1 1 1
0854,1637 0838,0854,16 37, 1638 2085 0838,0854,16 37, 1638 1110 1110
Yes Yes Yes Yes Yes Yes
-20C -20C -20C -20C -80C -80C
c c c c d d
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001101 Interferon beta-1a I0320330 Interferon gamma 1b I0320331 Interferon gamma-1b validation solution I0328000 Iobenguane sulfate Y0000839 Iobenguane sulfate - reference spectrum Y0001294 Iodixanol Y0001292 Iodixanol impurity C Batch n 2 2 2 2 1 1 1 Quantity Sale Information per vial Unit 0.5 mL 1 335 g of interferon beta-1a per mL CHNOS ; Batch 1 is valid until 30 November 2012 0.5 mL 0.2 ml 25 mg n/a 60 mg 10 mg 2 1 1 1 1 1 5-[acetyl[3-[[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl] amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6triiodobenzene-1,3-dicarboxamide 5-[acetyl[3-[acetyl[3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide 5-[acetyl[3-[acetyl[3-[[3-[3-[acetyl[3,5-bis[(2,3-dihydroxypropyl) carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropoxy]-2-hydroxypropyl] carbamoyl]-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl] amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6triiodobenzene-1,3-dicarboxamide 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodo benzene-1,3dicarboxamide 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3dicarboxamide about 1 mg per ml ; Batch 1 is valid until 31 March 2012 about 1 mg per ml 97.2% CHINOS Monograph 1639 1440 1440 1111,1112,111 3,2351 2351 2215 2215 Leaflet Yes Yes
Effective from 2013 Storage -80C -80C -80C +5C Extra charges d d d b l +5C +5C a a
Y0001291 Iodixanol impurity E
10 mg
2215
+5C
Y0001293 Iodixanol impurity H
10 mg
2215
+5C
I0320800 Iohexol I0320810 Iohexol impurity A I0320820 Iohexol impurity J Y0000672 Iohexol for peak identification I0329000 Iopamidol I0329010 Iopamidol impurity A Y0000406 Iopamidol impurity H I0330000 Iopanoic acid Y0001297 Iopentol Y0001020 Iopromide Y0001077 Iopromide impurity A Y0001021 Iopromide for system suitability 1 Y0001022 Iopromide for system suitability 2 I0340000 Iotalamic acid A0560000 Iotalamic acid impurity A Y0000555 Iotrolan Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
150 mg 50 mg 125 mg 10 mg 50 mg 10 mg 10 mg 100 mg 10 mg 100 mg 0.125 mg 5 mg 5 mg 150 mg 20 mg 100 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 41 5-Amino-2,4,6-tri-iodo-N-methylisophthalamic acid 98.7% CHINO 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3dicarboxamide N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-amino-2,4,6-triiodoisophthalamide 4-chloro-N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(2hydroxypropanoyl)amino)2,6-diiodobenzenz-1,3-dicarboxamide
1114 1114 1114,2215 1114 1115 1115, 1754 1115 0700 2215 1753 1753 1753 1753 0751 0751 1754 Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a a a a a a a a b a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000658 Iotrolan for system suitability Y0000141 Ioxaglic acid Y0000142 Ioxaglic acid impurity A I0360000 Ipratropium bromide Y0000276 Ipratropium impurity A I0361000 Ipratropium bromide impurity B Y0001166 Irbesartan Y0001156 Irbesartan impurity A I0375000 Isoconazole I0380000 Isoconazole nitrate I0400000 Isoemetine hydrobromide Y0000858 Isoflurane Y0000037 Isoflurane - reference spectrum I0460000 Isoleucine New I0465000 Isomalt Y0000070 Isomaltooligosaccharide I0500000 Isoniazid I0599990 Isoprenaline hydrochloride I0600000 Isoprenaline sulfate I0725000 Isopropyl hexadecanoate I0750000 Isopropyl tetradecanoate New I0775000 Isosorbide dinitrate I0775010 Isosorbide mononitrate I0775020 Isosorbide-2-nitrate I0800000 Isotretinoin Y0001218 Isotretinoin for peak identification I0900000 Isoxsuprine hydrochloride Y0000366 Isradipine Y0000367 Isradipine impurity D I7000000 Itraconazole Y0001100 Itraconazole for system suitability I8000010 Ivermectin Council of Europe, all rights reserved 2013 Batch n 1 2 1 5 1 3 1 1 1 1 1 1 1 1 5 1 1 1 2 2 4 3 4 3 4 1 1 1 1 2 1 2 Quantity Sale per vial Unit 5 mg 1 125 mg 20 mg 120 mg 10 mg 10 mg 60 mg 10 mg 200 mg 200 mg 25 mg 1.5 ml n/a 50 mg 3000 mg 0.9 mg 100 mg 50 mg 500 mg 100 mg 2 ml 350 mg 150 mg 50 mg 60 mg 10 mg 50 mg 125 mg 5 mg 150 mg 15 mg 150 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 90.6% of C48H74O14 (component H2B1a) ; Batch 1 is valid until 30 April 2012 42 99.2% CHNO methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl) -2,6-dimethylpyridine-3,5-dicarboxylate 94.3% CHO 97.9% CHO 40,8% CHNO ; Batch 2 is valid until 1 June 2013 99.9% CHNO; Isosorbide-5-nitrate ; Batch 3 is valid until 31 January 2013 97.0 % CHO ; Batch 3 is valid until 31 July 2012 Batch 4 is valid until 1 May 2013 1-(pentylamino)-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl] cyclopentanecarboxamide (1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1] octane (1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1methylethyl)-8-azoniabicyclo[3.2.1]octane 3-amino-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid Information Monograph 1754 2009 2009 0919 0772 0919 2465 2465 1018 1017 0080,0081 1666 1673 0770 1531 1506 0146 1332 0502 0839 0725 1117,1118 1117,1118 1117,1118 0693,1019 1019 1119 2110 2110 1335 1335 1336 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a a a a a a f b l a a a a a a a a f h g g(b) g(b) a g g a a f
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000575 Ivy leaf standardised tincture Y0000041 Josamycin Y0000042 Josamycin propionate Y0001315 Josamycin for peak identification K0100000 Kanamycin B sulfate K0200000 Kanamycin monosulfate Batch n 1 2 2 1 3 2 Quantity Sale Information per vial Unit 2 ml 1 0.20% (m/m) of hederacoside C; Ivy leaf standardised tincture CRS has been renamed as ivy leaf tincture HRS in 01/2013:2148. 150 mg 150 mg 25 mg 20 mg 150 mg 1 1 1 1 1 Batch 2 is valid until 31 January 2012 799 IU per mg of CHNOS,HO 1000 Ph. Eur. units per mg 975 Ph. Eur. units per mg Monograph 2148 1982,1983,20 702 1982,1983,20 702 1983 0032,0033,06 45 0032,0033,00 53, 0485,0645,12 89, 1290,20702 1020 1020,1742 1746 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]ethanone 1-[4-(3-hydroxyphenyl)piperidin-4-yl]propan-1-one 1746 1746 0921,1067,12 70 0798,0848 0922,1157,12 09 1-(3-benzoylphenyl)ethanone 3-[(1RS)-1-carboxyethyl]benzoic acid Batch 1 is valid until 31 December 2012 4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b) thiophen-9,10-dione 99.6 % CHClNO 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)-amino]ethyl]benzoic acid 93.8% CHO 0922 0922 1755 1755 1592 1592 2434,2483 0923 0923 1337 1647 1061 Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage -20C -20C +5C +5C +5C +5C Extra charges g(c) c a a a a
Y0000450 Ketamine hydrochloride - * narc K0551000 Ketamine impurity A Y0000246 Ketobemidone hydrochloride - reference spectrum Y0000244 Ketobemidone impurity B Y0000245 Ketobemidone impurity C K0600000 Ketoconazole K1000000 3-Ketofusidic acid K2000000 Ketoprofen K2000010 Ketoprofen impurity A K2000015 Ketoprofen impurity C Y0000486 Ketorolac trometamol Y0000626 Ketorolac trometamol for peak identification Y0000164 Ketotifen hydrogen fumarate - reference spectrum Y0000161 Ketotifen impurity G Y0001200 Kudzuvine root dry extract New L0050000 Labetalol hydrochloride New Y0001548 Labetalol impurity A L0129000 Lactitol monohydrate Y0000257 Lactobionic acid A1206000 Lactose (anhydrous)
1 2 1 1 1 2 3 2 4 3 1 2 1 3 1 2 n/a 2 1 1
10 mg 50 mg n/a 5 mg 5 mg 150 mg 10 mg 50 mg 10 mg 5 mg 10 mg 5 mg n/a 0.0225 mg 200 mg 120 mg 10 mg 60 mg 100 mg 100 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1-[(2-chlorophenyl)(methylimino)methyl]cyclopentanol
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C
k a l g g g a g g g g g l g c g g a g a
43
List of European Pharmacopoeia Reference Standards Order Code L0100000 Lactose Reference Standard Batch n 2 Quantity Sale Information per vial Unit 100 1 Batch 1 is valid until 31 January 2012 Monograph 0177,0178,01 87, 0188,0204,02 09, 1215,1570 0924,1230 10-15 0924,1230 99.7% CHNOS 2217 2217 2217 1756 1756 1756 2,3-dichlorobenzoic acid 1756 2219 2219 97.9% 4-(trifluoromethyl)aniline 99.7% CHN 0.99 mg per vial of pure leuprorelin peptide CHNO ; Batch 4 is valid until 1 February 2012 1848 2330 2330 2330 2334 0771,0874 1442 1442 0726,1728 0726 1728 100.0% CHNO (2RS)-2-(2-oxopyrrolidin-1-yl)butanoic acid ; Batch 1 is valid until 1 March 2013 (2Z)-2-(2-oxopyrrolidin-1-yl)but-2-enamide pyridin-2-ol (2R)-2-(2-oxopyrrolidin-1-yl)butanamide ((R)-etiracetam) 1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid 44 2535 2535 2535 2535 2535 1484 1484 1339 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
L0130000 Lactulose New Y0001510 Lactulose for peak identification Y0000188 Lactulose for system suitability Y0000425 Lamivudine Y0000518 Lamivudine for system suitability 1 Y0000426 Lamivudine for system suitability 2 Y0001030 Lamotrigine Y0001031 Lamotrigine for peak identification Y0001085 Lamotrigine for system suitability Y0001032 Lamotrigine impurity E Y0000773 Lansoprazole Y0000774 Lansoprazole for peak identification Y0001474 Lauric acid Y0000654 Leflunomide Y0000487 Leflunomide impurity A Y0000674 Leflunomide for peak identification Y0000685 Letrozole L0375000 Leucine L0376000 Leuprorelin L0376001 Leuprorelin - reference spectrum Y0000047 Levamisole hydrochloride for system suitability L0380000 Levamisole hydrochloride Y0000048 Levamisole - reference spectrum Y0001253 Levetiracetam Y0001254 Levetiracetam impurity A Y0001255 Levetiracetam impurity B Y0001256 Levetiracetam impurity C Y0001257 Levetiracetam impurity D L0390000 Levocabastine hydrochloride L0390008 Levocabastine impurity D L0399900 Levocarnitine Council of Europe, all rights reserved 2013
3 1 3 1 1 2 1 1 1 1 1 1 1 1 2 1 1 2 5 1 3 1 1 1 2 1 1 1 1 1 2
3000 mg 2600 mg 12 mg 150 mg 10 mg 10.3 mg 10 mg 20 mg 10 mg 10 mg 60 mg 1 mg 1500 mg 100 mg 25 mg 1 mg 70 mg 50 mg 1 mg n/a 60 mg 50 mg n/a 110 mg 10 mg 10 mg 10 mg 10 mg 125 mg 20 mg 125 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
99.7% CHO
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C
a a a a a a g g g a a a a g g g a a c l
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g g l a a a g a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code L0399905 Levocarnitine impurity A L0400000 Levodopa L0420000 Levodropropizine L0420002 Levodropropizine impurity A Y0001033 Levodropropizine impurity B Y0001048 Levodropropizine impurity C L0500000 Levomepromazine hydrochloride L0505000 Levomepromazine maleate L0551000 Levonorgestrel Y0001379 Levonorgestrel impurity B Y0001431 Levonorgestrel for system suitability L0570000 Levothyroxine sodium Y0001382 Levothyroxine for peak identification L0595000 Lidocaine L0600000 Lidocaine hydrochloride L0650000 Lincomycin hydrochloride Y0001393 Lincomycin hydrochloride for system suitability L0700000 Liothyronine sodium Y0000860 Liothyronine for peak identification L0702000 Lisinopril dihydrate Y0001235 Lisinopril for system suitability Y0001234 Lisinopril impurity F L0720000 Lithium clavulanate L0720800 Lithocholic acid Y0000112 Lobeline hydrochloride L0745000 Lomustine Y0001438 Long pepper for system suitability L0750000 Loperamide hydrochloride Y0000322 Loperamide hydrochloride for system suitability Y0000341 Loperamide oxide monohydrate Y0001498 Lopinavir Y0001506 Lopinavir for peak identification Y0001505 Lopinavir for system suitability Council of Europe, all rights reserved 2013 Batch n 2 2 1 2 1 1 1 1 2 1 1 3 1 1 2 3 1 7 1 2 1 1 5 2 1 2 n/a 2 1 1 1 1 1 Quantity Sale Information per vial Unit 50 mg 1 (E)- or (Z)-4-(trimethylammonio)but-2-enoate 100 mg 60 mg 20 mg 50 mg 300 mg 100 mg 50 mg 30 mg 10 mg 10 mg 100 mg 10 mg 50 mg 100 mg 250 mg 10 mg 50 mg 0.0046 mg 50 mg 2 mg 0.01 mg 125 mg 60 mg 50 mg 50 mg 600 mg 50 mg 15 mg 20 mg 200 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 45 95.3 % CHNO Lisinopril for performance test CRS 3 renamed as lisinopril for system suitability CRS 1 for the implementation of 01/2011:1120 (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino] hexanoyl]pyrrolidine-2-carboxylic acid (cyclohexyl analogue) 97.6% CHLiNO; 1 mg of CHLiNO corresponds to 1.157 mg of CHKNO 96.6 % CHINNaO 95.4% CHClNOS 89.3% CHINNaO 13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-5(10)-en-20-yn-3-one (2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol (dextrodropropizine) 1-phenylpiperazine 2,3-epoxypropan-1-ol Monograph 1339 0038 1535 1535 1535 1535 0505 0925 0926 0926 0926 0401,0728 0401 0727 0227,1242,13 63 0582,0583,09 96 0583 0401,0728 0728 1120 1120 1120 1140,1653 1189,1275 1988 0928 2477 0921,0929,17 29 0929 1729 2615 2615 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a g a a g g(c) a a a a a c c a g a c c c a a a a a a g a g g g a a
2615 Yes +5C a For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Code Y0000688 Loratadine Reference Standard Batch n 3 1 1 1 1 1 2 1 2 2 3 1 1 1 1 1 1 2 2 1 1 1 1 1 3 2 3 1 1 4 5 1 1 Quantity Sale per vial Unit 60 mg 1 20 mg 10 mg 50 mg 100 mg 0.8 mg 10 mg 50 mg 6 mg 0.0015 mg 60 mg 20 mg 140 mg 0.4028 mg 15 mg 50 mg 20 mg 60 mg 50 mg 20 mg 400 mg 100 mg 60 mg 20 mg 250 mg 10 mg 10 mg 100 mg n/a 1200 mg 1200 mg 100 mg 25 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 99.7% CHO ; Batch 3 is valid until 31 October 2012 98.8% CHO 99.5% CHO 99.4% CHOPS diethyl (2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl] butane dioate diethyl (2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate 2,5-dichloro-4-[[[(2,6-difluorophenyl)carbonyl]carbamoyl]amino]phenyl phenyl carbonate 99.5% CHClFNO 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde Batch 1 is valid until 31 August 2012 99.5% CHO ; Batch 2 is valid until 30 June 2012 (5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodiazepine-2,3dione ethyl 4-[(11RS)-8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-yl]piperidine-1-carboxylate ethyl 4-oxopiperidine-1-carboxylate Information Monograph 2124 2124 2124 2124 1121 1121 1121 2232 2232 2232 1538,1563 1538 2177 2177 2177 0558 0558 2114 0805,0806,09 30, 1654 2396 2523 2584 1445 2567 1343 1343 1343 0365,0925 2080 1235,1236 0435,0559,13 81, 1531 1237 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C -20C -20C +5C +5C +5C +5C Extra charges a a a a j j a a g a c c g g g a a a a a a a a g(c) g g(c) g(c) a l a a g
Y0000603 Loratadine for system suitability Y0000604 Loratadine impurity F Y0000605 Loratadine impurity H L0750500 Lorazepam - * psy Y0000576 Lorazepam for system suitability - * psy Y0000718 Lorazepam impurity D Y0001062 Losartan potassium Y0001072 Losartan impurity D Y0001076 Losartan for system suitability L0790000 Lovastatin Y0001136 Lovastatin for peak identification Y0001284 Lufenuron Y0001261 Lufenuron for peak identification Y0001265 Lufenuron impurity G L0800000 Lynestrenol Y0001034 Lynestrenol for peak identification Y0000397 Lysine acetate L0900000 Lysine hydrochloride Y0000745 Macrogol 40 sorbitol heptaoleate Y0001157 Macrogol polyvinyl alcohol grafted copolymer Y0001369 Macrogol 30 dipolyhydroxystearate M0088000 Magnesium aspartate dihydrate Y0001289 Magnolol M0120000 Malathion M0120005 Malathion impurity A M0120010 Malathion impurity B M0100000 Maleic acid Y0000143 Malic acid - reference spectrum M0160000 Maltitol M0200000 Mannitol M0206000 Maprotiline hydrochloride M0206040 Maprotiline impurity D Council of Europe, all rights reserved 2013
3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2- en-1-amine 1237 +5C g 46 For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Code Y0000819 Marbofloxacin Reference Standard Batch n 1 1 1 1 1 1 1 2 1 1 2 1 1 2 3 1 2 1 2 1 1 1 1 1 1 1 1 2 2 1 1 1 1 4 Quantity Sale per vial Unit 10 mg 1 20 mg 5 uc 20 mg 20 mg n/a 120 mg 150 mg 15 mg 15 mg 20 mg 60 l 40 l 100 mg 50 mg 10 mg 50 mg 100 mg 100 mg 120 mg 50 mg 25 mg n/a 10 mg 50 mg 5 mg 5 mg 5 mg 5 mg 100 mg 1 uc 10 mg 100 mg 150 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 47 ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide 5-methylthiazol-2-amine N-[(2Z)-3,5-dimethylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2benzothiazine-3-carboxamide 1,1-dioxide N-[(2Z)-3-ethyl-5-methylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2benzothiazine-3-carboxamide 1,1-dioxide 99.4% CHClNO 2,3-dimethylaniline Batch 1 is valid until 31 December 2012 99.1 % CHO Batch 2 is valid until 28 February 2013 Tris(1-methylethoxy)phosphane Tetrakis(1-methylethyl)methhylenediphosphonate Renamed for 01/2011:0622 ; Batch 1 is valid until 1 May 2013 4-chlorobenzhydrol 1-(4-chlorobenzhydryl)piperazine 4.3 log (ie 20000) infective viral units per vial Information Monograph 2233 2233 1057,0213,24 42 1208,1254 0845 0845 2393 0622 0622 0622 0641, 2350 2350 2350 0673,1593 0673 0673 1240 1240 1241 1593 1593 1593 1593 2055 2373 2373 2373 2373 2373 1698 1698 1698 0507 0619,0623 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a c a a l a a a a g g g a a c a g g a a a l a g g g g g f l f g a
Y0000820 Marbofloxacin for peak identification M0210000 Measles vaccine (live) BRP M0215000 Mebendazole Y0000144 Mebendazole for system suitability Y0000168 Mebendazole - reference spectrum Y0001086 Mebrofenin New M0220000 Meclozine dihydrochloride Y0001310 Meclozine impurity B Y0001311 Meclozine impurity H M0240000 Medronic acid Y0001107 Medronic acid impurity A Y0001106 Medronic acid impurity B M0250000 Medroxyprogesterone acetate M0250010 Medroxyprogesterone acetate for performance test Y0000598 Medroxyprogesterone acetate for system suitability M0252600 Mefenamic acid Y0001081 Mefenamic acid impurity A M0253000 Mefloquine hydrochloride Y0001514 Megestrol acetate Y0001524 Megestrol acetate for system suitability Y0001507 Megestrol acetate for peak identification M0260100 Megestrol acetate - reference spectrum Y0001209 Meglumine Y0001080 Meloxicam Y0001035 Meloxicam impurity A Y0001036 Meloxicam impurity B Y0001037 Meloxicam impurity C Y0001039 Meloxicam impurity D Y0001158 Melphalan hydrochloride Y0001513 Melphalan - reference spectrum Y0001457 Melphalan for system suitability M0300000 Menadione M0350000 Menthol Council of Europe, all rights reserved 2013
List of European Pharmacopoeia Reference Standards Order Reference Standard Code M0370000 Mepivacaine hydrochloride M0370020 Mepivacaine impurity B M0400000 Meprobamate - * psy M0500000 Mepyramine maleate Y0000679 Mepyramine impurity A Y0000680 Mepyramine impurity C Y0001252 Meropenem trihydrate Y0000297 Mesalazine New Y0001563 Mesalazine impurity A New Y0001569 Mesalazine impurity C Y0001040 Mesityl oxide Y0000337 Mesna - reference spectrum Y0000316 Mesna impurity C Y0000317 Mesna impurity D Y0000227 Meso-rich exametazime Y0000097 Mesterolone Y0000096 Mesterolone impurity A M0600000 Mestranol Y0000301 Metacresol - reference spectrum M0600500 Metacycline hydrochloride M0600900 Metamizole sodium M0600905 Metamizole impurity A Y0001481 Metamizole impurity E M0605000 Metformin hydrochloride Y0000770 Methacrylic acid-ethyl acrylate copolymer (1:1) - type A Y0000323 Methacrylic acid-ethyl acrylate copolymer (1:1) - type B M0610000 Methacrylic acid-ethylacrylate copolymer(1:1) - reference spectrum M0610030 Methacrylic acid-ethylacrylate copolymer (1:1), dispersion 30%-ref.sp M0620000 Methacrylic acid-methylmethacrylate copolymer(1:1)reference spectrum M0630000 Methacrylic acid-methylmethacrylate copolymer(1:2)reference spectrum M0800000 Methadone hydrochloride - reference spectrum Y0000428 Methanol - reference spectrum M0900000 Methaqualone - reference spectrum Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1 4 3 3 1 3 1 1 1 1 1 1 1 1 1 Quantity Sale per vial Unit 100 mg 1 60 mg 100 mg 1000 mg 10 mg 10 mg 110 mg 125 mg 15 mg 15 mg 100 mg n/a 10 mg 10 mg 0.5 mg 120 mg 30 mg 100 mg n/a 50 mg 100 mg 15 mg 15 mg 50 mg 200 mg 200 mg n/a n/a n/a n/a n/a n/a n/a 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 48 4-formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one 4-N-demethylanalgin 99.8% CHO ; Batch 1 is valid until 30 September 2012 17-hydroxy-1alpha-methylandrost-4-en-3-one 2-(acetylsulphanyl)ethanesulphonic acid 2,2'-(disulphanediyl)bis(ethanesulphonic acid) N-(4-methoxybenzyl)pyridin-2-amine pyridin-2-amine 87.0% CHNOS,3HO Information Monograph 1242 (RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide 1242 0407,1689 0278 0278 0278 2234 1699,1993 1699 1699 2358 1674 1674 1674 1925 1730 1730 0509 2077 0272,0820 1346 1346 1346 0931 1128 1128 1128 1129 1127 1130 0408,1787 1989 0510 Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a j a a g a a g g g(b) l a a a a a a l a a a a a a a l l l l l l l
List of European Pharmacopoeia Reference Standards Order Code Y0000754 Methenamine M0950000 DL-Methionine M0960000 Methionine M1000000 Methotrexate Y0000602 Methotrexate for peak identification Y0000663 Methotrexate impurity C M1000008 Methotrexate impurity D Y0000664 Methotrexate impurity E M1300000 Methylatropine bromide M1400000 Methylatropine nitrate M1450000 Methylcarbidopa M1470000 Methyl 2-(4-chlorophenoxy)-2-methylpropionate Y0001488 Methyl methacrylate M1500000 Methyldopa Y0001374 Racemic methyldopa Y0001083 Methyldopa for system suitability M1550000 Methylene chloride M1551000 2-(1-Methylethyl) pentanoic acid M1556000 Methyl 12-hydroxystearate Y0000398 Methyl nicotinate Y0000776 Methylergometrine maleate Y0000777 Methylergometrine for system suitability M1625000 Methylnitrosoindoline M1650000 Methyl parahydroxybenzoate Y0001017 Methylphenidate hydrochloride - * narc Y0001490 Methylphenidate impurity C Y0000910 Methylphenidate impurity mixture M1700000 Methylphenobarbital - * psy M1750000 Methylprednisolone M1755000 Methylprednisolone acetate M1755200 Methylprednisolone hydrogen succinate M1755220 Methylprednisolone hydrogen succinate for performance test Y0001376 2-methylpyrazine Council of Europe, all rights reserved 2013 Reference Standard Batch n 1 1 1 6 1 1 3 1 1 1 4 1 n/a 2 1 1 2 4 2 1 1 1 3 3 1 1 1 1 2 1 2 1 1 Quantity Sale per vial Unit 10 mg 1 50 mg 50 mg 100 mg 20 mg 10 mg 10 mg 10 mg 100 mg 100 mg 1 mg 0.5 ml 50 mg 50 mg 5 mg 0.024 mg 2 ml 25 mg 100 mg 25 mg 10 mg 0.53 mg 110 mg 150 mg 40 mg 10 mg 0.04 mg 500 mg 150 mg 100 mg 125 mg 50 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 49 (2RS)-2-phenyl-2-[(2R)-piperidin-2-yl]ethanamide Batch 2 is valid until 31 January 2012 100.0% CHO; batch 2 valid until 31/12/10 for use with monograph 2134 and 1999. (2S)-2-[[4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino] benzoyl]amino]pentanedioic acid (N-methylfolic acid, methopteridine) 4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino]benzoic acid (N10-methylpteroic acid) 4-[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid (4-aminoN10-methylpteroic acid, APA) 88.2 % CHNO ; Batch 5 is valid until 31 January 2013 Information Monograph 1545 0624 0788,1027 0560 0560 0560 0560 0560 0511,0919 0512 0755 0318 1975 0045,0755 0045 0045 0932 0678,1378 1497 2129 1788 1788 1108 0409,1262,21 34,1999 2235 2235 2235 0189 0312,0561 0933 0768,1131 1131 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g a a g g g g g a a a g g a a a g g a a g g a a k a a j a a a a
2446 +5C g For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000190 N-Methylpyrrolidone - reference spectrum M1770180 Methyl ricinoleate Y0000418 Methylrosanilinium chloride Y0000407 Methylrosanilinium for system suitability M1770200 Methyl stearate M1800000 Methyltestosterone Y0000861 Methyltestosterone for system suitability M1800900 Methylthioninium chloride M1800902 Methylthioninium impurity A M1808000 Metixene hydrochloride M1824990 Metoclopramide M1825000 Metoclopramide hydrochloride M1824995 Metoclopramide impurity A M1825010 Metoclopramide impurity E Y0000701 Metolazone Y0000702 Metolazone for system suitability Y0000171 Metoprolol succinate - reference spectrum M1830000 Metoprolol tartrate Y0000145 Metoprolol impurity A M1845000 Metrifonate M1850000 Metronidazole M1851000 Metronidazole benzoate Y0000069 Metronidazole benzoate - reference spectrum Y0000087 Metronidazole impurity A M1860000 Mexiletine hydrochloride Y0000202 Mexiletine impurity C Y0000203 Mexiletine impurity D M1875000 Mianserin hydrochloride Y0001041 Mianserin impurity B Y0000862 Mianserin for system suitability M1880000 Miconazole M1900000 Miconazole nitrate M2200000 Midazolam - * psy Y0000562 Midazolam impurity C Council of Europe, all rights reserved 2013 Batch n 1 2 1 1 3 1 1 1 2 1 1 2 1 1 1 1 1 1 2 1 2 1 1 2 1 1 1 2 1 1 1 1 2 2 Quantity Sale per vial Unit n/a 1 125 mg 40 mg 10 mg 100 mg 100 mg 10 mg 50 mg 20 mg 75 mg 100 mg 50 mg 25 mg 20 mg 80 mg 10 mg n/a 60 mg 10 mg 100 mg 50 mg 50 mg n/a 10 mg 100 mg 2 mg 2 mg 100 mg 10 mg 1.01 mg 70 mg 100 mg 50 mg 0.08 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 acide 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a] [1,4]benzodiazepine-3-carboxylique 50 1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy]dipropan-2-amine (2RS)-2-(2,6-dimethylphenoxy)propan-1-amine Batch 1 is valid until 31 January 2012 (14bRS)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a] azepine-8-sulfonic acid 2-methyl-4-nitroimidazole (2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol 4-(acetylamino)-5-chloro-N-(2-diethylaminoethyl)-2-methoxy benzamide N,N-diethylethane-1,2-diamine 99.4% CHClNOS 3-(dimethylamino)-7-(methylamino)phenothiazin-5-ylium Information Monograph 1675 0051,2367 1990 1990 0051,1497 0410 0410 1132 1132 1347 1348 0674,0856,13 03 1348 1575 1757 1757 1448 1028 1028,1448 1133 0675,0934 1424 0934 0675 1029 1029 1029 0846 0846 0846 0935,1335 0513,1148 0936,1065 0936 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage Extra charges l a g g a a a a a g a a a g a a l +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C a a g a a l a a a a a a a g g j g
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000599 Midazolam for system suitability - * psy Y0000539 Milk thistle standardised dry extract M2280000 Minocycline hydrochloride M2300000 Minoxidil Y0001432 Minoxidil for system suitability Y0000705 Mirtazapine Y0000721 Mirtazapine for system suitability Y0000490 Misoprostol Y0001162 Misoprostol for system suitability Y0000378 Mitomycin M2305000 Mitoxantrone hydrochloride M2305005 Mitoxantrone impurity A Y0000635 Modafinil Y0000636 Modafinil for system suitability Y0000251 Molgramostim Y0000821 Molsidomine Y0000822 Molsidomine impurity B Y0000823 Molsidomine impurity D M2900000 Mometasone furoate Y0001436 Montelukast dicyclohexylamine Y0001433 Montelukast racemate Y0001434 Montelukast sodium Y0001435 Montelukast for peak identification Y0000028 Morantel hydrogen tartrate Y0000451 Morphine hydrochloride (trihydrate) - * narc Y0000452 Morphine sulfate - * narc Y0000830 Morphine for system suitability - * narc Y0000772 Moxidectin Y0000747 Moxidectin for system suitability Y0000703 Moxifloxacin hydrochloride Y0000717 Moxifloxacin for peak identification Y0000226 Moxonidine Y0000222 Moxonidine impurity A M3600000 Mumps vaccine (live) BRP Council of Europe, all rights reserved 2013 Batch n 2 3 3 1 1 1 1 3 1 2 3 3 1 1 1 1 1 1 2 1 1 1 1 2 2 1 2 2 1 2 1 1 1 1 Quantity Sale Information per vial Unit 1 mg 1 Batch 1 is valid until 30 June 2012 120 mg 1 Content silibinin A and silibinin B: 26.9 % of ; Batch 2 is valid until 31 December 2012 125 mg 50 mg 10 mg 10 mg 10 mg 60 mg 5 mg 120 mg 50 mg 5 mg 110 mg 0.1 mg 0.3 ml 5 mg 10 mg 10 mg 100 mg 150 mg 20 mg 150 mg 20 mg 50 mg 25 mg 40 mg 15 mg 70 mg 10 mg 110 mg 10 mg 50 mg 10 mg 5 uc 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 99.7% CHClNO 4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine 4.6 log (ie40000) infective viral units per vial 51 96.1 % CHClFNO ; Batch 1 is valid until 31 May 2012 Batch 1 is valid until 31 August 2012 97.4% CHNO ; Batch 1 is valid until 31 May 2012 See leaflet 99.4% CHClNOS N-nitrosomorpholine morpholine-4-carbaldehyde 13.45 mg protein per ml CHNOS 99.3% CHNO ; Batch 1 is valid until 31 December 2012 97.7% CHClNO 1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl] amino] anthracene-9,10-dione 100.0% CHNOS 98.5% CHO ; Batch 2 is valid until 28 February 2012 90.9 % CHClNO ; Batch 2 is valid until 31 December 2012 Monograph 0936 2071,1860 1030 0937 0937 2338 2338 1731 1731 1655 1243 1243 2307 2307 1641 1701 1701 1701 1449 2583 2583 2583 2583 1546 0097,1839,18 41 1244,1784 1244, 0097 1656 1656 2254 2254 1758 1758 0538,1057 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes Yes Yes
Effective from 2013 Storage +5C -20C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -80C Extra charges j c a a a g g g(c) g(c) g a a a a d a g(b) a a a a a a a k k k g g g g g g d
List of European Pharmacopoeia Reference Standards Order Reference Standard Code M3805000 Mupirocin - reference spectrum M3805500 Mupirocin calcium - reference spectrum M3806000 Mupirocin lithium Y0000489 Mycophenolate mofetil Y0000519 Mycophenolate mofetil for peak identification Y0000692 Mycoplasma fermentans BRP Y0000690 Mycoplasma hyorhinis BRP Y0000691 Mycoplasma orale BRP Y0000689 Mycoplasma synoviae BRP Y0000485 Myo-inositol N0020000 Nabumetone N0020020 Nabumetone impurity D N0020030 Nabumetone impurity F Y0000146 Nadolol Y0001215 Nadolol impurity mixture N0025000 Nadroparin calcium Y0000077 Naftidrofuryl - reference spectrum Y0000120 Naftidrofuryl impurity A Y0000121 Naftidrofuryl impurity B Y0000331 Naftidrofuryl impurity F N0050000 Nalidixic acid N0075000 Naloxone hydrochloride dihydrate Y0000695 Naloxone for peak identification Y0000400 Naltrexone hydrochloride Y0000410 Naltrexone impurity C Y0000542 Nandrolone decanoate Y0000547 Nandrolone decanoate for peak identification Y0000548 Nandrolone decanoate for system suitability N0080000 Naphazoline hydrochloride N0100000 Naphazoline nitrate N0200000 Naphazoline impurity A New N0250000 Naproxen Y0000399 Naproxen (racemic) Y0000631 Naproxen impurity L Council of Europe, all rights reserved 2013 Batch n 1 1 2 2 5 1 1 1 1 1 1 2 4 1 1 1 1 1 2 1 1 2 1 1 1 1 1 1 3 2 5 2 1 1 Quantity Sale per vial Unit n/a 1 n/a 100 mg 30 mg 10 mg 1 ml 1 ml 1 ml 1 ml 1020 mg 60 mg 10 mg 10 mg 100 mg 0.01 mg 250 mg n/a 10 mg 25 mg 10 mg 100 mg 100 mg 10 mg 50 mg 15 mg 5 mg 10 mg 10 mg 50 mg 10 mg 10 mg 100 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1-(6-methoxynaphthalen-2-yl)ethanone 52 N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide (naphthylacetylethylenediamine) Batch 1 is valid until 1 June 2013 N-(3-butenyl)-noroxymorphone 2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic acid ethyl 2-[(naphtalen-1-yl)methyl]- 3-(tetrahydrofuran-2-yl)propanoate ; Batch 1 is valid until 31 December 2012 2-[(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3- (tetrahydrofuran-2-yl) propanoate 99.8% CHO 99.8% CHO (E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one 6,6'-dimethoxy-2,2'-binaphthalenyl 93.7% CHOLi Information Monograph 1450 1451 1450,1451 1700 1700 20607 20607 20607 20607 1805 1350 1350 1350 1789 1789 0828,1134 1594 1594 1594 1594 0701 0729,2099 0729 1790 1790 1992 1992 1992 0730,1162 0147 0147,0730 0731,1702 0731,1702 1702 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage Extra charges l l +5C +5C +5C -80C -80C -80C -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C a g g d d d d a a a a a a a l a a a a a a a a c c c g a g g g g
List of European Pharmacopoeia Reference Standards Order Code Y0001378 Naringin Y0001437 Nateglinide Y0001440 Nateglinide impurity A Y0001441 Nateglinide impurity B Y0001442 Nateglinide impurity C N0300000 Neamine N0399000 Neohesperidin-dihydrochalcone Reference Standard Batch n 1 1 1 1 1 4 1 Quantity Sale per vial Unit 20 mg 1 88.3% CHO 200 mg 1 99.9% CHNO 10 mg 15 mg 10 mg 0.5 mg 125 mg 1 1 1 1 1 Information Monograph 2563 2575 2575 2575 2575 0180,0197 1547 Yes Yes Leaflet Yes Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C Room temp. +20C +5C Extra charges a a a a a a a
trans-4-(1-methylethyl)cyclohexanecarboxylic acid N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-Lphenylalanine (Lphenylalanine isomer) N-[[cis-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (cis-isomer) 76.3% CHNO 89.9% CHO
N0399004 Neohesperidin-dihydrochalcone impurity B
10 mg
86.4% CHO ; 7-[[2-O-(6-deoxy--L-mannopyranosyl) --Dglucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1benzopyran-4-one (neodiosmin) Not to be used for microbiological assay
1547
Yes
N0400000 Neomycin sulfate
50 mg
0032,0033,00 53, 0180,0197,04 85, 0645 0197,20702 0046 0626
Yes
-20C
N0401000 Neomycin sulfate for microbiological assay N0500000 Neostigmine bromide N0550000 Neostigmine metilsulfate N0559000 Netilmicin sulfate Y0000520 Nevirapine (anhydrous) Y0000521 Nevirapine for peak identification Y0001499 Nevirapine hemihydrate Y0000388 Newcastle Disease Vaccine (inactivated) BRP
3 1 1 1 1 1 1 1
25 mg 50 mg 50 mg 25 mg 30 mg 0.058 mg 15 mg 4 uc
1 1 1 2 1 1 1 1
19850 IU per vial
Yes
-20C +5C +5C -20C +5C
a g g a a a a c
14656 IU per vial 99.8% CHNO
1351,20702 2255 2255 2479 Yes Yes
+5C +5C -20C
The kit contains :1 vial BRP1 NDV reference antigen, 1 vial BRP1 NDV control antigen, 1 vial BRP1 NDV coating antibody, 1 vial BRP1 NDV conjugated, detection antibody
0870
Y0001373 Nicergoline Y0000287 Nicergoline - reference spectrum Y0000283 Nicergoline impurity A Y0001356 Nicergoline impurity D Y0001362 Nicergoline for peak identification Y0001352 Nicergoline for system suitability N0560000 Niclosamide (anhydrous) N0600000 Nicotinamide N0590000 Nicotine - reference spectrum New N0590200 Nicotine ditartrate Y0001425 Nicotine ditartrate dihydrate Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 1 1 4 1
50 mg n/a 10 mg 20 mg 1 mg 10 mg 50 mg 50 mg n/a 120 mg 15 mg
1 1 1 1 1 1 1 1 1 1 1 53 92.8% CHN x 2 CHO ; Batch 3 is valid until 1 May 2013 [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10aoctahydroindol[4,3-fg]quinolin-9-yl]methyl 5-chloropyridine-3-carboxylate 5-bromopyridine-3-carboxylic acid
1998 1998 1998 1998 1998 1998 0679,0680 0047 1452,1792 1792 2599 Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C
g l g g g g g a l g g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001023 Nicotine for system suitability N0700000 Nicotinic acid Y0001268 Nicotinic acid impurity mixture N0750000 Nifedipine N0750010 Nifedipine impurity A N0750015 Nifedipine impurity B Y0000824 Niflumic acid Y0000825 Niflumic acid impurity A Y0000826 Niflumic acid impurity B Y0000827 Niflumic acid impurity E Y0000836 Nifuroxazide N0800000 Nikethamide Y0000829 Nilutamide Y0000894 Nilutamide impurity B N0845000 Nimesulide Y0001237 Nimesulide for peak identification N0845008 Nimesulide impurity D N0850000 Nimodipine New N0850010 Nimodipine impurity A N0900000 Nitrazepam - * psy N0900010 Nitrazepam impurity A N0905000 Nitrendipine Y0001456 Nitrendipine for peak identification N0905005 Nitrendipine impurity A N0930000 Nitric oxide - reference spectrum N0950000 Nitrofural Y0001377 Nitrofural for peak identification N1000000 Nitrosotriaminopyrimidine N1090000 Nizatidine Y0001278 Nizatidine for system suitability N1090060 Nizatidine impurity F N1080000 Nomegestrol acetate N1080005 Nomegestrol acetate impurity A Council of Europe, all rights reserved 2013 Batch n 3 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 4 2 4 1 2 2 1 3 1 1 1 1 1 1 1 1 2 Quantity Sale Information per vial Unit 1 mg 1 Batch 2 is valid until 30 June 2012 100 mg 0.12 mg 50 mg 20 mg 20 mg 10 mg 10 mg 10 mg 15 mg 10 mg 1 ml 110 mg 5 mg 100 mg 10 mg 0.004 mg 50 mg 1 mL 100 mg 25 mg 60 mg 10 mg 30 mg n/a 100 mg 0.11 mg 50 mg 250 mg 10 mg 10 mg 100 mg 50 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6alpha-methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate 54 (EZ)-N,N'-[thiazole-2,4-diylbis(methylenesulphanediylethylene)]bis(N'methyl-2-nitroethene-1,1-diamine) 99.3% CHNOS 99.8% CHNO ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5- dicarboxylate; (nitrophenylpyridine analogue) 3-amino-6-nitro-4-phenylquinol-2-one 2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate ; Batch 3 is valid until 1 June 2013 4-nitro-2-phenoxyaniline ; Batch 3 is valid until 31 October 2012 4-nitro-3-(trifluoromethyl)aniline 2-chloropyridine-3-carboxylic acid 2-hydroxy-N-(3-(trifluoromethyl)phenyl)pyridine-3-carboxamide 6-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate Monograph 1452, 1792, 2599 0459,0859 0459 0627,1013 0627 0627 2115 2215 2115 2115 1999 0233 2256 2256 1548 1548 1548 1245 1245 0415,0898,11 21 0415 1246 1246 1246 1550 1135 1135 0058 1453 1453 1453 1551 Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g(c) a g a a a g a g g a g g a g g g a a j a a a a l +5C +5C +5C +5C +5C +5C +5C a a a a a a a
List of European Pharmacopoeia Reference Standards Order Code Y0001314 1-nonadecanol Y0000670 Nonivamide Y0000755 Nonoxinol 9 N1100000 Noradrenaline tartrate Y0000681 Noradrenaline impurity D Y0000682 Noradrenaline impurity E Y0000686 Noradrenaline impurity F N1130000 Norcyclobenzaprine N1140000 Nordazepam -* psy N1200000 Norethisterone N1225000 Norethisterone acetate Y0000522 Norethisterone for system suitability N1230000 Norfloxacin N1230010 Norfloxacin impurity A Y0001015 Norfloxacin for system suitability Y0001301 Norfloxacin for peak identification Y0000724 Norgestimate Y0000725 Norgestimate for system suitability N1250000 Norgestrel N1279000 Norpseudoephedrine hydrochloride - * psy N1280000 Nortriptyline hydrochloride Y0001296 Nortriptyline for system suitability N1300000 Noscapine N1400000 Nystatin O0100900 Octoxinol 10 Y0000368 Octyl gallate O0101000 Octyldodecanol O0120000 Ofloxacin O0120010 Ofloxacin impurity A O0120050 Ofloxacin impurity E Reference Standard Batch n 1 1 1 6 1 1 1 1 1 2 1 1 1 1 2 1 1 1 1 2 2 1 1 6 2 1 4 1 2 3 Quantity Sale per vial Unit 400 mg 1 10 mg 10 mg 200 mg 15 mg 10 mg 10 mg 25 mg 50 mg 100 mg 100 mg 10 mg 50 mg 20 mg 8 mg 10 mg 10 mg 5 mg 30 mg 50 mg 10 mg 20 mg 100 mg 100 mg 300 mg 30 mg 400 mg 50 mg 20 mg 20 mg 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4] benzoxazine-6-carboxylic acid (FPA) (RS)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid 55 94.8% CHO 5825 IU per mg Cathine hydrochloride 7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (corresponding also to pefloxacin impurity F) Batch 1 is valid until 31 January 2012 Dipotassium clorazepate impurity B Batch 5 is valid until 31 August 2012 99.1% CHNO Information Monograph 0801,0802,08 47 2336,2337 1454 0254,0285,07 32, 2303 Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Yes -20C +5C +5C Yes Yes Yes +5C +5C +5C +5C +5C +5C +5C +5C +5C Yes -20C +5C +5C +5C +5C +5C +5C Extra charges a a g g g g a a j a a c a a a a a a a j a a a c g a a a a a
4[(1R)-2-amino-1-methoxyethyl]benzene-1,2-diol (noradrenaline methyl ether) 0285,0732 2-chloro-1-(3,4-dihydroxyphenyl)ethanone 0285,0732 N-benzyl-1-phenylmethanamine 0285,0732 0941 0898,1466 0234,1212,09 26 0850 0234 1248 1460 1248 1248 1732 1732 0940 0683 0941 0941 0102,0515,05 16 0517,1292,20 702 1553 2057 1136 1455 1455 1455
List of European Pharmacopoeia Reference Standards Order Code Y0001370 Olanzapine Reference Standard Batch n 1 1 1 n/a 1 1 1 1 1 1 1 4 1 1 2 4 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 Quantity Sale Information per vial Unit 200 mg 1 99.8% CHNS 5 mg 1 5-methyl-2-[(2-nitrophenyl)amino]thiophene-3-carbonitrile 10 mg 20 mg 2000 mg 30 mg 20 mg 100 mg 10 mg 60 mg 60 mg 50 mg 10 mg 10 mg 10 mg 200 mg 10 mg 30 mg 10 mg 10 mg 10 mg 10 mg 10 mg 200 mg 0.0008 mg 100 mg 5 mg 600 mg 100 mg 100 mg 300 mg 0.42 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (3R,4R,5S)-5-acetamido-4-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1carboxylic acid 56 99.7% CHNOP (3RS)-3-[(1H-imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4Hcarbazol-4-one (C-demethylondansetron) (3RS)-3-[(dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4Hcarbazol-4-one 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one Imidazole Omeprazole sulphone 89,9% CHClNO ; Batch 3 is valid until 1 June 2013 Batch 3 is valid until 31 May 2012 98.3% CHO 98.7 % CHO 82.2% CHO 99.3 % CHNO Monograph 2258 2258 2258 2472 2579 2454 1878 2600 2600 1457 1457 0942,1032 2374 0942,2372,23 74 0942,1032 2016 2016 2016 2016 2016 2016 2016 2016 2259 2259 1033,1332 1033 2450 1760 1759 2422 1759,1760 2422 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C -20C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g a a c a a a a a c a c c g g g g g g g g a a a a a g g a g a
Y0001392 Olanzapine impurity A Y0001380 Olanzapine for system suitability New Y0001204 Oleanolic acid Y0001479 Oleic acid New Y0001113 Triolein Y0000805 Oleuropein Y0001405 Olmesartan medoxomil Y0001424 Olmesartan medoxomil for system suitability O0146000 Olsalazine sodium O0146010 Olsalazine sodium for performance test O0150000 Omeprazole Y0001043 Omeprazole magnesium Y0001042 Omeprazole for peak identification O0151000 Omeprazole impurity D New Y0000218 Ondansetron hydrochloride dihydrate Y0000197 Ondansetron for LC system suitability Y0000196 Ondansetron for TLC system suitability Y0001345 Ondansetron impurity A Y0000195 Ondansetron impurity D Y0001326 Ondansetron impurity E Y0001320 Ondansetron impurity F Y0001346 Ondansetron impurity G Y0001125 Orbifloxacin Y0001147 Orbifloxacin impurity mixture O0180000 Orciprenaline sulfate Y0000895 Orciprenaline for system suitability Y0001501 Orientvine stem HRS Y0000100 Orphenadrine hydrochloride Y0000101 Orphenadrine citrate Y0001337 Oseltamivir phosphate (impurity B free) Y0001181 Orphenadrine for peak identification Y0001338 Oseltamivir impurity A Council of Europe, all rights reserved 2013
List of European Pharmacopoeia Reference Standards Order Reference Standard Code New Y0000102 Orphenadrine impurity E Y0001339 Oseltamivir impurity B Y0001340 Oseltamivir impurity C Y0001341 Oseltamivir impurity H Y0001207 Osthole O0200000 Ouabain Y0000638 Oxacillin sodium monohydrate Y0000560 Oxacillin for peak identification New Y0000271 Oxaliplatin New Y0000272 Oxaliplatin impurity B Batch n 2 1 1 1 1 2 1 1 4 8 Quantity Sale Information per vial Unit 60 mg 1 (RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy] ethanamine (metamethylbenzyl isomer) ; Batch 1 is valid until 1 May 2013 10 mg 10 mg 30 mg 20 mg 150 mg 110 mg 10 mg 250 mg 22 mg 1 1 1 1 1 1 1 1 1 99.9% CHNOPt ; Batch 3 is valid until 1 June 2013 91,2% CHNOPt; (SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2-diaminekN,kN'] platinum (diaquodiaminocyclohexaneplatinum) ; Batch 6 is valid until 31 July 2012 Batch 7 is valid until 1 June 2013 (OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamine-kN,kN'][ethane-dioato(2-)kO1,kO2]dihydroxyplatinum ; Batch 4 is valid until 1 April 2013 (SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-kO1,kO2]platinum (S,S-enantiomer of oxaliplatin) Batch 1 is valid until 1 March 2013 2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate 2-(2-diethylaminoethoxy)ethyl 2-phenyl-butyrate dihydrogen citrate methyl [5-(phenylsulphonyl)-1H-benzimidazole-2-yl]carbamate ethyl (1R,2R,3S,4R,5S)-4-acetamido-5-amino-2-azido-3(1-ethylpropoxy)cyclohexanecarboxylate (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1carboxylic acid tributylphosphane oxide 98.3 % CHO 80.0% CHO 93.8% CHNNaOS Monograph 1759,1760 2422 2422 2422 2557 0048 2260 2260 2017 2017 Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g a a g a g a a g g
New Y0000273 Oxaliplatin impurity C Y0000274 Oxaliplatin impurity D O0225000 Oxazepam - * psy Y0000543 Oxazepam for peak identification Y0000350 Oxeladin hydrogen citrate Y0000404 Oxeladin impurity C Y0000390 Oxeladin impurity D O0225800 Oxfendazole for veterinary use Y0000224 Oxfendazole impurity B Y0000225 Oxfendazole with impurity D Y0000709 Oxitropium bromide Y0000715 Oxitropium bromide impurity B Y0000713 Oxitropium bromide impurity D O0240000 Oxolinic acid O0240005 Oxolinic acid impurity A O0240010 Oxolinic acid impurity B O0250000 Oxprenolol hydrochloride O0260000 Oxibendazole Council of Europe, all rights reserved 2013
5 3 2 2 1 1 1 2 1 1 1 1 1 1 1 1 1 2
25 mg 10 mg 50 mg 0.008 mg 50 mg 10 mg 20 mg 50 mg 10 mg 10 mg 50 mg 15 mg 10 mg 50 mg 20 mg 20 mg 50 mg 100 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2017 2017 0778 0778 1761 1761 1761 1458 1458 1458 2170 Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g g j a g g g g g g a a g a a a g
(1R,2R,4S,5S,7s)-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9,9dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane (methylhyoscine) (1R,2R,4S,5S,7s,9r)-9-ethyl-9-methyl-7-[(2-phenylprop-2-enoyl)oxy]-3oxa-9-azoniatricyclo[3.3.1.02,4]nonane (apo-N-ethylhyoscine) 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7- carboxylate
2170 2170 1353 1353 1353 0628,0876,10 72
57
List of European Pharmacopoeia Reference Standards Order Reference Standard Code O0270000 Oxybuprocane hydrochloride O0288000 Oxybutynin hydrochloride O0288005 Oxybutynin impurity A Y0000492 Oxycodone hydrochloride - * narc Y0000453 Oxycodone impurity D O0290000 Oxymetazoline hydrochloride Y0001044 Oxymetazoline impurity A O0400000 Oxytetracycline O0500000 Oxytetracycline hydrochloride O0700000 Oxytocin O0770000 Oxytocin/Desmopressin validation mixture Y0000698 Paclitaxel Y0000699 Paclitaxel impurity C Y0000700 Paclitaxel natural for peak identification Y0000719 Paclitaxel semi-synthetic for peak identification Y0000739 Paclitaxel semi-synthetic for system suitability P0090000 Palmitic acid Y0000524 Pamidronate disodium pentahydrate P0100000 Pancreas powder (amylase and lipase) BRP P0200000 Pancreas powder (protease) BRP P0250000 Pancuronium bromide Y0000577 Pancuronium bromide for system suitability Y0000835 Pantoprazole sodium sesquihydrate Y0001001 Pantoprazole for system suitability P0270000 Papaverine hydrochloride P0300000 Paracetamol Y0000780 Paraffin (hard) Y0000058 Paraffin (liquid) - reference spectrum Y0000913 Paraffin (White soft) Y0000912 Paraffin (Yellow soft) P0305000 Parnaparin sodium Y0000578 Paroxetine hydrochloride (anhydrous) Council of Europe, all rights reserved 2013 Batch n 1 1 3 1 2 2 1 7 4 4 3 2 1 1 1 2 4 1 3 3 2 1 1 4 1 4 1 1 1 1 1 1 Quantity Sale per vial Unit 150 mg 1 150 mg 10 mg 100 mg 50 mg 80 mg 10 mg 100 mg 20 mg 1 mg 20.2 mg 40 mg 5 mg 10 mg 10 mg 1 mg 100 mg 10 mg 2000 mg 2000 mg 20 mg 20 mg 20 mg 0.5055 mg 25 mg 50 mg 10 mg n/a 10 mg 10 mg 250 mg 100 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 58 Batch 3 is valid until 31 December 2012 41.4 Ph. Eur. U. lipolytic activity per mg; 56.3 Ph. Eur. U. amylolytic activity per mg 1.48 Ph. Eur. U. per mg Vecuronium impurity B Batch 1 is valid until 1 April 2013 Batch 3 is valid until 29 February 2012 0.96 mg per vial of CHNOS about 0.1 mg oxytocin + 0.1 mg desmopressin per vial 99.4% CHNO N-debenzoyl-N-hexanoylpaclitaxel N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl] acetamide 89.9% CHNO ; Batch 6 is valid until 31 December 2012 7,8-didehydro-4,5 alpha-epoxy-14-hydroxy-3-methoxy -17methylmorphinan-6-one (14-hydroxycodeinone) 90.9% CHNO; 4-(diethylamino)but-2-ynyl()-2-(cyclohex-3-enyl)-2cyclohexyl-2-hydroxyacetate ; Batch 2 is valid until 31 January 2012 Information Monograph 1251 1354 1354 1793 1793 0943 0943 0198,0199 0198,1030 0779,0780 0712,0779,07 80 1794 1794 1794 1794 1794 0229,0882,14 74,2058,1663 1779 0350 0350 0681,1769 0681 2296 2296 0102,0573 0049 1034 0239,0240 1799 1554 0828,1252 2283 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a g g k a f f g g g(c) g(c) a a a a a a a a a g g a a g a a l a a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000281 Paroxetine hydrochloride hemihydrate Y0000233 Paroxetine impurity A Y0000579 Paroxetine hydrochloride (anhydrous) impurity C Y0000256 Paroxetine impurity D Y0000580 Paroxetine impurity E Y0000581 Paroxetine hydrochloride (anhydrous) impurity H Y0000630 Paroxetine for system suitability P0309000 Pefloxacin mesilate dihydrate P0309020 Pefloxacin impurity B P0309030 Pefloxacin impurity C New Y0001539 Pemetrexed disodium heptahydrate Y0001538 Pemetrexed for system suitability Y0001535 Pemetrexed impurity mixture P0307000 Penbutolol sulfate P0307005 Penbutolol impurity A P0310000 Penicillamine P0320000 Penicillamine disulfide P0400100 Pentaerythrityl tetranitrate diluted P0405000 Pentamidine diisetionate P0405500 Pentazocine - reference spectrum P0405510 Pentazocine hydrochloride - reference spectrum Y0000417 Pentazocine lactate - reference spectrum Y0001051 Pentetate sodium calcium P0500000 Pentobarbital - * psy P0510000 Pentoxifylline Y0000076 Pentoxyverine hydrogen citrate - reference spectrum Y0000098 Pentoxyverine impurity A Y0000099 Pentoxyverine impurity B P0525000 Pepsin powder Y0000010 Pergolide mesilate Council of Europe, all rights reserved 2013 Batch n 2 4 1 2 1 1 1 1 1 2 1 n/a 1 1 1 1 2 2 1 1 1 1 1 1 1 1 1 1 2 1 Quantity Sale Information per vial Unit 200 mg 1 97.4% CHClFNO 15 mg 1 (3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-phenylpiperidine (desfluoroparoxetine) 10 mg 5 mg 5 mg 10 mg 5 mg 200 mg 10 mg 0.01 mg 200 mg 20 mg 0.002 mg 100 mg 20 mg 100 mg 100 mg 600 mg 30 mg n/a n/a n/a 100 mg 500 mg 100 mg n/a 10 mg 10 mg 2000 mg 150 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1-phenylcyclopentanecarboxylic acid 2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate (caramiphen) 0.99 Ph. Eur. U. per mg 99.9% CHNOS 59 93.0% CHNOS; 3,3-(disulphanediyl)bis[(2S)-2-amino-3methylbutanoic] acid 10.0% CHNO (2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1-dimethylethyl) amino] propan-2-ol 1-ethyl-6-chloro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3carboxylic acid (chlorinated homologue of pefloxacin) 1-ethyl-6-fluoro-5-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3carboxylic acid (isopefloxacin) 78.6 % (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-1-benzyl-4-(4-fluorophenyl) piperidine (N-benzylparoxetine) (3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine ((+)-trans-paroxetine) (3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4fluorophe- nyl)piperidine (cis-paroxetine) [(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol Monograph 2018,2283 2018,2283 2283 2018,2283 2283 2283 2018 1460 1460 1460 2637 2637 2637 1461 1461 0566 0566 1355 1137,1436 1462 1463 2000 2353 0200,0419 0851 1621 1621 1621 0682 1555 Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g g g g a a a a a a g g a a h a l l l +5C +5C +5C +5C +5C +5C +5C a j a l a a a f
List of European Pharmacopoeia Reference Standards Order Reference Standard Code New Y0000237 Perindopril impurity A New Y0000207 Perindopril for stereochemical purity Y0000238 Perindopril tert-butylamine Y0000771 Perindopril for peak identification P0550000 Perphenazine Y0001045 Perphenazine for system suitability Y0000021 Pertussis toxin BRP Batch n 2 2 2 1 1 1 1 Quantity Sale Information per vial Unit 10 mg 1 (2S,3aS,7aS)-octahydro-1Hindole-2-carboxylic acid ; Batch 1 is valid until 1 May 2013 40 mg 40 mg 5 mg 100 mg 5 mg 0.05 mg 1 1 1 1 1 2 Batch 1 is valid until 1 June 2013 Monograph 2019 2019 2019 2019 0629,0904 0629 See leaflet, 1356, 1595, 1931, 1932, 1933, 1934, 2065, 2067, 2329 0420 1-methyl-4-phenylpiperidine (MPP) 5-methyl-2-phenyl-2,4-dihydro-3-pyrazol-3-one 2-benzylpyridine 0420 0421 0421 1357 1357 0189,0201,06 30 0201 0201 Batch 3 is valid until 30 October 2012 99.2% CHKNOS 0781 0148 0113,0114,01 48, 0149 1138 1138 1138 0782,0796,11 61,2575 0422,1574 (4-butyl-4-hydroxy-1,2-diphenyl-3,5)-pyrazolidinedione 0422 1035 0632,1205 Batch 2 is valid until 31 August 2012 0632,1035 2042 0103 60 Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C -20C Extra charges a a a a a a g(d)
P0600000 Pethidine hydrochloride - reference spectrum P0600002 Pethidine impurity A P0800000 Phenazone Y0001138 Phenazone impurity A P0850000 Pheniramine maleate Y0001428 Pheniramine impurity A P0900000 Phenobarbital - * psy Y0001350 Phenobarbital impurity A Y0001351 Phenobarbital impurity B P0950000 Phenoxyethanol P1000000 Phenoxymethylpenicillin P1100000 Phenoxymethylpenicillin potassium Y0001127 Phentolamine mesilate Y0001251 Phentolamine mesilate for system suitability P1109000 Phentolamine mesilate - reference spectrum P1150000 Phenylalanine P1200000 Phenylbutazone Y0000147 Phenylbutazone impurity B P1240000 Phenylephrine P1250000 Phenylephrine hydrochloride Y0000683 Phenylephrine hydrochloride for peak identification Y0000229 Phenylmercuric acetate - reference spectrum P1255100 Phenylmercuric borate - reference spectrum Council of Europe, all rights reserved 2013
1 1 2 1 2 1 4 1 1 4 2 4 1 1 1 4 1 1 2 3 3 1 1
n/a 20 mg 20 mg 20 mg 250 mg 20 mg 200 mg 15 mg 15 mg 1 mL 250 mg 250 mg 10 mg 10 mg n/a 60 mg 100 mg 20 mg 60 mg 50 mg 2 mg n/a n/a
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
l +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C g a a g g j g g a a a a a l a g g a a a l l
List of European Pharmacopoeia Reference Standards Order Reference Standard Code P1260000 Phenylpropanolamine hydrochloride - * Drug Precursor P1290000 Phenytoin Y0001167 Phenytoin for system suitability P1300000 Phenytoin sodium Y0000493 Phloroglucinol (anhydrous) Y0000761 Pholcodine - * narc Y0000798 Pholcodine for peak identification - * narc Y0000766 Phthalic acid P1500000 Phthalylsulfathiazole P1600000 Physostigmine salicylate P1605000 Physostigmine sulfate P1609000 Phytomenadione P1609010 trans-Epoxyphytomenadione P1645000 Picotamide monohydrate P1645005 Picotamide impurity A Y0001508 Picrotin Y0001528 Picrotoxinin Y0000124 Pidolate impurity B Y0000123 Pidolic acid P1650000 Pilocarpine hydrochloride P1700000 Pilocarpine nitrate Y0000106 Pilocarpine nitrate for system suitability Y0000525 Pimobendan Y0000401 Pimobendan for system suitability P1750000 Pimozide P1800000 Pindolol Y0001520 Pioglitazone hydrochloride Y0001519 Pioglitazone for system suitability Y0001476 Pipemidic acid trihydrate Y0000061 Pipemidic acid trihydrate - reference spectrum P1890000 Piperacillin P1900000 Piperazine adipate P2000000 Piperazine citrate P2100000 Piperazine hydrate Y0001217 Piperine Council of Europe, all rights reserved 2013 Batch n 1 1 1 1 1 1 1 1 1 1 1 3 2 1 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 3 1 1 1 n/a Quantity Sale per vial Unit 50 mg 1 Norephedrin hydrochloride 100 mg 20 mg 250 mg 210 mg 10 mg 10 mg 20 mg 100 mg 100 mg 100 mg 150 mg 10 mg 125 mg 25 mg 40 mg 40 mg 60 mg 125 mg 50 mg 50 mg 20 mg 10 mg 0.1 mg 150 mg 100 mg 120 mg 15 mg 15 mg n/a 100 mg 250 mg 250 mg 250 mg 30 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 61 94.5% CHNOS 99.8% CHClNOS 98.3 % CHO (2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentane-dioic acid 4-methoxybenzene-1,3-dicarboxylic acid 87.0% trans-phytomenadione, 12.6% cis-phytomenadione, 0.09% transepoxyphytomenadione CHO; Vitamin K1 benzene-1,2-dicarboxylic acid Information Monograph 0683 1253,1988 0521,1253 0521 2301,2302 0522 0522 2348 0352 0286 0684 1036 1036 1358 1358 2486 2486 1619 1619 0633 0104 0104,0633 2179 2179 1254 0634,0871,17 89 2601 2601 1473 1743 1168,1169 0423 0424 0425 2477,2453 Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges i a a a a k k a a g f a a a a a g a a g g g a a a g a a a l a g g g g
List of European Pharmacopoeia Reference Standards Order Code Y0000288 Piracetam P2120000 Piretanide Y0001458 Piretanide for system suitability P2120002 Piretanide impurity A P2130000 Piroxicam Y0001475 Piroxicam for system suitability P2150000 Pivampicillin P2152000 Pivmecillinam hydrochloride P2152015 Pivmecillinam impurity C P2155001 Plastic additive 01 P2155003 Plastic additive 03 E0800000 Plastic additive 04 P2155005 Plastic additive 05 P2155008 Plastic additive 08 P2155009 Plastic additive 09 P2155010 Plastic additive 10 P2155011 Plastic additive 11 P2155012 Plastic additive 12 P2155013 Plastic additive 13 P2155014 Plastic additive 14 P2155015 Plastic additive 15 P2155016 Plastic additive 16 P2155017 Plastic additive 17 P2155018 Plastic additive 18 O0140000 Plastic additive 20 E1260000 Plastic additive 21 Council of Europe, all rights reserved 2013 Reference Standard Batch n 2 1 1 1 1 3 4 1 2 2 1 1 1 1 3 3 2 2 3 2 2 2 2 2 1 1 1 Quantity Sale per vial Unit 120 mg 1 99.8% CHNO 250 mg 100 mg 10 mg 20 mg 50 mg 15 mg 50 mg 100 mg 10 mg 2 ml 100 mg 500 mg 500 mg 500 mg 250 mg 250 mg 500 mg 250 mg 250 mg 250 mg 500 mg 250 mg 250 mg 100 mg 100 mg 100 mg 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 Oleamide R Erucamide R 62 4-phenoxy-3(1H-pyrrol-1-yl)-5-sulphamoylbenzoic acid Batch 2 is valid until 31 January 2013 Y0001475 replaces P2130100 99.2% CHNOS 99.6% CHClNOS methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydo- 1H-azepin-1-yl) methylene]amino]methyl]-5,5-dimethylthiazolidin-4-carboxylate (2RS)-2-ethylhexyl) benzene-1,2-dicarboxylate N,N'-ethylenedialcanamide Epoxidised soya oil Epoxidised linseed oil ethylene bis[3,3-bis[3-(1,1-dimethylethyl)-4-hydroxyphenyl]butanoate] ; Batch 2 is valid until 31 March 2012 pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate] ; Batch 2 is valid until 31 January 2012 4,4',4''-(2,4,6-trimethylbenzene-1,3,5-triyltrismethylene)trio[2,6-bis(1,1dimethylethyl)phenol] Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate Tris (2,4-di-1,1-dimethylethylphenyl) phosphite R 1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1,3,5triazine-2,4,6-trione 2,2'-Di(octadecycloxy)-5,5'-spirobi(1,3,2-dioxaphosphorinane) R Dioctadecyl disulphide ; Batch 1 is valid until 29 August 2012 Didodecyl 3,3'-thiodipropionate R Dioctadecyl 3,3'-thiodipropionate R Information Monograph 1733 2001 1556 1556 1556 0944 0944 0808,0852 1359 1359 90001,90002, 30114 90001,30114 90001,30114 90001,30114 30103,30104, 30105,30106 30103,30105, 30106,30107 30103,30105, 30106,30107 30103,30105, 30106,30107 30103,30105, 30106,30107 30103,30105, 30106 30103,30105, 30106 30103,30104, 30105,30106 30103,30105, 30106 30103,30105, 30106 30103 30103,30105, 30106,30107 30103,30107 Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a g a a a g g a c a a a a a a a a a a a a a a a a a a
Y0000038 Pirenzepine dihydrochloride monohydrate
List of European Pharmacopoeia Reference Standards Order Reference Standard Code P2155022 Plastic additive 22 Batch n 1 Quantity Sale Information per vial Unit 100 mg 1 Copolymer of dimethyl butanedioate and 1-(2-hydroxyethyl)-2,2,6,6tetramethylpiperidin-4-ol Synonyms: copolymer of dimethyl succinate and (4-hydroxy-2,2,6,6tetramethylpiperidin-1-yl)ethanol 200 mg 1 di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate containing about 27% of (tri(isooctyl)2,2',2''- [monooctyl- stannylidyne)tris (thio)] triacetate. Tin-content of 15.4% 320-67-282 Ph. Eur. D-Antigen Units per ml for types 1-2-3, respectively Monograph 30103 Leaflet
P2155023 Plastic additive 23
30110,30111
+5C
P2160000 Poliomyelitis vaccine (inactivated) BRP
0.5 ml
0214,2066,20 65, 2328,2061,20 67, 1934,2329,20 720 See leaflet, 0215 1464 1464 1464 1464 1464 0733
Yes
-80C
P2161000 Poliomyelitis vaccine (oral) BRP P2163920 Poloxamer 124 P2164009 Poloxamer 188 P2164020 Poloxamer 237 P2164021 Poloxamer 338 P2164030 Poloxamer 407 P2170000 Polyacrylate - reference spectrum P2400000 Polymyxin B sulfate Y0000355 Polymyxin B sulfate for microbiological assay Y0000289 Polysorbate 20 - reference spectrum Y0000290 Polysorbate 40 - reference spectrum Y0000291 Polysorbate 60 - reference spectrum Y0000007 Polysorbate 80 - reference spectrum Y0000792 Poly(vinyl acetate) dispersion 30 per cent P2600000 Poly(vinyl chloride) P2649610 Potassium clavulanate - reference spectrum Y0001168 Potassium clavulanate impurity G Y0000315 Potassium hydrogen aspartate hemihydrate P2650000 Potassium sorbate Y0001275 Potassium sucrose octasulfate P2660000 Povidone Y0000466 Povidone (iodinated) Y0001266 Pramipexole dihydrochloride monohydrate Council of Europe, all rights reserved 2013
3 1 1 1 1 1 1 5 2 1 1 1 1 1 1 1 1 1 2 1 2 1 1
1 ml 30 mg 100 mg 100 mg 100 mg 100 mg n/a 25 mg 25 mg n/a n/a n/a n/a 1500 mg 100 mg n/a 5 mg 50 mg 100 mg 100 mg 50 mg 10 mg 5 mg
5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
log CCID50/ml for types 1,2,3 and total virus content: 6.99, 6.06, 6.83 and 7.20, respectively
Yes
-20C +5C +5C +5C +5C +5C
d a a a a a l a a l l l l
65.1% polymyxin B1, 12.5% polymyxin, 3.3% polymyxin B3, 9.1% polymyxin B1-I 205000 IU per vial
0203 20702 0426 1914 0427 0428 2152 90001,90002, 30114 1140 1653 2076
Yes
+5C -20C
+5C +5C
b a l
Yes
-20C +5C +5C
g(c) a a a a a a
Batch 1 is valid until 30 November 2012 92.6% CHKOS
0618 1796 0685 1142 2416 Yes
+5C +5C +5C +5C
63
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001187 Pramipexole for system suitability Y0001267 Pramipexole impurity D Y0000215 Pravastatin sodium - reference spectrum Y0000223 Pravastatin impurity A Batch n 1 1 1 5 Quantity Sale per vial Unit 15 mg 1 5 mg n/a 0.1 mg 1 1 1 (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl] heptanoic acid (6'-epipravastatin) 76.4% CHO 99.8% CHNO (11bRS)-2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a] isoquinolin-4-one 99.1% CHO 1,2-dihydroprednicarbate 99.2% CHO; Prednisolone CRS 6 is suitable for monographs 01/2011:0335, 01/2008:0353, 01/2008:0354 and 01/2008:0735 only. Information Monograph 2416 (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine 2416 2059 2059 Leaflet Yes
Effective from 2013 Storage +5C +5C -20C Extra charges a a l c
Y0000204 Pravastatin 1,1,3,3-tetramethylbutylamine P2669000 Prazepam -* psy P2670000 Praziquantel Y0001533 Praziquantel for system suitability P2675000 Praziquantel impurity A P2680000 Prazosin hydrochloride P2698000 Prednicarbate Y0001443 Prednicarbate for system suitability P2698060 Prednicarbate impurity F P2700000 Prednisolone Y0001359 Prednisolone for peak identification Y0001355 Prednisolone for system suitability P2800000 Prednisolone acetate
2 1 3 n/a 2 1 2 1 1 7 1 1 4
30 mg 50 mg 200 mg 10 mg 10 mg 50 mg 100 mg 10 mg 10 mg 150 mg 10 mg 10 mg 120 mg
1 1 1 1 1 1 1 1 1 1 1 1 1
2059 1466 0855 0855 0855 0856 1467 1467 1467 0335,0353,03 54, 0735 0353 0353 Yes Yes Yes Yes Yes
-20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
c j a a a a a a a a a a a
Batch 3 is valid until 1 April 2013
0734,0736,09 33, 0975,1467,03 34 0734 1212 0734,0736 0549,0735,08 10 0354 0993,0593 Yes
Y0000582 Prednisolone acetate for peak identification P2804000 Prednisolone hexanoate P2805000 Prednisolone pivalate P2810000 Prednisolone sodium phosphate P2900000 Prednisone P2920000 Pregnenolone isobutyrate Y0000263 Prekallikrein activator in albumin BRP P2939000 Prilocaine P2939060 Prilocaine hydrochloride Y0001408 Prilocaine impurity B P2939025 Prilocaine impurity E P2940000 Primaquine diphosphate P2950000 Primidone Council of Europe, all rights reserved 2013
1 1 1 4 4 5 3 1 1 1 1 2 2
10 mg 10 mg 100 mg 100 mg 100 mg 200 mg 1 mL 150 mg 100 mg 80 mg 25 mg 500 mg 150 mg
1 1 1 1 1 1 3 1 1 1 1 1 1 99.9% CHNO ; Batch 1 is valid until 31 May 2012 64 2-methylbenzenamine hydrochloride (RS)-N-(methylphenyl)-2-(propylamino)propanamide 30 IU per vial ; Batch 2 is valid until 30 April 2012
+5C +5C +5C +5C +5C -20C
a a a a a a b a a a a g a
See leaflet, 20615 1362 1363 1362,1363 1362,1363 0635 0584
Yes
-20C +5C +5C +5C +5C +5C
Yes
+5C
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000369 Primidone for peak identification P3000000 Probenecid P3050000 Procainamide hydrochloride P3090000 Procaine benzylpenicillin P3100000 Procaine hydrochloride P3200000 Prochlorperazine maleate P3300000 Progesterone Y0000148 Progesterone impurity C Y0000179 Proguanil hydrochloride - reference spectrum Y0000181 Proguanil impurity C Y0000182 Proguanil impurity D P3350000 Proline P3390000 Promazine hydrochloride P3400000 Promethazine hydrochloride Y0000769 Promethazine impurity D Y0000797 Promethazine for peak identification P3490000 Propacetamol hydrochloride - reference spectrum Y0000455 Propafenone hydrochloride Y0000456 Propafenone impurity B Y0000278 Propanol - reference spectrum New Y0000016 Propofol Y0000017 Propofol for peak identification Y0000018 Propofol impurity J P3500000 Propranolol hydrochloride P3600000 Propranolol hydrochloride for performance test Y0000318 Propylene glycol dilaurate Y0000319 Propylene glycol monolaurate P3640000 Propyl gallate P3650000 Propyl parahydroxybenzoate P3700000 Propylthiouracil P3750000 Propyphenazone P3760000 Protirelin P3760020 D-His-Protirelin Council of Europe, all rights reserved 2013 Batch n 1 1 1 2 1 1 2 1 1 2 2 3 1 2 1 1 1 1 1 1 5 3 3 2 3 1 1 2 3 1 4 3 2 Quantity Sale per vial Unit 5 mg 1 100 mg 100 mg 250 mg 100 mg 100 mg 50 mg 10 mg n/a 10 mg 10 mg 60 mg 100 mg 50 mg 10 mg 10 mg n/a 10 mg 10 mg n/a 370 mg 0.1 ml 20 mg 30 mg 20 mg 100 mg 100 mg 50 mg 150 mg 100 mg 200 mg 5.03 mg 0.1 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 5.03 mg per vial of pure protirelin peptide CHNO approx. 0.1 mg per vial 65 99.9% CHO 2,6-bis (1-methylethyl)-1,4-benzoquinone 99.8% CHO ; Batch 4 is valid until 1 May 2013 (2E)-1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]-3phenylprop-2-en-1-one (2RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine S-oxide 1,5-bis(4-chlorophenyl)biguanide 1,5-bis(1-methylethyl)biguanide Batch 2 is valid until 1 April 2013 (20R)-20-hydroxypregn-4-en-3-one 39.7% CHNO (procaine); 96.3% CHNOS Information Monograph 0584 0243 0567 0115 0050 0244,20303 0429 0429 2002 2002 2002 0785,0910,09 11, 1049 0475,1365,20 303 0524 0524 0524 1366 2103 2103 2036 1558 1558 1558 0568,0923 0568 2087 1915 1039 0431,0852,12 63 0525 0636 1144 1144 Yes Yes Yes Leaflet Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a g a a a l g g a g g g g l a a l +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C g g g g g a a a a a a c c
List of European Pharmacopoeia Reference Standards Order Code P3800000 Proxyphylline Reference Standard Batch n 1 3 1 n/a 1 1 1 1 2 3 1 1 1 2 1 1 1 1 1 1 1 2 4 1 2 1 1 1 1 2 3 Quantity Sale per vial Unit 100 mg 1 50 mg 100 mg 30 mg 25 mg 25 mg 10 mg 20 mg 30 mg 30 mg 20 mg 10 mg 100 mg 5 mg 250 mg 20 mg 20 mg 30 mg 5.075 mg 5.125 mg 300 mg 300 mg 86 mg 110 mg 1.1 mL 10 mg 5 mg 110 mg 10 mg 20 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 1 1 1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(methoxycarbonyl)-3- phenylpropyl]amino] propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril methylester) 99.7% CHClNOS 11 IU per vial 99.9% CHNOS ethanethioic acid benzyl [[(2RS)-2-benzyl-3-sulfanylpropanoyl]amino]acetate 92.9% CHO 6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Batch 2 is valid until 31 January 2012 pyridin-3-yl-dimethylcarbamate 3-hydroxy-1-methylpyridinium 1-methyl-2-[(Z)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine Star anise oil Information Monograph 0526 Batch 2 is valid until 31 October 2012 0487,1367 2108 1843 0117 0117 1680 1680 0859 1255 1255 1255 0245 0245 0288 2180 1827 1763 1763 1763 0017,0018,00 19 0017,0018,00 19 See leaflet, 0451 2171 2171 2171 2171 2375 2375 1368 1368 Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a i a c a a a a a g g g a a g a g a a a a a c a g a a g g a a
P3850000 Pseudoephedrine hydrochloride - * Drug Precursor Y0000387 Pseudoisoeugenyl 2-methylbutyrate for peak identification Y0001537 Purified quillaia saponins P3900000 Purpureaglycoside A P4000000 Purpureaglycoside B Y0000402 Pyrantel embonate Y0000403 Pyrantel impurity A P4050000 Pyrazinamide P4099900 Pyridostigmine bromide P4099910 Pyridostigmine impurity A Y0001486 Pyridostigmine impurity B P4100000 Pyridoxine hydrochloride Y0001226 Pyridoxine impurity A P4200000 Pyrimethamine Y0000659 Pyrrolidone Y0001009 Quercetin dihydrate New Y0001491 Quinapril hydrochloride New Y0001502 Quinapril for peak identification New Y0001503 Quinapril for system suitability Q0100000 Quinidine sulfate Q0200000 Quinine sulfate R0100000 Rabies vaccine (inactivated) for veterinary use BRP Y0000896 Racecadotril New Y0000897 Racecadotril impurity A Y0000898 Racecadotril impurity G Y0000902 Racecadotril for peak identification Y0001134 Raloxifene hydrochloride Y0001135 Raloxifene hydrochloride for peak identification R0145000 Ramipril R0145005 Ramipril impurity A
66
List of European Pharmacopoeia Reference Standards Order Reference Standard Code R0145010 Ramipril impurity B Batch n 3 Quantity Sale Information per vial Unit 10 mg 1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-[(methylethoxy)carbonyl]-3- phenylpropyl] amino]propanoyl]octahydrocyclopenta[b]pyrrole- 2-carboxylic acid (ramipril isopropyl ester) 10 mg 1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-cyclohexylpropyl]amino] propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid (hexahydroramipril) ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro -1Hcyclopenta[e]pyrrolo[1,2a]pyrazin-2-yl]-4-phenylbutanoate (ramipril diketopiperazine) 1,1'-N-[methylenebis(sulphanediylethylene)]bis(N'-methyl-2-nitroethene-1,1diamine) ; Batch 4 is valid until 1 February 2012 Monograph 1368 Leaflet
R0145015 Ramipril impurity C
1368
+5C
R0145020 Ramipril impurity D R0150000 Ranitidine hydrochloride Y0000416 Ranitidine impurity J Y0000411 Ranitidine for system suitability Y0000457 Repaglinide Y0000458 Repaglinide for system suitability Y0000459 Repaglinide impurity E R0200000 Reserpine R0250000 Residual solvents solution class 1 Y0000767 Resorcinol R0300000 Retinol acetate R0290000 Retinol esters R0500500 Reviparin sodium Y0000377 Ribavirin R0600000 Riboflavin Y0000757 Riboflavin for peak identification R0630000 Riboflavin sodium phosphate Y0000662 Ribonucleic acid Y0000149 Rifabutin Y0000184 Rifabutin impurity A R0700000 Rifampicin R0800000 Rifampicin quinone R0900000 Rifamycin B R0950000 Rifamycin S R1000000 Rifamycin sodium Y0001074 Rifaximin Y0001075 Rifaximin for system suitability Y0000250 Rilmenidine dihydrogenophosphate - reference spectrum Council of Europe, all rights reserved 2013
4 3 5 2 1 2 2 3 4 1 6 1 1 2 3 3 2 1 2 1 2 4 2 2 3 1 1 1
10 mg 100 mg 0.00025 mg 20 mg 20 mg 6 mg 10 mg 100 mg 1500 mg 20 mg 1000 mg 100 mg 250 mg 150 mg 100 mg 0.12 mg 250 mg 100 mg 150 mg 20 mg 100 mg 100 mg 50 mg 50 mg 300 mg 160 mg 10 mg n/a
1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1368 0946,1453 0946 0946 2135 2135 Yes Yes
+5C +5C -20C +5C +5C +5C +5C +5C Yes Yes +5C +5C -20C +5C +5C Yes Yes +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C Yes +5C
a a c a a a a a g g c a a a a a a a a a a a a a c a a l
2-ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2oxoethyl]benzoic acid 99.8% CHNO Batch 3 is valid until 30 April 2012 benzene-1,3-diol 1 050 000 IU per g
2135 0528 20424 2348 0218,0219,02 20, 1192,1193 0217,0218,02 19, 0220 0828
99.9% CHNO ; Batch 1 is valid until 31 May 2012 Vitamin B2 Batch 2 is valid until 31 October 2012 100.0 % 95.5% CHNO 1-(2-methylpropyl)piperidin-4-one
2109 0292,0786 0292 0786 2090 1657 1657 0052 0052
Rifamycin impurity A 856 IU per mg 98.0% CHNO
0432 0432 0432,20702 2362 2362 2020
67
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000187 Rilmenidine for system suitability R1000600 Risperidone Y0000370 Risperidone for system suitability Y0001276 Risperidone impurity K Y0000714 Ritonavir Y0000706 Ritonavir for peak identification Y0001516 Rivastigmine hydrogen tartrate Y0001485 Rivastigmine for system suitability Y0001515 Rivastigmine impurity D Y0001302 Rizatriptan benzoate Y0001303 Rizatriptan for system suitability R1300000 RK 13 cells Y0000594 Rocuronium bromide - reference spectrum Y0000527 Rocuronium for peak identification Y0000742 Ropivacaine hydrochloride monohydrate Y0000743 Ropivacaine impurity G Y0000786 Rosmarinic acid R1500000 Roxithromycin Y0000220 Roxithromycin for system suitability R2000000 Rubella vaccine (live) BRP Y0000494 Ruscogenins S0040000 Saccharin S0050000 Saccharin sodium S0100000 Salbutamol Y0000030 Salbutamol impurity B Y0000071 Salbutamol impurity D Y0000031 Salbutamol impurity F Y0000034 Salbutamol impurity G Y0000032 Salbutamol impurity I Council of Europe, all rights reserved 2013 Batch n 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 2 5 2 1 1 1 1 2 4 5 4 3 4 Quantity Sale per vial Unit 30 mg 1 50 mg 20 mg 0.015 mg 80 mg 10 mg 350 mg 1.0114 mg 10 mg 200 mg 15 mg 1 ml n/a 10 mg 10 mg 5 mg 50 mg 125 mg 5 mg 5 uc 10 mg 30 mg 50 mg 50 mg 5 mg 10 mg 10 mg 5 mg 0.006 mg 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol 5-[(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2hydroxybenzaldehyde ; Batch 4 is valid until 31 January 2013 93.4% CHNO x HSO; 1,1'-[oxybis[methylene(4-hydroxy-1,3phenylene)]]bis[2-[(1,1- dimethylethyl)amino]ethanol] 2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)phenyl] ethanone (1RS)-2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4benzyloxyphenyl]ethanol 68 3.6 log (ie 4000) infective viral units per vial 38.2% ruscogenin 60.4% neoruscogenin (+)-(2R)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide ((R)ropivacaine) Batch 1 is valid until 28 February 2013 96.7% CHNO cell lines (kidney, rabbit) titration of live measles, mumps and rubella vaccines 3-[(1R)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate ((R)enantiomer) 99.9% CHNO 3-[2-[4-(1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one (desfluoro risperidone) 99.6% CHNOS Information Monograph 2020 1559 1559 1559 2136 2136 2629,2630 2629,2630 2629,2630 2585 2585 0162,1057 1764 1764 2335 2335 1447,2382, 2524 1146 1146 1057,0162 1847 0947 0787 0529,1033 0529 0529,0687 0529,0687 0529 0529 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Liquid nitrogen -20C +5C +5C +5C +5C +5C -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g a a g g g a a d l g(c) a a a a a d a a a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001186 Salbutamol impurity J S0150000 Salbutamol sulfate Y0001288 Salbutamol sulfate for system suitability Y0000669 Salicin S0200000 Salicylic acid Y0000405 Salicylic acid impurity B Y0000422 Salmeterol xinafoate Y0000423 Salmeterol xinafoate for system suitability New Y0001559 Salvianolic acid B Y0001052 Santonin Y0001049 Saquinavir mesilate Y0001056 Saquinavir for system suitability Y0001483 Saw palmetto extract Y0000814 Selamectin Y0000815 Selamectin for system suitability S0360000 Selegiline hydrochloride S0360090 (RS)-Selegiline hydrochloride S0400000 Senna extract S0450000 Serine S0460000 Sertaconazole nitrate Y0000828 Sertraline hydrochloride Y0001285 Sertraline impurity E Y0000866 Sertraline for peak identification Y0000867 Sertraline for system suitability Y0000371 Sestamibi labelling kit Y0001046 Sevoflurane New Y0001578 Sildenafil citrate New Y0001579 Sildenafil impurity A S0500000 Silicone elastomer S0600000 Silicone oil S0650000 Simvastatin Y0001066 Simvastatin for peak identification Y0001208 Sinomenine S0660000 Sisomicin sulfate Council of Europe, all rights reserved 2013 Batch n 1 2 1 1 2 1 2 1 1 1 1 1 1 1 1 1 2 1 1 2 2 1 2 2 2 1 1 1 2 1 4 1 1 2 Quantity Sale per vial Unit 0.00045 mg 1 50 mg 10 mg 50 mg 100 mg 10 mg 50 mg 25 mg 15 mg 20 mg 70 mg 0.3033 mg 8000 mg 100 mg 5 mg 50 mg 25 mg 50 mg 50 mg 125 mg 200 mg 15 mg 5.4 mg 6.18 mg 22 mg 1 ml 100 mg 10 mg 2000 mg 1 ml 100 mg 10 mg 20 mg 60 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 81.8 % CHNO 77.7% CHNOS ; Batch 1 is valid until 29 February 2012 69 99.4% CHO 98.8 % CHNOS 5-[2-ethoxy-5[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2methylpropyl)-6,7-dihydro-1H-pyrazol[4,3-d]pyrimidin-7-one Batch 1 is valid until 30 September 2012 99.9% CHClN ; Batch 1 is valid until 31 March 2012 Mandelic acid CRS has been labelled as sertraline impurity E CRS in anticipation of 01/2011:1705 corrected 7.1 Batch 1 is valid until 31 January 2012 Batch 1 is valid until 31 March 2012 Batch 1 is valid until 31 October 2012 97.6% CHNO 92.2 % CHO 99.8% CHO 99.5% CHNOS 4-hydroxyisophthalic acid 99.6% CHNO ; Batch 1 is valid until 30 April 2012 99,6% CHO Information Monograph 0687 0687 0687 2312,1583 0366,1185 0366 1765 1765 2663 1391,1809 2267 2267 2579 2268 2268 1260 1260 0206,0207,02 08, 1261 0788,1027 1148 1705 1705 1705 1705 1926 2269 2270 2270 30109 30108 1538,1563 1563 2450 0331, 1351 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C 0 +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C -20C Extra charges a a a a a a a a a a a a a g g g g c a a g a g g a g(b) a a a a g(c) g(c) a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000014 Sodium alendronate S0695000 Sodium amidotrizoate Y0000300 Sodium aminosalicylate dihydrate - reference spectrum Y0000039 Sodium ascorbate S0700000 Sodium calcium edetate S0710000 Sodium cetostearyl sulfate S0750000 Sodium cromoglicate Y0001300 Sodium cromoglicate for system suitability S0760000 Sodium cyclamate S0765000 Diclofenac sodium Y0001410 Sodium fusidate S0781000 Sodium hyaluronate - reference spectrum S0780000 Sodium hyaluronate BRP Y0001468 Sodium iodohippurate Y0000620 Sodium laurilsulfate Y0000808 Sodium phenylbutyrate Y0000809 Sodium phenylbutyrate impurity C S0785000 Sodium picosulfate Y0001104 Picosulfate for system suitability Y0000210 Sodium polystyrene sulfonate - reference spectrum Y0000268 Sodium propionate - reference spectrum S0800000 Sodium salicylate S0808000 Sodium stearyl fumarate S0808060 Sodium stearyl maleate S0900000 Sodium taurocholate BRP S0930000 Sodium valproate S0945000 Somatostatin S0947000 Somatropin Batch n 3 1 1 1 1 1 2 1 2 3 1 1 2 1 1 1 1 1 1 1 1 1 1 2 2 4 5 3 Quantity Sale per vial Unit 150 mg 1 83.3% CHNNaOP 125 mg n/a 50 mg 100 mg 100 mg 10 mg 20 mg 100 mg 100 mg 10 mg n/a 300 mg 15 mg 40 mg 5 mg 10 mg 100 mg 0.5 mg n/a n/a 100 mg 50 mg 10 mg 10000 mg 150 mg 2.32 mg 55 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2.32mg somatostatin peptide per vial CHNOS 3.86 mg somatropin monomer per vial ; Batch 2 is valid until 31 August 2012 Batch 1 is valid until 31 March 2012 4-cyclohexylbutanoic acid Information Monograph 1564 1150 1993 1791 0231 0847 0562 0562 0774 1002,1281 0848 1472 0912 2352 0802 2183 2183 1031 1031 1909 2041 0413 1567 1567 0350 0678 0949 See leaflet, 0950, 0951,0952 0950,0951,09 52 0592 99,7% CHO ; Batch 1 is valid until 1 April 2013 2048 Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a l a a a a a a g b l a a g a a a a l l +5C +5C +5C +5C +5C -20C -20C a a a a a c c
Y0000711 Somatropin/desamidosomatropin resolution mixture S0950000 Sorbic acid New Y0000385 1,4-Sorbitan
1 2 2
33 mg 10 mg 50 mg
1 1 1
1.7 mg somatropin per vial
Yes
-20C +5C +5C
c a a
70
List of European Pharmacopoeia Reference Standards Order Code S1000000 Sorbitol Reference Standard Batch n 3 Quantity Sale per vial Unit 1200 mg 1 97.9 % CHO Information Monograph 0435,0436,04 37, 1235,1236,13 37, 1381,1531,20 48 2004 N-[4-[[(1-methylethyl)amino]acetyl]phenyl]methanesulphonamide 81.3% CHClNO and CHClNO 2004 1849 1152 1152 1658 2419 4500 IU per mg Spiramycin I: 87.3%, Spiramycin II: 0.2%, Spiramycin III: 4.4% 95.9% CHClNOS 99.6% CHOS; Spironolactone CRS 2 is suitable for monograph 01/2008:0688 only. 99.7% CH 0.050% of hypericin; St. John's wort standardised dry extract CRS has been renamed as St. John's wort dry extract HRS in 01/2013:1874 Batch 1 is valid until 30 October 2012 (5,17)-17-hydroxy-17-methylandrostan-3-one 0179,0293,19 82,20702 1766 1766 0688 0688 1630 1874 2389 1568 1568 1568 0350 99.6% CHNO Plastic additive 19 2130 2130 0229,0882,14 74, 2058,30103, 30105, 30106, 30107 0702,0753,08 01, 0802,0847,09 69, 1123,1340,14 11 0356 71 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet Yes
Y0000114 Sotalol hydrochloride Y0000115 Sotalol impurity B Y0001011 Spanish sage oil for peak identification Y0000597 Spectinomycin hydrochloride Y0000549 Spectinomycin for system suitability Y0000655 Spectinomycin sulfate tetrahydrate Y0001126 Spike lavender oil S1100000 Spiramycin Y0000381 Spirapril hydrochloride monohydrate Y0000332 Spirapril for system suitability S1200000 Spironolactone Y0001295 Spironolactone for system suitability Y0000185 Squalane Y0001050 St. John's wort standardised dry extract Y0001091 Standardised artichoke leaf dry extract S1250000 Stanozolol S1250010 Stanozolol impurity A Y0001420 Stanozolol impurity B S1300000 Starch BRP Y0000408 Stavudine Y0000421 Stavudine for system suitability S1340000 Stearic acid
1 1 1 2 1 1 1 5 1 1 3 1 1 1 1 2 1 1 4 1 1 3
25 mg 20 mg 250 mg 100 mg 20 mg 10 mg 400 l 200 mg 60 mg 15 mg 150 mg 2.055 mg 250 l 500 mg 60 mg 50 mg 10 mg 10 mg 50000 mg 100 mg 10 mg 100 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
+5C +5C +5C -20C -20C -20C +5C -20C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C
a a g a a c g a a a a a a c c a a a a a a a
S1350000 Stearyl alcohol
250 mg
99.5% CHO ; Batch 1 is valid until 30 September 2012
Yes
+5C
Y0000868 Streptokinase for system suitability Council of Europe, all rights reserved 2013
30 l
Yes
-20C
List of European Pharmacopoeia Reference Standards Order Reference Standard Code S1400000 Streptomycin sulfate S1500000 Succinylsulfathiazole Y0001324 Sucralfate Y0001344 Sucralose Y0001342 Sucralose impurity B S1600000 Sucrose Batch n 4 1 1 1 1 1 Quantity Sale per vial Unit 100 mg 1 77 000 IU per vial 100 mg 10 mg 550 mg 0.5 mg 100 mg 1 1 1 1 1 1,6-dichloro-1,6-dideoxy-?-D-fructofuranosyl 6-chloro-6-deoxy-?-Dglucopyranoside (1',6,6'-trichloro-1',6,6'-trideoxysucrose) Information Monograph 0032,0033,00 53, 0485,20702 0357 1796 2368 2368 0177,0178,01 87, 0188,0204,02 09, 1061,1570,23 18 1569 1269 2209 99.7% CHNOS 2209 2209 0107 0294 0294 pyrimidin-2-amine 0294 0295 0295 0740 0741 1476 0358,1571 0637 0108 N-(4-(5-methyl)-isoxazol-3-ylsulphamoyl)phenylacetamide 4-amino-N-(3-methylisoxazol-5-yl)benznesulphonamide 0108 0108 0638 1571 0863 98.1 % CHNOS ; Batch 3 is valid until 28 February 2013 2-hydroxy-5-[[4-[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]azo]benzoic acid 72 0863,1457 0863 Yes Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -20C +5C +5C +5C +5C +5C Extra charges a a a a a a
S1608100 Sufentanil - reference spectrum S1609000 Sufentanil citrate - reference spectrum Y0000529 Sulbactam sodium Y0000528 Sulbactam Y0000550 Sulbactam for peak identification S1700000 Sulfacetamide sodium S1800000 Sulfadiazine Y0001480 Sulfadiazine for identification of impurity F Y0001469 Sulfadiazine impurity A S1900000 Sulfadimidine Y0001495 Sulfadimidine for peak identification S1950000 Sulfadoxine S1975000 Sulfafurazole S1975600 Sulfaguanidine S2000000 Sulfamerazine S2050000 Sulfamethizole S2100000 Sulfamethoxazole Y0000412 Sulfamethoxazole impurity A Y0000413 Sulfamethoxazole impurity F S2150000 Sulfamethoxypyridazine S2151000 Sulfanilamide S2159100 Sulfapyridine S2155000 Sulfasalazine S2155010 Sulfasalazine derivative for resolution
1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 1 1 1 4 1
n/a n/a 10 mg 150 mg 20 mg 50 mg 100 mg 15 mg 20 mg 100 mg 50 mg 50 mg 100 mg 60 mg 100 mg 100 mg 50 mg 5 mg 5 mg 50 mg 100 mg 20 mg 250 mg 20 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1
l l +5C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C a c a a a a a a a g a a a a a a a a a a a a
List of European Pharmacopoeia Reference Standards Order Code S2158000 Sulfathiazole S2159000 Sulfinpyrazone Y0001238 Sulfinpyrazone for system suitability S2159010 Sulfinpyrazone impurity A S2159015 Sulfinpyrazone impurity B S2160000 Sulfisomidine S2180000 Sulindac S2190000 Sulpiride S2191000 Sulpiride impurity A S2192000 Sulpiride impurity B Y0000530 Sultamicillin Y0000531 Sultamicillin tosilate Y0000532 Sultamicillin for peak identification Y0000022 Sumatriptan succinate Y0000026 Sumatriptan impurity mixture Y0000027 Sumatriptan for system suitability S2200000 Suxamethonium chloride S2400000 Suxibuzone S2400004 Suxibuzone impurity B S2400006 Suxibuzone impurity C S5000001 Swine erysipelas bacteria, serotyp 1 (for vaccines - vet. use) BRP S5000002 Swine erysipelas bacteria, serotyp 2 (for vaccines - vet. use) BRP Y0001417 Tadalafil T0010000 Talampicillin hydrochloride T0014000 Tamoxifen citrate T0015000 Tamoxifen citrate for performance test Y0000650 Tamsulosin hydrochloride Y0000653 Tamsulosin racemate New Y0000651 Tamsulosin impurity D New Y0000652 Tamsulosin impurity H Y0001102 Teicoplanin New Y0001560 Tanshinone IIa Y0001047 Teicoplanin for identification Council of Europe, all rights reserved 2013 Reference Standard Batch n 1 1 1 3 3 1 3 4 3 2 1 2 1 1 7 4 1 1 1 1 1 1 1 1 2 3 1 1 2 2 1 1 1 Quantity Sale per vial Unit 100 mg 1 30 mg 0.5 mg 20 mg 20 mg 50 mg 50 mg 100 mg 20 mg 20 mg 10 mg 200 mg 10 mg 50 mg 3 mg 2 mg 1000 mg 50 mg 10 mg 10 mg 1 mg 1 mg 200 mg 50 mg 80 mg 30 mg 10 mg 10 mg 10 mg 10 mg 52 mg 15 mg 40 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 73 2-methoxy-5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl]amino]propyl] benzenesulfonamide ; Batch 1 is valid until 1 June 2013 (2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine ; Batch 1 is valid until 1 June 2013 51550 IU per ampoule 98.4 % CHO (4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl butanedioate 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4H-pyrazole-3,5-dione 6.5 x10 Cfu per vial 2.6 x10 Cfu per vial 99.9% CHNO 98.8% CHNOS Batch 6 is valid until 31 August 2012 92.5% CHNOS Contains 0.3% m/m of E-isomer Batch 3 is valid until 31 January 2013 [(2RS)-1-ethylpyrrolidin-2-yl]methanamine methyl 2-methoxy-5-sulphamoylbenzoate 1,2-diphenyl-4-[2-(phenylsulphonyl)ethyl]pyrazolidine-3,5-dione 1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dione Information Monograph 0742 0790 0790 0790 0790 0639 0864 1045,1348 1045,1490 1045 2211 2211,2212 2211 1573 1573 1573 0248 1574 1574 1574 See leaflet, 0064 See leaflet, 0064 2606 0808,0852 1046 1046 2131 2131 2131 2131 2358 2663 2358 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C -20C Extra charges a a a a a a g a g a a a a c c c g a a a e(b) e(b) a a g g a a a a a a a
List of European Pharmacopoeia Reference Standards Order Code Y0000648 Telmisartan Reference Standard Batch n 1 2 3 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 3 2 1 2 2 1 2 1 1 1 1 1 2 2 Quantity Sale per vial Unit 30 mg 1 10 mg 0.26 mg 50 mg 5 mg 5 mg 5 mg 5 mg 100 mg 0.0042 mg 40 mg 0.5 mg 10 mg 10 mg 10 mg 10 mg 10 mg 10 mg 100 mg 15 mg 250 mg 100 mg 20 mg 30 mg 50 mg 50 mg 0.4 mg 100 mg 2 mg 10 mg 10 mg 20 mg 20 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 74 delta-5-testosterone-3,17-dienantate 99.8% CHO 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl] butan-1-one 1-(3,5-dihydroxyphenyl)-2-[(1,1-dimethylethyl)amino]-ethanone 2-chloro-6,7-dimethoxyquinazolin-4-amine 2,2'-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine) 1-(furan-2-ylcarbonyl)piperazine 1-[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine (3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4benzodiazepin-3-yl acetate (3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4benzodiazepin-2-one (5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3dione (5RS)-7-chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4benzodiazepine-2,3-dione Batch 2 is valid until 1 April 2013 Information Monograph 2154 Batch 1 is valid until 31 January 2013 2154 2154 0954 0954 0954 0954 0954 1156 1156 2021 2021 2021 2021 2021 2021 1734 1734 0690 0690 1270 0955 0955 1373 1048 1048, 1736 1736 1048 1048 1048 1048 1373 Yes Yes Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C -20C -20C -20C -20C +5C Extra charges g g g j a a a a g g a a a a a a a a a a a a a g g g(c) g(c) g(c) g(c) g(c) g(c) g
Y0000649 Telmisartan for peak identification Y0001003 Telmisartan for system suitability T0040000 Temazepam - * psy Y0000344 Temazepam impurity C Y0000345 Temazepam impurity D Y0000346 Temazepam impurity F Y0000347 Temazepam impurity G T0040800 Tenoxicam Y0001114 Tenoxicam impurity mixture Y0000621 Terazosin hydrochloride dihydrate Y0000666 Terazosin for system suitability Y0000622 Terazosin impurity A Y0000665 Terazosin impurity E Y0000623 Terazosin impurity L Y0000624 Terazosin impurity N Y0000535 Terbinafine hydrochloride Y0001143 Terbinafine for system suitability T0050000 Terbutaline sulfate T0050015 Terbutaline impurity C T0060000 Terconazole T0071000 Terfenadine T0080000 Terfenadine impurity A T0100000 Testosterone T0210000 Testosterone caproate T0240000 Testosterone decanoate Y0000696 Testosterone decanoate for system suitability T0250000 Testosterone enantate Y0001317 Testosterone enantate for system suitability Y0001312 Testosterone enantate for peak identification Y0001313 Testosterone enantate impurity H Y0000342 Testosterone for impurity D identification Y0000343 Testosterone for system suitability Council of Europe, all rights reserved 2013
1373 +5C g For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code T0260000 Testosterone isocaproate Y0000716 Testosterone isocaproate for system suitability T0300000 Testosterone propionate Y0001409 Testosterone propionate for system suitability T0400000 Tetanus vaccine (adsorbed) Y0001087 Tetra-O-acetyl-mannose triflate T0500000 Tetracaine hydrochloride Y0001002 Tetracaine for system suitability T0550000 Tetracosactide T0600000 Tetracycline hydrochloride Batch n 2 1 2 1 3 1 1 1 3 2 Quantity Sale per vial Unit 50 mg 1 99.9% CHO 5 mg 60 mg 5 mg 30 mg 60 mg 100 mg 2 mg 0.366 mg 100 mg 1 1 1 1 1 1 1 2 1 366 g per vial of CHNOS 96.7% CHClNO 490 IU per ampoule for challenge assays in guinea-pigs 260 IU per ampoule for challenge assays in mice 100.0% CHFOS Testosterone propionate CRS 1 is suitable for 01/2008:1048 only ; Batch 1 is valid until 31 March 2012 Information Monograph 1048,1737 1737 0297 0297 See leaflet, 20708 2294 0057 0057 0644 0173,0198,01 99, 0210,0211,16 54 2478 1738 7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 99.5% CHNO 1738 2101 1839,1841 0298 0300,0301 0299,0302 1706,0884 2,2-dimethoxy-N-methylethanamine 1-methyl-2-(methylsulphanyl)-1H-imidazole 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4methylthiazol-2(3H)-thione 1706 1706 0303 0303,0531 0531 0109 99.8% CHOS 1648 1648 1648 1625 0212 0212 2005 75 Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C -20C -20C +5C +5C -20C +5C Extra charges g g g g a c g g c a
Y0001165 Tetrandrine Y0000015 Tetrazepam - reference spectrum Y0000008 Tetrazepam impurity C Y0000460 Tetryzoline hydrochloride Y0000723 Thebaine - * narc T0700000 Theobromine T0800000 Theophylline Y0000294 Theophylline - reference spectrum Y0000336 Thiamazole Y0000372 Thiamazole impurity A Y0000373 Thiamazole impurity C Y0000467 Thiamine hydrochloride Y0000059 Thiamine impurity E Y0000060 Thiamine nitrate - reference spectrum T1100000 Thiamphenicol Y0000546 Thioctic acid Y0000592 Thioctic acid for system suitability Y0000545 Thioctic acid containing impurity B Y0000109 Thiomersal T1200000 Thiopental Y0001478 Thiopental for system suitability Y0000704 Thioridazine Council of Europe, all rights reserved 2013
1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 1 1 1 1 1 1
20 mg n/a 20 mg 10 mg 10 mg 100 mg 100 mg n/a 125 mg 15 mg 20 mg 10 mg 10 mg n/a 125 mg 110 mg 10 mg 30 mg 30 mg 500 mg 10 mg 10 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
a l g a k a g l a a a a a l
+5C +5C +5C +5C +5C +5C +5C +5C
a a a a g a a g
List of European Pharmacopoeia Reference Standards Order Reference Standard Code T1300000 Thioridazine hydrochloride Y0000541 Thioridazine for system suitability T1305100 Thioxanthene T1305000 Thioxanthone T1340000 Threonine T1350000 Thymol T1410000 Tiabendazole Y0000414 Tiamulin for peak identification Y0000333 Tiamulin hydrogen fumarate Y0000379 Tiamulin - reference spectrum Y0000151 Tianeptine sodium - reference spectrum Y0000152 Tianeptine for system suitability Y0000153 Tianeptine impurity A T1405000 Tiapride hydrochloride T1405050 Tiapride N-oxide T1410900 Tiaprofenic acid T1410910 Tiaprofenic acid impurity C Y0000748 Tibolone - reference spectrum Y0000668 Tibolone for system suitability Y0000465 Ticarcillin monosodium T1420010 Ticarcillin impurity A Batch n 1 1 3 2 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 Quantity Sale per vial Unit 100 mg 1 0.21 mg 20 mg 10 mg 50 mg 50 mg 50 mg 10 mg 500 mg n/a n/a 30 mg 20 mg 60 mg 20 mg 50 mg 20 mg n/a 10 mg 250 mg 50 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 93.2% CHNNaOS Correction factor 1.054 89.8% CHNOS; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(thiophen-3-yl) acetyl]-amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (decarboxyticarcillin) 6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid ethyl 7-bromoheptanoate 98.6% CHNOS Information Monograph 0586 0586, 2005 1347 1347 0785,1049 0791 0866 1659 1659,1660 1660 2022 2022 2022 1575 1575 1157 1157 1739 1739 0956 0956 Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges g g g g a g g g g l l +5C +5C +5C +5C +5C +5C +5C +5C +5C g g a a g g l b a a
T1423000 Ticlopidine hydrochloride T1423025 Ticlopidine impurity F Y0000325 Tilidine hydrochloride hemihydrate - reference spectrum T1450000 Timolol maleate Y0000644 (R)-timolol Y0001270 Timolol for system suitability T1470000 Tinidazole Y0000899 Tinidazole impurity A T1471000 Tinidazole impurity B T1490000 Tinzaparin sodium Y0000292 Tioconazole - reference spectrum Y0000282 Tioconazole for system suitability Council of Europe, all rights reserved 2013
3 2 1 3 1 1 1 1 4 1 1 1
50 mg 10 mg n/a 100 mg 20 mg 5.045 mg 100 mg 10 mg 20 mg 250 mg n/a 50 mg
1 1 1 1 1 1 1 1 1 1 1 1 76 2-methyl-5-nitro-1H-imidazole 1-[2-(ethylsulphonyl)ethyl]-2-methyl-4-nitro-1H-imidazole ; Batch 3 is valid until 31 July 2012
1050 1050 1767 0572 0572 0572 1051 1051 1051 0828 2074 2074 Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g g l a a a a a a a l a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001188 Tiotropium bromide monohydrate Y0001189 Tiotropium for system suitability Y0001179 Tiotropium impurity mixture Y0001216 Tiotropium impurity F T1500000 Tobramycin Y0000383 All-rac-alpha-tocopherol for peak identification Y0000384 All-rac-alpha-tocopheryl acetate for peak identification T1550000 alpha-Tocopherol T1600000 alpha-Tocopheryl acetate Y0001210 Tobramycin for identification T1610000 RRR-alpha-Tocopheryl hydrogen succinate T1700000 Tolbutamide Y0000154 Tolfenamic acid T1707000 Tolnaftate Y0001123 Tolnaftate for system suitability Y0000461 Torasemide anhydrous Y0001366 Torasemide impurity E Y0000462 Torasemide for system suitability Y0000155 Tramadol hydrochloride Y0000156 Tramadol impurity A Y0000157 Tramadol impurity E Y0000072 Tramazoline hydrochloride monohydrate Y0000065 Tramazoline impurity A Y0000066 Tramazoline impurity B Batch n 1 1 1 1 4 1 2 6 8 1 1 1 1 1 1 1 1 2 3 4 3 1 1 1 Quantity Sale per vial Unit 10 mg 1 10 mg 0.08 mg 10 mg 49 mg 15 mg 30 mg 500 mg 500 mg 250 mg 150 mg 100 mg 100 mg 60 mg 10 mg 10 mg 0.0006 mg 5 mg 75 mg 25 mg 15 mg 20 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine 75% CHNO; Mixture of 1-acetyl-N-(5,6,7,8-tetrahydronaphthalen-1yl)-4,5-dihydro-1H-imidazol-2-amine and 1-[(EZ)-1-[(5,6,7,8tetrahydronaphthalen-1-yl)imino]ethyl]imidazolidin-2-one (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino] propanoyl]octahydro-1H-indole-2-carboxylic acid (hexahydrotrandolapril) ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydro pyrazino[1,2-a]indol-2(1H)-yl]-4-phenylbutanoate (trandolapril diketopiperazine) (1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol ; Batch 3 is valid until 31 January 2013 (2RS)-2-[(dimethylamino)methyl]cyclohexanone ethyl [[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]carbamate 97.4% CHO ; Vitamin E 97.8% CHO Suitable for identification tests only 98.6% CHO dithiophen-2-ylmethanone 49 mg per vial of CHNO; Suitable for LC assay only Information Monograph 2420 2420 2420 2420 0645 0692 0439 0692,1256,20 432 0439,0691,12 57 0645 1258,1259 0304 2039 1158 1158 2132 2132 2132 1681 1681 1681 1597 1597 1597 Yes Yes Yes Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Extra charges a a a a a a a a a a a a g a a a a a g g g g g g
Y0000501 Trandolapril Y0000495 Trandolapril impurity C Y0000496 Trandolapril impurity D
1 1 1
10 mg 10 mg 10 mg
1 1 1
2245 2245 2245
+5C +5C +5C
a a a
T1810000 Tranexamic acid T1820000 Trapidil T1820002 Trapidil impurity A Council of Europe, all rights reserved 2013
4 1 1
50 mg 50 mg 20 mg
1 1 1 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 77
0875 1576 1576
Yes
+5C +5C +5C
a g a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code T1820004 Trapidil impurity B Y0001172 Trehalose dihydrate T1850000 Tretinoin T1899000 3,4,6-Tri-O-acetyl-D-glucal - reference spectrum G0400010 Triacetin - reference spectrum T1899990 Triamcinolone T1900000 Triamcinolone acetonide Y0001459 Triamcinolone acetonide for system suitability T1950000 Triamcinolone hexacetonide Y0000050 Triamcinolone impurity C Y0000837 Triamterene Y0000870 Triamterene impurity B T1975000 Triazolam - * psy Y0000165 Tribenoside New Y0000166 Tribenoside impurity A Batch n 1 1 2 1 1 2 5 1 2 1 1 1 1 1 4 Quantity Sale per vial Unit 20 mg 1 1,2,4-triazol-3-amine 250 mg 1 89.8% CHO,2HO 50 mg n/a n/a 150 mg 150 mg 10 mg 100 mg 10 mg 10 mg 0.5 mg 10 mg 150 mg 70 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 98.9% CHO 90.3% CHO; 3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)-alpha-Dglucofuranose ; Batch 2 is valid until 31 January 2012 Batch 3 is valid until 1 May 2013 2,7-diamino-6-phenylpteridin-4-ol 9-fluoro-11,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione 98.6% CHFO ; Batch 4 is valid until 1 July 2012 Information Monograph 1576 2297 0693,1019,13 85 1325 1106 1376 0533,0867,10 75 0533 0533,0867 1376 0058 0058 1065 1740 1740 Yes Yes Yes Yes Leaflet
Effective from 2013 Storage +5C +5C +5C Extra charges g a g(b) l l +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C a a a a a a a j g g(c)
Y0001055 Tributyl acetylcitrate Y0000279 Tri-n-butyl phosphate Y0000799 Tributyl acetylcitrate for peak identification T1977990 Tricaprin T1977995 Tricaproin T1978000 Tricaprylin Y0000111 Trichloroacetic acid - reference spectrum T1985000 Trichlorotrifluoroethane T1986000 Triethyl citrate - reference spectrum T2000000 Trifluoperazine hydrochloride T2005000 Triflusal T2005010 Triflusal impurity B Y0000720 Triglycerol diisostearate Y0000108 Trihexyphenidyl hydrochloride Y0000068 Trihexyphenidyl impurity A T2009000 Trilaurin Y0001319 Trimebutine maleate Y0001260 Trimebutine for system suitability Council of Europe, all rights reserved 2013
2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1
1 mL 300 l 25 mg 150 mg 40 mg 225 mg n/a 2.5 ml n/a 100 mg 50 mg 25 mg 200 mg 100 mg 20 mg 1250 mg 10 mg 1.017 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 78 1-phenyl-3-(piperidin-1-yl)propan-1-one 2-hydroxy-4-(trifluoromethyl)benzoic acid
1770 1682 1770 1410 1410 1410 1967 0393 1479 0059,20303 1377 1377 2032 1626 1626 1410 2182 2181,2182 Yes Yes Yes
+5C +5C +5C -20C -20C -20C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C
a g a c c c l g l a a a a a a c a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000092 Trimetazidine dihydrochloride - reference spectrum Y0000093 Trimetazidine for system suitability T2100000 Trimethadione New Y0001497 3-Trimethylsilyl-1-propanesulfonic acid sodium salt T2200000 Trimethoprim Y0000684 Trimethoprim for system suitability T2200010 Trimethoprim impurity B T2450000 Trimethyltetradecylammonium bromide T2500000 Trimipramine maleate Y0000759 Trimipramine for peak identification T2500100 Trimyristin T2501200 Tristearin T2545000 Trolamine Y0001184 Trolamine impurity A Y0001183 Trolamine impurity B T2550000 Trometamol T2580000 Tropicamide Y0001247 Tropicamide impurity C Y0001248 Tropicamide impurity D Y0001316 Tropicamide for peak identification Y0000616 Tropisetron hydrochloride Y0000618 Tropisetron impurity B T2580300 Tropine Y0000429 Trospium chloride Y0000432 Trospium impurity A Y0000431 Trospium impurity B Y0000430 Trospium impurity C Y0000497 Troxerutin T2600000 Trypsin BRP T2610000 Tryptophan T2800000 Tubocurarine chloride T2880000 Tylosin T2880100 Tylosin D Council of Europe, all rights reserved 2013 Batch n 1 2 1 1 1 3 4 2 1 1 1 1 2 1 1 3 1 1 1 1 1 1 1 1 1 2 2 1 2 1 1 1 2 Quantity Sale per vial Unit n/a 1 50 mg 250 mg 120 mg 50 mg 15 mg 200 mg 100 mg 0.51 mg 500 mg 100 mg 2250 mg 250 mg 1 ml 100 mg 50 mg 10 mg 10 mg 10 mg 40 mg 10 mg 50 mg 10 mg 20 mg 20 mg 5 mg 30 mg 100 mg 100 mg 100 mg 150 mg 5 mg 1 1 1 1 Batch 2 is valid until 31 January 2013 (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone ; Batch 3 is valid until 2 February 2012 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 79 87.75% CHClNO 1035 IU per mg 0.707 microkatal per mg hydroxydiphenylacetic acid (benzilic acid) (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate ; Batch 1 is valid until 30 September 2012 (1R,3r,5S)-3-hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium] 1H-indole-3-carboxylic acid (2RS)-3-hydroxy-2-phenylpropanoic acid (tropic acid) Phenylacetic acid Ethanolamine Diethanolamine Batch 2 is valid until 30 October 2012 100% CHNO 91.8 % CHOSSi,Na Information Monograph 1741 1741 0440 2645 0060 0060 0060 0378 0534 0534 1410 1410 1577 1577 1577 1053 1159,1197 1159 1159 1159 2102 2102 1308 1798 1798 1798 1798 2133 0476,0579,05 80, 0694 1272 0305 1273,1274,16 61, 20702 Yes Yes Yes Leaflet
Effective from 2013 Storage Extra charges l a a a a a a g g g c c a g a a a a a a g a a a a a a a a a g g
+5C +5C +5C +5C +5C +5C +5C +5C +5C -20C -20C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
0.00075 mg 1
1273,1274,16 +5C g 61 For extra charges, please see supply terms and conditio
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000498 Tylosin phosphate for peak identification T2880200 Tylosin tartrate - reference spectrum T2900000 Tyrosine T3000000 Tyrothricin New U0020000 Ubidecarenone U0020001 Ubidecarenone for system suitability U0020008 Ubidecarenone impurity D Batch n 1 1 1 2 2 3 2 Quantity Sale per vial Unit 10 mg 1 n/a 50 mg 20 mg 50 mg 1 mg 5 mg 1 1 1 1 1 1 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]benzene-1,4dione Batch 1 is valid until 1 June 2013 Information Monograph 1273,1274,16 61 1274 0782,0895,11 61, 1272,1384 0907,1662 1578 1578 1578 Leaflet Yes
Effective from 2013 Storage +5C Extra charges g l +5C Yes +5C +5C +5C +5C a a a a a
U0100000 Uracil arabinoside U0600000 Urea U0800000 Ursodeoxycholic acid New Y0001163 Ursodeoxycholic acid for system suitability Y0000834 Valaciclovir hydrochloride (anhydrous) Y0001225 Valaciclovir for system suitability Y0001096 Valaciclovir impurity D Y0001097 Valaciclovir impurity E Y0001098 Valaciclovir impurity F para-toluenesulfonate Y0001099 Valaciclovir impurity G Y0000583 Valerian standardised dry extract V0030000 Valine Y0000584 Valnemulin hydrochloride Y0000533 Valnemulin hydrogen tartrate Y0000585 Valnemulin for peak identification Y0000586 Valnemulin impurity E
2 2 2 2 1 1 1 1 1 1 3 1 1 1 1 1
60 mg 100 mg 100 mg 1.26 mg 100 mg 10 mg 10 mg 10 mg 12 mg 10 mg 400 mg 50 mg 10 mg 120 mg 20 mg 10 mg
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl 2-hydroxyacetate (pleuromulin) 98.7% CHNOS 2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-ethyl-L-valinate 2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy) carbonyl]-L-valinate 2-hydroxyethyl L-valinate N,N-dimethylpyridin-4-amine 0.43 % of C15H22O2 ; Batch 2 is valid until 31 August 2012 Batch 1 is valid until 1 May 2013
0760 0743 1189,1275 1275 1768 1768 1768 1768 1768 1768 0453,1898,18 99,2400,2526 0770,0771,07 96 2137 2137 2137 2137 Yes Yes Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C -20C +5C +5C +5C +5C +5C
a a a a a a a a a f c a a a a a
V0033000 Valproic acid Y0001422 Valproic acid for system suitability Y0001132 Valsartan Y0001131 Valsartan for peak identification Y0001145 Valsartan for system suitability V0045000 Vancomycin hydrochloride V0050000 Vanillin Council of Europe, all rights reserved 2013
2 1 1 1 1 3 1
100 mg 10 mg 10 mg 10 mg 0.202 mg 100 mg 100 mg
1 1 1 1 1 1 1 80 102000 IU per vial
1378 1378,0678 2423 2423 2423 1058,20702 0747 Yes Yes Yes Yes
+5C +5C +5C +5C +5C -20C +5C
a a a a a a a
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001198 Varicella vaccine ( live) Y0000561 Vecuronium bromide Y0000625 Vecuronium for peak identification Y0001093 Vedaprofen Y0001118 Vedaprofen impurity mixture Y0000587 Venlafaxine hydrochloride Y0000588 Venlafaxine for system suitability V0100000 Verapamil hydrochloride V0100018 Verapamil impurity I V0100026 Verapamil impurity M Y0000661 Verbenalin V0180000 VERO cells Y0001400 Vigabatrin Y0001401 Vigabatrin impurity A Y0001402 Vigabatrin impurity B Y0001404 Vigabatrin impurity D Y0001403 Vigabatrin impurity E V0300000 Vinblastine sulfate V0305000 Vinblastine sulfate - reference spectrum V0400000 Vincristine sulfate V0405000 Vincristine sulfate - reference spectrum V0500000 Vindesine sulfate V0500010 Vindesine sulfate - reference spectrum Y0000463 Vinorelbine tartrate Y0000464 Vinorelbine impurity B Y0000589 Vinpocetine Y0000590 Vinpocetine impurity A Batch n 1 1 1 1 1 2 3 1 3 2 1 1 1 1 1 1 1 4 1 5 1 2 1 2 3 1 1 Quantity Sale per vial Unit 420 mg 1 10 mg 10 mg 5 mg 0.006 mg 50 mg 1 mg 100 mg 5 mg 10 mg 11 mg 1 ml 10 mg 25 mg 20 mg 50 mg 10 mg 5 mg n/a 4.96 mg n/a 5.11 mg n/a 50 mg 7 mg 10 mg 10 mg 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 (12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6, 12,13,13a,13boctahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12carboxylate (ethyl vincaminate) (13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido [3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine) ethyl (13aS,13bS)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1Hindolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (methoxyvinpocetine) 4-O-deacetylvinorelbine 5.11 mg per vial of CHNOS 4.98 mg per vial of CHNOS 94.7% CHNO; (5RS)-5-ethenylpyrrolidin-2-one (2E)-2-(2-aminoethyl)but-2-enoic acid 4-aminobutanoic acid 2-[(2RS)-2-aminobut-3-enyl]propanedioic acid 5.01 mg per vial of CHNOS (2RS)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4-dimethoxy-phenyl)ethyl] (methyl)amino]ethyl]-3-methylbutanenitrile hydrochloride 5,5'-[[2-(3,4-dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxyphenyl)-2-(1methylethyl)pentanenitrile] 0.97 mg per vial of CHO Cell lines (kidney, african green monkey, Cercopithecus aethiops) titration of live measles, mumps and rubella vaccines Batch 1 is valid until 31 March 2012 Batch 2 is valid until 31 December 2012 Information Monograph 0648 1769 1769 2248 2248 2119 2119 0573 0573 0573 1854 0213,0538,10 57 2305 2305 2305 2305 2305 0748,0749 0748 0748,0749 0749 1276 1276 2107 2107 2139 2139 Yes Yes Yes Yes Leaflet Yes
Effective from 2013 Storage -80C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C Liquid nitrogen +5C -20C +5C +5C +5C -80C -80C -80C -80C -80C +5C +5C Extra charges d g g g g g g g g g a d a c a a a g(d) l d l g(d) l g(d) g(d) a a
Y0000591 Vinpocetine impurity B Y0000790 Vinpocetine impurity C
1 1
10 mg 10 mg
1 1
2139 2139 Yes
+5C +5C
a a
81
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000760 Vinpocetine impurity D Batch n 1 Quantity Sale Information per vial Unit 10 mg 1 (12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo [3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine) 200 mg 120 mg 10 mg 10 mg 50 mg 10 mg 10 mg 125 mg 50 mg 15 mg 0.02 mg 500 mg 100 mg 10 mg 100 mg 20 mg 60 mg 10 mg 15 mg 50 mg 50 mg 100 mg 10 mg 0.465 mg 200 mg 10 mg 40 mg 20 mg n/a 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 82 N,N'-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazol[1,2-a] pyridin-3-yl] acetamide Batch 1 is valid until 31 January 2013 Batch 2 is valid until 1 April 2013 6-[[6-(acetylamino)hexanoyl]amino]hexanoic acid 95.6% CHClNOS 99.1% CHClNO 99.5% CHNO 1-[(2,5)-5-hydroxymethyl-2,5-dihydro-2-furyl]-5-methyl pyrimidine-2,4 (1,3)-dione 1-(3-chloro-2,3-dideoxy--D-ribofuranosyl)-5-methylpyrimidine-2,4(1,3)dione N-(2-aminoethyl)-2-(4-1,1-dimethylethyl-2,6-dimethylphenyl) acetamide 99.2% CHO 2,6-dimethylphenyl isothiocyanate 87.5% CHNS ; methyl (2,6-dimethylphenyl)carbamodithioate (2RS,3SR)-2-(2,4-difluorophenyl)-3-pyrimidin-4-yl-1-(1H-1,2,4-triazol-1-yl) butan-2-ol (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4triazol-1-yl)butan-2-ol (epi-voriconazole) [(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid ((+-)-camphorsulfonic acid) Monograph 2139 Leaflet
Y0000793 Vinyl acetate Y0001395 Voriconazole Y0001396 Voriconazole impurity B Y0001398 Voriconazole impurity D Y0001397 Voriconazole impurity E W0100000 Warfarin sodium Y0000778 Warfarin sodium clathrate X0075000 Xylazine hydrochloride Y0000158 Xylazine impurity C Y0000159 Xylazine impurity E Y0001224 Xylazine impurity mixture X0080000 Xylitol X0100000 Xylometazoline hydrochloride X0101000 Xylometazoline impurity A X0200000 Xylose Y0000656 Yohimbine hydrochloride Z1900000 Zidovudine Z1902000 Zidovudine impurity A Z1904000 Zidovudine impurity B Z2000000 Zinc acexamate Z2000010 Zinc acexamate impurity A Y0001286 Ziprasidone hydrochloride monohydrate Y0001272 Ziprasidone for system suitability 1 Y0001241 Ziprasidone for system suitability 2 Z2500000 Zolpidem tartrate - * psy Z2500010 Zolpidem impurity A Z3000000 Zopiclone -* psy New Z3001000 Zopiclone oxide Y0000062 Zuclopenthixol decanoate - reference spectrum Council of Europe, all rights reserved 2013
1 1 1 1 1 2 1 1 2 2 1 1 2 1 1 1 2 2 2 1 1 1 1 1 3 3 2 3 1
2152 2576 2576 2576 2576 0698,0699 0699 1481 1481 1481 1481 1381 0972,1162 1162 1278 2172 1059 1059 1059 1279 1279 2421 2421 2421 1280 1280 1060 1060 1707 Yes Yes Yes Yes Yes Yes Yes
+5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C +5C
g g g g g g g g g g g a g g a g a a a a a a a a j a j g l
List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0000534 Zuclopenthixol for system suitability Y0000083 Zuclopenthixol impurity B Batch n 1 1 Quantity Sale per vial Unit 0.26 mg 1 10 mg 1 2-chloro-9H-thioxanthen-9-one Information Monograph 1707 1707 Leaflet Yes
Effective from 2013 Storage +5C +5C Extra charges a a
83

EP Latest

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

EP Latest

Uploaded by

Copyright:

Available Formats

List of European Pharmacopoeia Reference Standards Order Reference Standard Code Y0001484 Medroxyprogesterone acetate for peak identification

0.01025 mg 1 0.00856 mg 1 10 mg 30 mg 25 mg 10 mg 70 mg 15 mg 10 mg 60 mg 20 mg 10 mg 10 mg n/a 50 mg 94.7 mg 10 mg 20 mg 50 mg 10 mg 20 mg 0.004 mg n/a 10 mg 20 mg 10 mg 100 mg 10 mg 0.06 mg 50 mg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

100 mg 10 mg 60 mg 50 mg 20 mg 125 mg 20 mg 10 mg 100 mg 20 mg 20 mg 10 mg 1.0015 mg 10 mg 10 mg 150 mg 10 mg 15 mg

Y0001069 Amlodipine impurity B

1491 2081 2082

For extra charges, please see supply terms and conditio

Effective from 2013 Storage +5C +5C +5C Extra charges j j a

100 mg 10 mg 100 mg 250 mg 150 mg

-20C -20C -20C +5C +5C

100 mg 10 mg 160 mg 15 mg 285 mg 10 mg 15 mg 50 mg 20 mg 15 mg 40 mg 20 mg 0.5 ml 2.7 mg 10 mg 100 mg 50 mg

+5C +5C +5C

For extra charges, please see supply terms and conditio

92.9% CHClNOS 62.9 IU per mg

+5C -20C +5C +5C +5C +5C +5C +5C

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

Effective from 2013 Storage +5C Extra charges g

100 mg 70 mg 20 mg 5 mg n/a n/a 5 mg n/a 1 mg 0.4 ml 20 mg 10 mg n/a n/a 100 mg 60 mg 100 mg

99.8% CHNO See leaflet

-20C +5C +5C -20C

+5C -20C -20C -20C -20C

+5C +5C +5C

250 mg 500 mg 60 mg 50 mg 60 mg 10 mg 10 mg 50 mg 200 mg 50 mg 10 mg 20 mg 10 mg

1 1 1 1 1 1 1 1 1 1 1 1 1 Loss of 12.1% m/m (U= 0.2%, n=10, k=2.23)

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

Effective from 2013 Storage +5C Extra charges g

100 mg 10 mg 60 mg 150 mg 200 mg 10 mg 10 mg 10 mg 0.02 mg 20 mg 40 mg n/a 10 mg 15 mg

+5C +5C +5C

+5C +5C +5C +5C +5C +5C

+5C +5C +5C +5C

100 mg 10 mg 1.01 mg n/a 250 mg

1 1 1 1 1 100% CHO (RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine Replaces Cetirizine impurity mixture CRS

+5C +5C Yes Yes +5C +5C

1 1 1 1 1 1 1 14 Batch 1 is valid until 30 April 2012

+5C +5C +5C +5C +5C +5C Yes +5C

0379 1189,1275 1774 0137 0137

For extra charges, please see supply terms and conditio

15 mg 200 mg 100 mg 100 mg 0.01 mg 10 mg 200 mg 15 mg 10 mg 10 mg 2 mg 100 mg 50 mg 50 mg

Clemastine fumarate impurity C

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

25 mg n/a 250 mg 80 mg 1000 mg 5 mg 100 mg 70 mg 20 mg 20 mg

20702 0891 0321,0736,07 67

-20 C +5C +5C +5C +5C -20C -20C +5C

2120 0036 0892

1194 1194 2394

For extra charges, please see supply terms and conditio

100 mg 0.013 mg 10 mg 10 mg 10 mg 50 mg 100 mg

+5C +5C +5C +5C +5C +5C +5C

+5C +5C +5C +5C +5C

For extra charges, please see supply terms and conditio

For extra charges, please see supply terms and conditio

32 mg 100 mg 10 mg n/a 100 mg 50 mg 2 mg 100 mg 100 mg 100 mg 100 mg 100 mg 55 mg 20 mg

See leaflet, 20706 1719 1719 0898 0486 1199